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Abstract
Cutaneous melanoma is a cancer of melanocytes, the pigment-producing cells in our
skin. It is one of the most aggressive human malignancies, constituting only about 2%
of all dermatological cancers but being responsible for over 75% of all deaths from skin
cancer. It has recently become a major public health problem, as it is now the fifth most
common cancer in the United Kingdom after its incidence more than quadrupled in the
last three decades. For these reasons, understanding the biological processes that are
involved in its development is of great importance for devising novel treatments and for
the management of patients in the clinic.
The study of the genetic factors that influence melanoma risk can uncover mech-
anisms that are relevant in the transition from a benign melanocyte to a malignant
melanoma. Approximately 10% of all melanoma cases are familial, and about half of
these familial cases can be explained by pathogenetic variants in genes such as cyclin-
dependent kinase inhibitor 2A (CDKN2A), cyclin-dependent kinase 4 (CDK4 ), breast
cancer 2 (BRCA2 ), BRCA1-associated protein-1 (BAP1 ) and in the promoter of the
telomerase reverse transcriptase (TERT ). However, about 50% of all familial melanoma
cannot be explained by mutations in known genes. In this dissertation, I detail the
methodology I followed in an effort to uncover additional high-penetrance melanoma
susceptibility genes.
I analysed exome and genome sequence data from a total of 184 individuals that
belong to 105 melanoma-prone families from the United Kingdom, The Netherlands
and Australia that did not have any pathogenetic variants in known susceptibility
genes. I applied different gene prioritisation strategies and developed novel software
tools in order to devise a list of plausible melanoma susceptibility candidate genes;
these analyses suggested that genes regulating telomere function could be influencing
melanoma risk. After performing functional experimental analyses, our research team
was able to determine that carriers of rare variants in the protection of telomeres (POT1 )
gene, a member of the shelterin complex that safeguards telomere integrity, are at high
risk for developing melanoma. We successfully described the mechanism by which this
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happens, showing that the variants identified either disrupt POT1 mRNA splicing or
abolish the ability of POT1 to bind to telomeres, and lead to increased telomere length
in carriers when compared to melanoma cases with wild-type POT1.
The main finding of the work described in this dissertation is the identification of
telomere dysfunction as an important contributor to the risk of developing melanoma,
and possibly other cancers. Our analyses suggest that POT1 is the second most com-
monly mutated high-penetrance melanoma susceptibility gene reported thus far, and
moreover, that rare variants in this gene constitute the first hereditary mechanism for
telomere lengthening in humans.
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Chapter 1
Introduction
1.1 From peas to man: A (very) brief history of ge-
netics
The study of genetics started more than a century ago, when the Austrian monk Gregor
Mendel performed his classic experiments with common pea plants and deduced the
basic principles of heredity, which he described in a paper written in German in 1866 [1].
Mendel, after careful characterisation of several generations of pea plants, hypothesised
that physical characteristics were transmitted from parents to offspring in packets of
information he termed ‘elements’. The material responsible for carrying these elements
was identified about a decade later, albeit unwittingly, by the German biologist Walther
Flemming while he was studying cell division [2]. This fibrous material, which he termed
‘chromatin’, would later be shown to be formed of chromosomes [2], while Mendel’s
elements would form the basis for the definition of gene [3]. These discoveries, whose
importance was unrecognised at the time, would launch a scientific revolution that would
completely change the way researchers studied the laws of heredity over the coming
century.
The identification of chromosomes as the carriers of heredity in the turn of the
nineteenth century by Walter Sutton [4] and Theodor Boveri [5], along with the ob-
servation that chromosomes contain nucleic acids by Oskar Hertwig and Albert von
Kölliker (reviewed in [6]), sparked huge interest in the scientific community to identify
the mechanism by which chromosomes could preserve and transmit information from
generation to generation. In 1953, James Watson and Francis Crick proposed that spe-
cific nucleotide base pairing in deoxyribonucleic acid (DNA) could provide a mechanism
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for copying and transmitting information, making it the most likely gene carrier [7]. A
few years later, scientists had managed to decipher the genetic code and efforts began
to sequence genes and whole genomes.
Between 1977 and 1982, researchers were able to determine the complete genome
sequences of the ΦX174 and λ bacteriophages [8, 9], the simian virus SV40 [10] and the
human mitochondrion [11]. The success with these relatively small genomes prompted
scientists to initiate efforts to sequence the entire human genome, and by 1990 the
Human Genome Project had been launched with the participation of numerous research
institutions around the globe [12]. This tremendous enterprise yielded the first draft of
the human genome (covering about 94% of the total sequence) in 2001 [12], followed
by the publication of the gold standard reference covering ~99% of the euchromatic
sequence in 2004 [13].
In the few years since the publication of the human genome, sequencing technologies
have evolved at an accelerated pace, bringing down the cost and the amount of human
resources necessary for generating high-quality genome sequences [14]. As such, the last
decade has seen a dramatic increase in the number of organisms that have had their
whole genome sequenced, as well as the number of projects attempting to catalogue
and understand all existing natural human variation. Examples of these are The 1000
Genomes Project [15], the UK10K Project [16] and the National Heart, Lung and Blood
Institute Grand Opportunity Exome Sequencing Project (NHLBI GO ESP) [17]. Other
endeavours have focused on charting the different elements encoded by and influencing
regulation of the human genome, examples of which are The Encyclopaedia Of DNA
Elements (ENCODE) [18], The National Institutes of Health Roadmap Epigenomics
Mapping Consortium [19] and BLUEPRINT [20]. All of these interdisciplinary, mul-
tinational collaborations have allowed a much deeper understanding of the relationship
between the human genome and the regulation of important biological processes, as well
as the essential role it plays in health and disease.
1.2 The human genome: Its structure and gene con-
tent
In 1956, the long-standing quest to determine the number of chromosomes in human dip-
loid cells was finally settled by two studies authored by the laboratories of Albert Levan
and John Hamerton [21, 22]. These researchers were able to improve the karyotyping
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techniques of the time by adding steps to treat cells with colchicine and an hypotonic
solution [23], and finally determined that diploid cells possess 46 chromosomes including
one sex-determining pair. Other pre-sequencing era genome measurements included
the estimation of the size of the whole human genome, which was approximated to
be between 3000 and 3200 megabases (Mb) by physical maps [24], and guesses on the
number of genes it contains, which were generally in the range of 50,000-100,000 [25].
The delivery and initial analysis of the human genome helped refine these meas-
urements and allowed an unprecedented description of our genomic landscape. The
analysis revealed that the human genome showed marked variation in the distribution
of features such as CpG islands and transposable elements, that it had many more
segmental duplications than other previously sequenced eukaryotes, and that it seemed
to contain only between 30,000 and 40,000 genes, among other remarks [12]. Many of
these observations were confirmed with subsequent analyses and studies, whereas some
estimates were further refined with the release of the gold standard reference genome
and advances in assembly techniques and bioinformatic algorithms. For example, the
amount of segmental duplication was estimated at ~5.3% of the euchromatic sequence
as compared to a lower bound of 3.6% in the draft sequence, and the number of protein-
coding genes was brought even lower to 20,000-25,000 [13].
The new estimated upper bound on the number of genes left many scientists per-
plexed. It was comparable to that of the simple nematode Caenorhabditis elegans [26],
an organism composed of about 1,000 cells, and much lower than those in the single-
celled pathogen Trichomonas vaginalis [27] and in common crops such as maize [28] and
wheat [29]. Where did the perceived complexity in humans come from, if not from our
protein-coding genes? Part of the explanation came from experiments that showed that
the great majority of human genes are capable of generating more than one protein via
alternative splicing [30], which less complex organisms, such as T. vaginalis, cannot do
as their genes lack introns [27]. Proteins generated by human genes were also estimated
to participate in many more interactions with each other than those of organisms of
lower perceived complexity, such as C. elegans and Drosophila melanogaster, with the
size of each species’ interactome seeming to correlate better with complexity [31]. Other
factors that may contribute to explain organism complexity relate to the amount of gene
duplication in species such as T. vaginalis, maize and wheat [27, 28, 32], the intricate
patterns of post-translational protein modification in humans [33], and gene expression
regulatory mechanisms [34, 35].
However, protein-coding genes, their regulation, interactions and modifications offer
16 Introduction
only a small part of the answer. The realisation that the number of genes in an organism
and its perceived complexity did not seem to correlate pointed to additional factors, hid-
den in the non-protein-coding genome, contributing at least as importantly as proteins
to biological function. In fact, John Mattick soon noticed that the proportion of protein-
coding DNA in an organism decreases as a function of its complexity, with prokaryotes
having less than 25% of non-coding sequences and humans having approximately 98.5%
[36]. Additionally, it was estimated that the amount of genome that is transcribed
into ribonucleic acid (RNA) greatly exceeds the amount that is translated into proteins,
significantly adding weight to this hypothesis [37]. Given these observations, efforts
began to identify and study the diverse repertoire of biological elements encoded by
our genome, beyond protein-coding genes, that participate in structural, regulatory and
functional tasks.
Undoubtedly, the ENCODE project has been the largest collaboration, launched in
2004, with the aim of providing a complete catalogue of all the functional components
encoded by the human genome [38]. In 2012, the Consortium published their extensive
set of analyses in a series of 30 papers published in Nature, Genome Biology and Genome
Research (for an overview of these publications, see the Nature ENCODE explorer
at http://www.nature.com/encode/). By using different approaches such as chromatin
immunoprecipitation (ChIP-seq), RNA sequencing (RNA-seq) and mass spectrometry
in more than 140 human cell lines, ENCODE was able to assign a biochemical function
to the vast majority of the human genome [18]. About 62% of the genome was found
to be covered by different RNA-encoding elements, the majority in intronic regions,
and included long non-coding (lnc)RNAs and small RNAs, comprising small nuclear
(sn)RNAs, small nucleolar (sno)RNAs, micro (mi)RNAs and transfer (t)RNAs [18, 39].
Additionally, about 56% of the genome was found to be enriched for histone modific-
ations, and smaller regions were classified as open chromatin (15%) or transcription-
factor-binding sites (8%) [18]. ENCODE also described regions of DNA methylation,
long-range physical genomic interactions, and gave an estimate of the amount of human
genome under purifying selection (3-8%), among other remarks [18].
Other projects have been initiated with the aim of understanding and cataloguing
natural human variation. The 1000 Genomes Project was the first such undertaking,
launched in 2008, that sequenced large numbers of individuals in order to discover and
haplotype all forms of DNA polymorphisms present in humans [40]. The 1000 Genomes
Project Consortium published the results of their pilot phase in 2010, followed two years
later by a detailed description of the findings in the genomes of 1,092 individuals from
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14 populations [15, 40]. So, although humans are thought to share about 99.9% of their
genetic sequence with each other (reviewed in [41]), the Consortium reported around 38
million single nucleotide polymorphisms (SNPs), 1.4 million short insertions or deletions
(indels) and more than 14,000 larger structural variants which showed marked differences
in allele distribution across populations [15]. In 2012, the NHLBI GO ESP published
an analysis of more than 15,000 genes in 6,515 individuals, in which they reported
that individuals carry an excess of rare variants, thought to have arisen recently and
attributable to explosive population growth [17]. These efforts have provided us with a
deeper understanding of the history and migration patterns of human populations, the
burden of rare variants typically carried by any single individual, regions of the genome
that are essential in determining phenotypic characteristics, and genes that might play
an important role in susceptibility to disease.
With other projects currently on-going with the aim of cataloguing all human vari-
ation and elucidating the biological function of these elements [16, 19, 20], our un-
derstanding of the human genome is likely to increase dramatically in the next years.
However, at this moment, the ease of rapidly generating whole-genome or targeted
sequencing of hundreds of individuals, coupled with the continued development of bioin-
formatic tools and the ability to search tens of in-depth catalogues of human variation
and diverse encoded DNA elements, has substantially helped the identification of the
genomic regions that play an important role in health and disease.
The present dissertation principally deals with the use of the above-mentioned se-
quencing methodologies, variation catalogues and bioinformatic tools in order to search
for melanoma-predisposing genome regions in a cohort of high-density melanoma families
from the United Kingdom (UK), The Netherlands and Australia. In the next section,
I discuss the basis of cancer aetiology in humans, with special emphasis on the known
genetic components of cancer development as it is the main focus of my work. The
remaining sections provide a detailed description of melanoma and its risk factors, as it
is the phenotype I have studied in the course of the last four years. Finally, I conclude
this introduction with a discussion of the unanswered questions in melanoma genetics
and the methodology I followed in an effort to answer them.
1.3 The basis of cancer aetiology in humans
Cancer is a disease of the genome [42]. As early as 1890, David von Hansemann examined
cancer cells under a microscope and noticed striking aberrations in their chromosomes,
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such as multipolar mitoses, breakage, asymmetry and altered chromosomal dosage [43,
44]. This observation made him postulate, contrary to beliefs at the time, that cancer
was a disease of the internal hereditary material of the cell [44]. Following on these
observations, Boveri made yet another landmark contribution to genetics: By studying
sea urchin eggs, he hypothesised that tumours might originate as a consequence of cells
passing abnormal numbers of chromosomes to their daughters [45, 46]. With their work,
von Hansemann and Boveri laid the theory of the genetic origin of cancer.
Other experiments followed to show that cancer was caused by the progressive accu-
mulation of somatic alterations in genomes [47]. By 1930, Katsusaburo Yamagiwa and
Koichi Ichikawa had reported that exposing rabbits to coal tar could produce carcinomas
with metastatic potential [48], and Ernest Kennaway had identified individual chemical
compounds that generated tumours in mice and rabbits [49]. These chemical compounds
were later shown to bind covalently to DNA and induce genetic mutations [50–53],
thus providing the molecular link between exposure to certain chemicals and cancer
development.
This hypothesis could explain well an observation that had been made in the 1770s.
The British surgeon Percivall Pott had described that chimney sweeps, who were exposed
to coal tar when working, were particularly likely to develop cancer of the scrotum, and
ascribed it to be “a disease brought on them by their occupation” [54]. Since then,
other industries in which workers face increased cancer risks have been described, such
as mining, chemical manufacturing and iron and steel founding [55]. These observations
established an important role for environmental risk factors in cancer development.
1.3.1 Environmental risk factors and their role in cancer devel-
opment
Environmental risk factors, which include all non-genetic aspects such as diet, lifestyle
and infectious agents, cause the majority of human cancers [56]. More than 100 agents
have been classified as ‘carcinogenic to humans’ by the International Agency for Research
on Cancer (IARC), which belongs to the World Health Organisation [57]. These agents,
which are known as carcinogens, can have genotoxic or non-genotoxic mechanisms of
action, or both. Genotoxic carcinogens can directly cause DNA damage, such as the
chemicals in coal tar, whereas non-genotoxic carcinogens can have diverse modes of
action and can alter diverse processes such as immune suppression, endocrine modific-
ation and inflammatory responses [58]. In this subsection, I review several of the most
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established or commonly found carcinogens, their modes of action and the malignancies
with which they have been causally associated.
1.3.1.1 Asbestos
Asbestos encompasses a series of naturally occurring silicate mineral fibres with desirable
industrial properties such as tensile strength and resistance to heat, and that therefore
are of commercial interest [59]. Asbestos fibres can be classified in two types: chrysotile,
which is the most commonly used type and is flexible and easily breakable, and the
amphiboles, which are rigid, sharp and durable [59]. The negative health effects of
asbestos exposure have been known for more than a century, when in 1899, Montague
Murray diagnosed the first fatal case of asbestosis arising from occupational exposure
[60]. However, proper legislation regarding dust control in North American mines was
not enacted until 1971 [61]. Because of this, asbestos is still present in buildings, and
given the long latency period between initial exposure and disease manifestation (15 to
40 years), it still continues to pose a major health challenge [59]. Distinct modes of action
have been described, with some sources noting its genotoxic effects, causing DNA base
oxidation, breakage, mutations and deletions and chromosomal aneuploidy (reviewed in
[62]) that alter processes such as cell proliferation, cell death and inflammation [63], and
other sources describing non-genotoxic effects such as the generation of reactive oxygen
and nitrogen species (ROS and RNS, respectively) and also mitogenic and cytotoxic
consequences [62, 63]. Given these different effects, which might depend on the studied
fibre type, lung clearance, genetics and other characteristics [59], the IARC has included
both mechanisms of action in its classification of asbestos as carcinogenic to humans.
Exposure to asbestos can be occupational, as in the case of factory workers, or
environmental, in the case of individuals living or working in communities near asbestos
mining plants or buildings with a high asbestos content. Workers are mainly at risk
of inhaling asbestos fibres when processing materials such as talc or vermiculite that
might be contaminated [61], and studies have established that they have a much higher
incidence of malignancies such as mesothelioma and lung cancers, among other diseases
[61, 64, 65]. The risk for lung cancer can be modified by other factors such as smoking and
persistent inflammation (reviewed in [62]). There is also evidence that environmentally-
exposed individuals can develop mesothelioma, albeit at much lower frequencies [64, 66,
67].
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1.3.1.2 Alcoholic beverages
Alcoholic beverages are pervasive in our society. In surveys conducted in 2012, more
than half of people aged 18 or over reported drinking alcohol in the last month in the
United States (US) [68], and more than half of adults reported consuming alcohol in
the last week in the UK [69]. More than a century ago, French pathologists noticed
an increase in the incidence of oesophageal cancer in absinthe drinkers [70], and since
then, numerous studies have been conducted that show an association between alcohol
consumption and cancers of the oral cavity, pharynx, larynx and oesophagus (reviewed
in [71]). Finally, in 1988, the IARC concluded there was sufficient evidence for the
carcinogenicity of alcoholic beverages in humans, and that malignant tumours of the
oral cavity, larynx, pharynx, oesophagus and liver can be causally associated with their
consumption [72].
Ethanol metabolism has been identified as the major mechanism by which alcoholic
beverages can cause cancer. Ethanol is metabolised to acetaldehyde by the alcohol de-
hydrogenase (ADH) enzymes and cytochrome P450, family 2, subfamily E, polypeptide
1 (CYP2E1), and is further converted to acetate by aldehyde dehydrogenases [73]. This
in turn causes genotoxic and non-genotoxic effects: Acetaldehyde can bind to DNA and
form stable adducts [74], interfering with DNA synthesis and repair, and its production
can generate ROS and an activation of other carcinogens present in the environment such
as tobacco smoke (reviewed in [73]). Individuals that carry a certain polymorphism in
one of the aldehyde dehydrogenase genes, ALDH2, have a much less efficient enzyme
and thus accumulate higher levels of acetaldehyde, and have therefore been identified as
a high-risk group for the development of oesophageal cancer (reviewed in [73]). Other
mechanisms by which alcohol may cause cancer relate to an increase in the levels of
hormones such as oestrogen, which increase breast cancer risk [75], an increase in the
permeability of mouth and throat cells to other carcinogens [76], and a decrease in folate
levels [77].
The proportion of all cancer cases and deaths attributable to alcohol intake worldwide
has been estimated to be 3.6% and 3.5%, respectively [78]. Therefore, diminishing alco-
hol consumption has been highlighted as an important and generally underemphasised
strategy for cancer prevention when compared to other preventive programs focusing on
tobacco usage and genetic screening, among others [79].
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1.3.1.3 Coal tar and soot
As discussed previously, coal tar and soot present in chimneys were the first occupational
agents to be associated with an increase in cancer risk. In the years since Pott described
the link between occupational exposure to coal and scrotal cancer [54], many other
reports describing an association between skin cancers and soot were subsequently
published (reviewed in [80]). As a result of his observations, Pott recommended that
chimney sweeps take a daily bath, and his suggestion was so successful that it managed
to greatly reduce the incidence of scrotal cancer in workers that followed his advice
compared to those that did not [81, 82]. This evidence, and numerous studies that
were conducted subsequently, led the IARC to conclude in 1973 that coal and soot are
carcinogenic to humans.
The mechanism of carcinogenicity of coal has been studied extensively. In 1936,
Alfred Winterstein reported that he could isolate benzo[a]pyrene (BP) from coal tar
boiling at high temperature (Winterstein A. Festschrift. Basel: Emil Barell; 1936; quoted
by [83]), and subsequent experiments showed that BP applied on mouse skin, even at
low doses, was highly carcinogenic and generally produced squamous cell carcinomas
[84]. Other researchers were later able to dissect the metabolism of BP: Upon exposure,
BP is converted to BP-7,8 epoxide and then further hydrolysed and metabolised, in
steps involving the microsomal epoxide hydrolase and cytochrome P450 enzymes, to the
carcinogenic diol-epoxide 2 (DE 2) [85]. This species is highly reactive and can bind DNA
[85, 86], and it has been shown by several studies that it can cause genetic mutations in
both prokaryotes and eukaryotes (reviewed in [87]).
Exposure to coal tar and soot has been associated principally with higher incidences
of lung and skin cancer, but limited evidence also exists linking it to bladder cancer [57].
1.3.1.4 Tobacco smoke
As early as 1930, tobacco smoking was proposed to be the underlying cause of the
phenomenal rise in lung cancer that was seen after the end of the First World War, a
suspicion that was confirmed over the next 20 years as more studies were carried out
investigating lung cancer aetiology [88–90]. In numerous experimental systems in which
mice, rats, Syrian hamsters, rabbits and dogs were exposed to mixtures of cigarette
smoke and air, significant increases in lung tumours as well as emphysema and other
cancers were observed (reviewed in [91]). Additionally, cigarette-smoke condensate was
found to increase the incidence of tumours when applied to mouse and rabbit skin, as
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well as acting as a potential co-carcinogen when used in conjunction with other agents
(reviewed in [91]). Some of these studies, in conjunction with others, were considered
by the IARC when it classified tobacco smoking as a confirmed carcinogen in 1986 [57].
Cigarette smoke contains more than 60 well-known carcinogens, most of which require
metabolic activation upon exposure, a step that generally involves the cytochrome P450
enzymes [92]. In addition to BP, which has also been found as a carcinogenic agent
in coal tar, other compounds found in tobacco smoke that can form DNA adducts are
N-nitrosodimethylamine, N´-nitrosonornicotine and ethylene oxide, among others [92].
Accordingly, in human cell line experiments, hotspots for the formation of BP-DNA
adducts have been found in genes important in cancer progression such as Kirsten rat
sarcoma (RAS) viral oncogene homolog (KRAS ) and tumour protein p53 (TP53 ) [93,
94]. In the case of KRAS, adducts were found to preferentially affect important codons
for kinase activation, and in the case of TP53, they matched the mutational signature
observed in human lung cancers, implicating the genotoxicity of these carcinogens as
a highly likely contributor to their aetiology. Other studies reporting higher levels of
adduct formation resulting from exposure to other tobacco carcinogens support the
causal relationship between smoking and cancer (reviewed in [92]).
Not only lung cancer has been causally associated with tobacco smoking. According
to the IARC, there is sufficient evidence to support a causal role for smoking in the
aetiology of many different types of malignancies, including myeloid leukaemia, and
colorectal, liver, oesophageal, stomach and bladder cancers, among others. Second-hand
smoking has also been linked to lung, laryngeal and pharyngeal cancers (reviewed in
[57]).
Tobacco smoking has been identified as the main cause of cancer-related deaths
worldwide, being responsible for approximately 16% of all cancers in developed countries
(Stewart BW, Kleihues P. World Cancer Report. Lyon, France: IARCPress; 2003;
quoted by [95]), and thus has influenced policymaking (for examples, see [96, 97]) and
sparked numerous campaigns around the world to reduce its prevalence (for examples,
see refs. [98, 99]).
1.3.1.5 Solar radiation
The link between exposure to solar radiation and skin cancer was suspected as far back
as 1894, when Paul Unna described what he referred to as ‘seaman’s skin’: chronically
sun-exposed skin that presented hyperkeratosis and squamous cell carcinomas (Unna,
PG. Die Histopathologie der Hautkrankheiten. Berlin: August Hirschwald; 1894; quoted
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by [100, 101]). Experiments in diverse model organisms over the next 70 years helped
clarify the carcinogenic effects of ultraviolet (UV) light, one of the radiation types that
the Sun emits (reviewed in [100]). In 1992, the IARC analysed data from numerous
patients and animal studies and concluded that there was sufficient evidence to support
a causal role for solar radiation in the development of cutaneous malignant melanoma
and non-melanocytic skin cancer in humans [102].
Solar radiation is the combination of UV radiation and visible light that reaches
the Earth’s surface [103]. Solar UV radiation that reaches Earth is mainly composed
of two wavelengths: UVA, which comprises about 95%, and UVB, which contributes
the rest [103]. UV radiation seems to have both genotoxic and non-genotoxic effects:
it can create cyclobutane pyrimidine dimers (CPDs) and (6,4)-photoproducts (6-4PPs)
between adjacent pyrimidine bases in the same DNA strand [104] (Fig. 1.1), and it can
also cause other systemic effects such as activation of the cell survival nuclear factor
(NF)-κB signalling pathway [105] and generation of ROS [106], which appear to be
independent of DNA damage. Although thymine bases in CPDs are not especially
mutagenic [107], cytosine bases in these structures are chemically unstable and usually
deaminate to generate uracil bases, which may then be incorrectly paired with adenine
during replication inducing a C-to-T transition. The same outcome happens if the CPD
occurs in a 5-methylcytosine (mC)-containing pyrimidine site, as is frequently the case
for solar-induced DNA lesions, because they can rapidly deaminate to form thymine
(reviewed in [108]). Therefore, the induction of C-to-T transitions at dipyrimidine sites
is the signature consequence resulting from UV radiation.
The incidence rate for malignant melanoma, one of the cancer types for which UV
radiation is an important risk factor, has more than quadrupled in the last 30 years in
the UK [110]. This dramatic increase has been attributed to lifestyle factors such as the
popularity of holidays in lower latitudes and the surge in sunbed usage [111], and has
led to increasing numbers of campaigns targeting unsafe exposure to UV radiation (for
examples, see [112–114]).
UV radiation, as one of the major causes of malignant melanoma, is revisited in
Section 1.6.
1.3.1.6 Other carcinogenic agents
In addition to the carcinogens discussed above, there are about 100 other agents that
have been classified in this category by the IARC. These can be chemicals (e.g., aflatoxins
or benzene), occupations (e.g. aluminium production or painting), metals (e.g. arsenic
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Figure 1.1: Types of DNA damage caused by UV radiation. An overview of
the structure changes induced by UV radiation in adjacent pyrimidine bases, in this
example, thymines are shown. Phosphate and sugar groups forming the DNA backbone
are shown in orange and light orange, respectively. In the case of CPDs, the double
bonds between carbons 5 and 6 become saturated, forming a four-membered ring. In
6-4PPs, a bond is formed between carbons 6 and 4 of two adjacent pyrimidines. Figure
taken from ref. [109]. Copyright 2013 by W.H. Freeman and Company. Used with
permission of the publisher.
or nickel compounds), dusts and fibres (e.g. leather or wood dust), radiation sources
(e.g. X or gamma radiation), biological agents (e.g. hepatitis B or C or HIV viruses),
personal habits (e.g. consuming areca nuts or Chinese-style salted fish), or drugs (e.g.
cyclosporine or tamoxifen) [57]. The value of identifying these carcinogenic agents lies
in actionable measures, such as educational campaigns and prevention programmes,
aimed at diminishing exposure to them. For example, encouraging results can be seen
from efforts of tobacco control campaigns and consequential reductions in lung cancer
incidence and mortality in the US [115, 116].
Exposure to carcinogens is an established cause of malignancy, but genetic predispos-
ition also plays an important role in cancer aetiology. In the next subsection, I discuss
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the genetic factors that have been identified in cancer predisposition, the importance of
familial studies and the biological insight we have gained from such analyses.
1.3.2 Genetic risk factors and their influence on cancer develop-
ment
In 1866, the same year in which Mendel published the basic principles of heredity, French
surgeon Paul Broca published perhaps what is the first report on the existence of familial
predisposition to malignancy. He constructed the pedigree of his wife’s family, who
suffered from early-onset breast cancer, and found fifteen cases of breast, liver and
uterine cancer spread across four generations of women (Broca P. Traité des tumeurs.
Paris: P. Asselin; 1866; pedigree reproduced by [117]) (Fig. 1.2). Then, in 1913, the
American pathologist Aldred Warthin published a study of 3,600 cancer cases that had
been examined in the University of Michigan in the period from 1895 to 1913. Of all
the carcinoma cases where detailed family history was available, he determined that as
many as 15% had a familial history of the disease, and thus supported the idea that
predisposition to malignancy could be inherited [118]. One of the families in his original
study has been followed now for more than a century, and the causes for its cancer-
prone phenotype have now been defined molecularly, contributing enormously to our
knowledge of the biological processes underlying cancer development [119]. With his
work, Warthin provided solid evidence for the importance of genetic factors in cancer
aetiology, and thus has been referred to as “the father of cancer genetics” [120].
Studies of other families, in which many different types of cancer seemed to cluster,
followed Broca’s and Warthin’s reports (reviewed in [121]), and epidemiological studies
carried out several decades later supported an important role for genetic predisposition
to cancer [122]. However, with the exception of these rare malignancies, the origin
of common cancers was still considered to have predominantly environmental causes
throughout almost all of the twentieth century [123].
Germline transmission of predisposition to certain malignancies, such as the child-
hood cancer retinoblastoma and syndromes of multiple endocrine neoplasms, had been
recognised in the 1980s [124–126]. Several years earlier, scientists had started to regard
cancer as a multi-stage process, having a fixed number of rate-limiting steps that should
be overcome before malignancy could progress [121]. The American geneticist Alfred
Knudson, after meticulously studying 48 cases of retinoblastoma, formulated in 1971
his groundbreaking two-hit hypothesis: he postulated that in the hereditary form of the
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Figure 1.2: Paul Broca’s pedigree evidences familial predisposition to cancer.
This pedigree, possibly the first report on familial cancer, shows fifteen cases of different
malignancies spread across four generations of women. Circles represent females, squares
represent males. Numbers in symbols refer to numbers of unaffected offspring. Pedigree
adapted from ref. [117].
disease, one mutation was inherited while the other happened somatically, whereas in the
sporadic form both happened somatically [127]. Knudson’s hypothesis was confirmed
in 1986 with the successful isolation of the gene responsible for retinoblastoma [128],
now known as RB1, and the characterisation of its aberrations in retinoblastoma DNA
samples.
Since these landmark discoveries, many other genes have been discovered that, when
mutated, predispose their carrier to the development of malignancies. Almost all of
these have been categorised as tumour suppressor genes, and echo Knudson’s two-hit
hypothesis in the mechanism by which they contribute to cancer development [129].
Tumour-suppressor genes normally have functions inhibiting cellular growth or genomic
instability, and thus inactivation of both copies of the gene in a cell leads to the loss of
these protective functions. Genes that contribute positively to cell proliferation can also
be affected by germline mutations, although this happens much less frequently. These
genes are referred to as proto-oncogenes, and inherited mutations render the encoded
proteins constitutively active [129], so a single copy of the gene harbouring the mutation
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is sufficient to promote tumourigenesis. Because of their modes of action, tumour
suppressor and proto-oncogenes show distinct patterns of germline and somatic altera-
tions, with tumour suppressors displaying truncating or disruptive mutations distributed
throughout the encoded protein and proto-oncogenes displaying clusters of mutations in
key residues that activate them.
The discoveries mentioned above, along with other genetic models in epidemiological
studies of cancer clustering, supported the hypothesis that a substantial proportion of
cancer incidence might be accounted for by genetic effects [123], and thus obligated
researchers to revisit the theory for the origins of common cancer. The importance
of genetic effects in the aetiology of common cancers was further supported, in 1990,
by the discovery of a genomic region linked to early-onset familial breast cancer [130].
Four years later, breast cancer 1 (BRCA1 ), the gene responsible for the disease, was
identified by positional cloning methods [131]. It is now recognised that between 5 and
10% of all cancers are inherited, and that the interaction between genetic factors, or
gene-environment interactions, might play an important role in a further 15% [132].
These numbers give us an idea of the importance of genetic make-up in cancer aetiology.
However, identifying cancer susceptibility genes is not an easy task. Although a
strong genetic component can be suspected in families where there are multiple affected
individuals across generations or individuals that present with multiple primary cancers
or with an early age of onset, various confounding factors can greatly complicate its
isolation. For example, the allele might show incomplete penetrance, in which case
some carriers will not be affected by the disease. It can also be the case that sporadic
forms of the disease, termed phenocopies, arise in non-carrier family members. In these
situations, a genotype comparison between affected and unaffected family members will
not be informative [133]. Despite these and other difficulties, such as small family size
or uncertain family history when assessing affected pedigrees [133], hundreds of genomic
regions have been found to influence cancer susceptibility over the last 30 years.
The advent of next-generation sequencing (NGS) technologies and other analysis
methodologies has facilitated the discovery of cancer-predisposing genes and their rel-
ative contributions to disease development. Over 100 high-penetrance genes have been
identified to date [129], and hundreds of other genomic regions have been associated with
cancer risk [134], deepening our understanding of the biological processes that underlie
normal cell proliferation and maintenance. In this subsection, I review the different
models of cancer risk inheritance that have been proposed, the most established tumour
suppressor genes and proto-oncogenes and the technologies that have been developed in
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their identification.
1.3.2.1 Mendelian inheritance of elevated cancer risk
Germline variants with strong cancer-predisposing effects can be inherited in a simple
Mendelian fashion, and generally underlie an early-onset of cancer and the appearance
of multiple primaries [135]. High-penetrance mutations in cancer-predisposing genes can
show different modes of transmission, with the majority displaying autosomal dominant
inheritance but some others requiring germinal bi-allelic inactivation to promote cancer
progression [136]. Syndromes that show autosomal dominant inheritance in families are
generally recessive at the molecular level, with one inactivated allele being transmit-
ted germinally from generation to generation and the other one being inactivated by
subsequent somatic mutations [135].
In general, rare germline variants with large effects (for example, underlying lethal
childhood cancers) tend to be purged rapidly by natural selection, because the carriers
generally do not reproduce [135]. In contrast, variants that predispose to later-onset
cancer, such as those in BRCA1, are removed more slowly from the population’s gene
pool. Therefore, rare alleles with large effects will tend to be younger than common
alleles with smaller effects, and will generally not be associated with any polymorphisms
in the genomic vicinity [135]. This distinction is important because it impacts the
methodologies used for gene identification, with whole-genome or exome sequencing
(WGS and WES, respectively) being better suited for the identification of rare alleles
with large effects and genome-wide association studies (GWAS) being more useful in the
identification of common alleles with weak effects. The genes described in this Subsection
belong to the first category, and have been identified by linkage and candidate gene
studies.
1.3.2.1.1 RB1 and retinoblastoma: The prototypical example of an inher-
ited cancer-predisposition syndrome The gene underlying almost all cases of
childhood retinoblastoma, RB1, was identified in 1986 by Stephen Friend and colleagues
[128] following Knudson’s hypothesis [127]. Accordingly, the majority of inherited cases
present with bilateral retinoblastoma, whereas this proportion is much lower among
sporadic cases [137], evidencing the different numbers of rate-limiting mutational steps
required for cancer development in mutation carriers versus non-carriers. RB1 is the
prototypical tumour suppressor gene, displaying about 90% penetrance and showing
autosomal dominant inheritance in families [137]. It has since been found mutated in
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other cancers, such as oesteosarcoma and small-cell lung carcinoma [138].
The biology of RB1 has been studied extensively in the three decades since its
discovery. Shortly after its isolation, two research teams found that its gene product was
the target of two virus-encoded oncogenes, adenovirus E1A and SV40 large T antigen
[139, 140], implicating that tumour-promoting and suppressor genes could act in the
same biological pathway. Further studies established that the RB1 protein acted as an
inhibitor of cell proliferation given that its over-expression caused cell-cycle arrest at the
G1 phase, and, conversely, its deficiency caused fast G1 progression (reviewed in [138]).
In the following years, researchers reported that RB1 was able to exert its molecular
functions by inhibiting members of the E2F family of transcription factors and cyclin-
dependent kinases (CDKs), which promote cell cycle entry (reviewed in [141]).
Retinoblastoma is a rare cancer, with an incidence of only about 12 cases per million
young children in the US, similar to several European countries [142]. Although more
than 500 distinct mutations in the RB1 gene have been described [143], novel mutations
are constantly being reported as most of the germline mutations underlying hereditary
retinoblastoma arise de novo [144, 145].
1.3.2.1.2 BRCA1 and BRCA2 : High risk for breast and ovarian cancer
The first report of breast cancer might be a 1500 BC Egyptian papyrus which described
tumours of the breast and their palliative treatment, although this is disputed [146, 147].
In any case, it is clear that breast cancer has been recognised for centuries. It is by far the
most common cancer in women, and indeed, the most prevalent cancer in the majority of
countries worldwide [148]. Broca’s pedigree (Fig. 1.2) showed breast cancer segregating
as an autosomal dominant trait, and accordingly, modern analyses have estimated a 96%
chance that Mrs. Broca harboured a BRCA1 or BRCA2 mutation, and that the other
cancers seen in the family represent metastatic disease [117].
Familial studies in the mid-1990s led to the isolation of BRCA1 and BRCA2 [131,
149], the two genes underlying the great majority of multi-case breast cancer families
[150]. A meta-analysis considering several estimates of the penetrance of mutations in
these genes reported that the breast and ovarian cancer risk was around 60% and 40% for
BRCA1, and 50% and 18% for BRCA2 mutation carriers, respectively [151]. However,
although these genes confer high cancer risks and might explain a large proportion of
multiple-case breast cancer families, they only account for about 2-6% of all breast
cancer cases [152]. This is the reason why other genes and susceptibility regions have
been intensively searched for using other methods, such as GWAS and WES.
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The BRCA proteins interact with several regulatory proteins, and have an important
role in the transcriptional regulation of the DNA damage response and thus in its
associated cell cycle checkpoints. Upon DNA damage, BRCA1 is phosphorylated by sev-
eral kinases, including ataxia telangiectasia-mutated (ATM) and ATM-related (ATR),
and participates in double-strand (ds) DNA break (DSB) repair (reviewed in [153]).
BRCA1 has also been shown to transcriptionally co-activate NF-κB-regulated genes,
which might contribute to maintain genomic stability [154]. It is thought that BRCA1 -
haploinsufficient cells need to accumulate further genomic damage before inactivating
the wild-type allele, because although tumours display BRCA1 loss-of-function, its bi-
allelic inactivation in normal cells results in cellular lethality [155]. The mechanism by
which BRCA1 haploinsufficiency predisposes to breast carcinogenesis might therefore
represent a modification of the two-hit hypothesis, with an additional third hit (genomic
instability) required before the inactivation of the wild-type allele [155].
BRCA2 may also play an important role in DSB repair, as shown by the chromosomal
breakage and abnormal mitotic exchanges observed in BRCA2 -deficient cells (reviewed
in [153]). Through its binding to the RAD51 recombinase, its synergistic interactions
with P53 and its association with CDKs, BRCA2 promotes genomic stability and the
response to radiation-induced DNA damage [156, 157]. Loss of the BRCA2 wild-type
allele is commonly seen in tumours from germline mutation carriers [158, 159].
Other methodologies have been used to find important genes in breast cancer suscept-
ibility. For example, WES has identified germline mutations in the DNA repair genes
Fanconi anaemia complementation group C (FANCC ) and Bloom syndrome (BLM )
[160], and GWAS has found a few other low-penetrance loci influencing breast cancer
risk (reviewed in [161]).
1.3.2.1.3 DNA mismatch repair genes, APC and familial colon cancer syn-
dromes One of the families in Warthin’s original report, Family G, had several mem-
bers that presented with colon, stomach and abdominal cancers across two generations
[118]. This family has been followed regularly, initially by Warthin and his colleagues
and subsequently by other researchers, for more than a century now (reviewed in [162]).
Their cancer-prone phenotype is now known as Lynch syndrome (in honour of one of the
physicians that has been studying it for several decades) or hereditary nonpolyposis colon
cancer [132]. The molecular basis for their phenotype remained elusive throughout the
twentieth century, but in 2000, Hai Yan and colleagues tested one member of this family
and identified a T to G transversion at a splice acceptor site in the mutS homolog 2
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(MSH2 ) gene [163], encoding a protein important for DNA mismatch repair [164]. Since
then, mutations in any of the five DNA mismatch repair genes (MSH2, MSH6, mutL
homolog 1 [MLH1 ], PMS1 postmeiotic segregation increased 1 [PMS1 ] and PMS2 ) have
been found to underlie this syndrome [132]. Because of these defects, a type of DNA
replication error called microsatellite instability is the mutational hallmark of colorectal
tumours in Lynch syndrome [132]. It presents as an autosomal dominant disease with
early onset, and has a typically high penetrance (~85%) [132, 164]. The development
of cancer in these individuals follows the two-hit hypothesis, with the wild-type allele
often found inactivated by deletion, somatic mutations or epigenetic alterations [165].
The other major subtype of hereditary colorectal cancer is known as familial adeno-
matous polyposis (FAP). Individuals with this disease, in contrast to Lynch syndrome,
present at a young age with hundreds to thousands of adenomatous polyps in the colon
and rectum, and have a greatly increased risk of developing colorectal cancer [132]. The
gene underlying this syndrome was discovered by linkage analysis in 1987 [166], and
is now known as adenomatous polyposis coli (APC ). The APC protein behaves as a
tumour suppressor, having a myriad of important cellular functions in cell cycle control,
migration, differentiation and apoptosis that it exerts through its modulation of the
integration/wingless (Wnt) signalling pathway [132]. Abrogation of APC function is
not only important in tumours from individuals with hereditary disease, as mutations
in APC are the earliest genetic alteration found in sporadic cases as well [167, 168].
Malignancy then ensues with the acquisition of additional somatic mutations in genes
such as KRAS and TP53 [168].
The susceptibility to colon cancer has also been linked to other genes such as mutY
homolog (MUTYH ), axin 2 (AXIN2 ), mothers against decapentaplegic homolog 4 (SMAD4 ),
bone morphogenetic protein receptor, type IA (BMPR1A) and phosphatase and tensin
homolog (PTEN ), among others (reviewed in [169]). GWAS have also uncovered several
different loci associated with the risk of colorectal cancer and adenomas (reviewed in
[161]).
1.3.2.1.4 TP53 and the multi-cancer Li-Fraumeni syndrome In 1969, Fre-
derick Li and Joseph Fraumeni reported four families in which children and young
adults presented with a high frequency of different types of malignancies, including
soft-tissue sarcomas and breast cancer, and often with multiple primaries [170]. Some
years later, two groups identified germline mutations in the tumour suppressor TP53 in
six families presenting with this syndrome [171, 172]. Since then, many other mutations
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in TP53, both in coding and non-coding regions, have been described. These mutations
are sometimes associated with inhibition of growth arrest, apoptosis, or transcriptional
activation, and their activity can be influenced by genetic background, accumulation
of further genetic alterations or other epigenetic or environmental factors (reviewed in
[173]). Although the germline alterations result in TP53 loss of function, experiments
made in vitro suggest that missense mutations harbour oncogenic potential (reviewed in
[173]). This observation could help explain why only a fraction of tumours present loss
of the wild type allele (following Knudson’s hypothesis) [174].
TP53 encodes an important tumour suppressor gene that integrates signals from
multiple pathways and controls cell cycle progression and fate (reviewed in [175]). Muta-
tions in this gene have been found in a fraction of virtually every sporadically-occurring
malignancy [173], and given its pivotal role in maintaining genomic stability, has been
referred to as “the guardian of the genome” [176].
Because not all families with Li-Fraumeni syndrome have segregating mutations in
TP53, other genes have been searched in connection with the phenotype. Genes in the
P53 pathway, such as checkpoint kinase 1 (CHEK1 ), CHEK2, cyclin-dependent kinase
inhibitor 2A (CDKN2A) and PTEN have all been considered as candidates, however,
their involvement in the aetiology of the disease remains unconvincing (reviewed in
[176]).
1.3.2.1.5 RET : A proto-oncogene activated by germline mutations Mul-
tiple endocrine neoplasia (MEN) syndromes are a group of diseases in which endocrine
glands present with two or more tumours, and in which ectopic hormone production
is common (reviewed in [124]). MEN syndromes are generally divided into three main
types: MEN1, MEN2 and MEN4, which are characterised by different combinations of
endocrine tumours [177]. MEN2 is further divided in MEN2A, MEN2B and familial
medullary thyroid carcinoma (FMTC), that have medullary thyroid carcinoma as their
principal clinical characteristic [178]. In 1993, two groups studying MEN2A and FMTC
families discovered germline mutations in a proto-oncogene called rearranged during
transfection (RET ), and most of these mutations affected the same cysteine residue in
the protein [179, 180]. A year later, MEN2B was also attributed to germline mutations
in the same gene [181]. Since then, numerous studies have shown that >95% of MEN2A
patients carry mutations affecting any one of 6 different cysteine residues that result
in constitutive RET signalling, and that the MEN2B phenotype is almost exclusively
associated with two different methionine and alanine substitutions that result in protein
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conformational changes (reviewed in [182]). In contrast to tumour suppressors, which
normally require inactivation of both copies of the gene before tumourigenesis can
progress, proto-oncogenes require mutation of only one copy, as it is enough to render
them constitutively active. Since the discovery that certain cancer-prone families carry
activating mutations in RET, only a handful of other genes have been found that
predispose to cancer through gain-of-function mutations [129].
RET encodes a single-pass transmembrane receptor tyrosine kinase (RTK) that is
highly evolutionarily conserved and participates in spermatogonial stem cell mainten-
ance, kidney induction, neural crest cell migration among other biological processes
[182]. Upon co-receptor- and ligand-binding, RET autophosphorylates and activates the
mitogen-activated protein kinase (MAPK)-RAS-rapidly accelerated fibrosarcoma (RAF)
and the phosphatidylinositol-3 kinase (PI3K) pathways [183], providing a biological
explanation for the observed cancer-prone phenotype upon its constitutive activation.
RET is notorious not only for being the first proto-oncogene discovered to be implicated
in a cancer predisposition syndrome, but also because variable penetrance has been
observed depending on the amino acid affected in germline mutation carriers (reviewed in
[132]). Interestingly, RET germline loss-of-function mutations have also been observed
in patients with Hirschsprung’s disease, which is a common congenital malformation
characterised by functional intestinal blockage [132]. A small number of patients have
been observed with both Hirschsprung’s and MEN2, as they seem to carry mutations that
lead both to a decrease in RET expression and constitutive kinase activation (reviewed
in [184]).
RET has also been implicated more broadly in diverse sporadic tumour types, such as
pancreatic ductal carcinoma, invasive breast cancer and acute myeloid leukaemia (AML),
among others (reviewed in [182]). Because of its mode of action and its possible implic-
ation in several cancer types, RET constitutes an important therapeutic target. Several
small-molecule RTK inhibitors that target RET, such as vandetanib and cabozantinib,
have been tested on patients with thyroid cancers, with varying results depending on
RET germline status and the identity of the mutations (reviewed in [182]).
1.3.2.1.6 CDKN2A and CDK4 : Melanoma risk increased by mutations
in both a tumour suppressor and a proto-oncogene By 1994, the tumour
suppressor CDK4 inhibitor (INK4A, also called p16, one of the proteins encoded by the
CDKN2A locus) had emerged as an important player in human cancer development.
INK4A is an inhibitor of CDK4 and CDK6, and thus prevents G1/S transition by
34 Introduction
inhibiting RB1 hyperphosphorylation (reviewed in [185]) (Fig. 1.3a,b). Deletions in
this gene had been originally reported at high frequencies in a number of cell lines,
including those derived from melanoma, lung, bladder, leukaemia and brain cancers,
among other malignancies [186, 187]. Only two years before, a potential melanoma
predisposition locus, named MLM, had been mapped via linkage studies in melanoma-
prone kindreds to the same chromosomal location, 9p21 [188]. Several studies then
ensued that demonstrated that MLM and INK4A were the same gene and delineated
some of the predisposing mutations, which appeared to be missense in its majority [189–
192]. These mutations were later shown to impair the ability of INK4A to inhibit CDK4
and CDK6, thus providing a rationale for the cancer-predisposing syndrome observed in
carriers [193] (Fig. 1.3c).
However, not all the families that showed disease linkage to chromosome 9p21 had
mutations in INK4A, and furthermore, not all melanoma-prone families showed link-
age to 9p21. CDKN2A not only encodes INK4A, but also the structurally unrelated
alternate reading frame (ARF) (Fig. 1.3a). ARF stabilises P53 signalling and thus
suppresses growth by blocking mouse double minute 2 homolog (MDM2), an important
negative regulator of P53 (reviewed in [185]) (Fig. 1.3b). Although almost half of the
CDKN2A germline alterations in melanoma-prone kindreds affect the shared exon 2 and
thus disrupt both gene products (Fig. 1.3c), mutations affecting only ARF have been
described [196, 197], and a role for this tumour suppressor in melanoma susceptibility
is further supported by studies in mice (reviewed in [185]). Both INK4A and ARF
behave like classic tumour suppressors, with loss of the wild type allele frequently
seen in tumour cell lines and, some times, in uncultured tumours (reviewed in [198]).
These observations evidence the importance of both products of the CDKN2A locus in
melanoma susceptibility.
In some of the families that did not show linkage to the CDKN2A locus, germline
mutations were found in the gene encoding one of the INK4A-binding partners, CDK4,
two years later [199]. Mutations were found to cluster in the arginine at position 24,
displaying the properties of a proto-oncogene. Arginine 24 was shown to be important
for INK4A binding, but not for its kinase activity [199], and thus this mutation results
in constitutional CDK4 activation by preventing INK4A-mediated inhibition (Fig 1.3d).
These observations established that the functions of both a tumour suppressor and
a proto-oncogene, that cooperate in the same pathway, can be altered by germline
mutations that result in the same phenotype.
Genetic susceptibility to familial melanoma, as the subject of this dissertation, is
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Figure 1.3: Known melanoma susceptibility genes and their functions. a)
Organisation of the CDKN2A locus and its alternatively spliced products INK4A and
ARF. Both proteins are structurally unrelated, but they share exon 2. The green
rectangles depict untranslated regions (UTRs). b) Normal physiological function of the
INK4A and ARF tumour suppressors. INK4A prevents the Cyclin D-CDK4/6 (depicted
as ’4/6-D’) complex from phosphorylating RB1, and thus E2F-mediated cell cycle
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thus contributes to its stability. c) Effect on the cell cycle of a disruptive mutation
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constitutively phosphorylates RB1. Adapted from refs. [194, 195].
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further discussed in Section 1.6.
1.3.2.1.7 Other high-penetrance cancer-predisposing mutations and auto-
somal recessive inheritance of cancer predisposition Many other cancer-predisposing
genes have been discovered by diverse methodologies such as linkage studies, candidate
gene analyses and genome-wide mutation analyses (reviewed in [129]). These genes have
different inheritance patterns, penetrances, mechanisms of disease (requiring biallelic
inactivation or showing haploinsufficiency or dominant-negative effects, or constitutive
activation in the case of proto-oncogenes) and participate in a diverse array of biological
processes, such as cell cycle regulation and DNA repair (reviewed in [129]). Other
examples of autosomal-dominant inheritance of cancer predisposition are Cowden syn-
drome, caused by germline mutations in PTEN, von Hippel-Lindau disease, caused by
alterations in the eponymous VHL, and juvenile polyposis, caused by mutations in the
SMAD4 and BMPR1A genes (reviewed in [132]).
There are other cancer predisposition syndromes that are inherited in an autosomal-
recessive manner. Examples of these are ataxia telangiectasia (A-T), caused by germline
mutations in ATM, Nijmegen breakage syndrome (NBS), caused by mutations in nibrin
(NBN ), and the Bloom (BS) and Werner (WS) syndromes, caused by mutations in
the DNA helicase genes BLM and WRN, respectively. All of these syndromes are
characterised by telomere abnormalities and genomic instability (reviewed in [200]).
1.3.2.2 Polygenic model of cancer risk inheritance
Studies of cancer-prone families carrying deleterious alleles of some of the genes men-
tioned in Section 1.3.2.1 suggested that additional genetic components might be involved
in the aetiology of their cancers, albeit with lower or modifier effects. For example,
although specific mutations in RET can distinguish MEN2A and FMTC from MEN2B,
they cannot distinguish between MEN2A and FMTC, suggesting that other genes might
play a role in predisposition to these syndromes [133, 182]. Additionally, only about a
fifth of the total clustering of familial breast cancer is observed in families carrying a
predisposing BRCA1 or BRCA2 mutation, but diverse twin and familial studies suggest
that genetic components are significant in the aetiology of the remaining families [123].
In fact, a polygenic risk model was found to best describe the distribution of breast
cancer not due to BRCA1 or BRCA2 mutations in a population-based series, with the
quintile most at risk showing 40-fold higher risk than the quintile least at risk [201].
Similar conclusions have been reached in other studies (reviewed in [123]) (Fig. 1.4).
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Figure 1.4: Polygenic model of the distribution of cancer risk in the population
and in individual cases. Models of cancer risk that take into account several
predisposition loci with small effects have been found to fit observed population-based
data. Cases show an enrichment of high-risk alleles when compared to the rest of the
population. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews
Cancer ([122]), copyright (2010).
Two models for polygenic predisposition to cancer have been formulated. The first
of these, comprising common low-penetrance alleles predisposing to common cancers,
is practically impossible to explore using linkage or candidate gene approaches, and
thus GWAS have been carried out to compare allele frequencies in cases and controls.
These common alleles are thought to have arisen once during evolution, and thus can
be marked and genotyped in large numbers of cases and controls with high-density SNP
arrays [123]. GWAS have been successful at pinpointing more than 200 low-penetrance
genomic regions that influence cancer risk (reviewed in [134]), but identifying the causal
alterations within these regions remains a daunting task. The second model involves
rare alleles with moderate effects that are thought to have arisen recently or multiple
times during evolution, and thus cannot be marked by SNPs in the vicinity. Several
examples of these alleles have been found principally in breast cancer, such as variants
in CHEK2, BRCA1 -interacting protein C-terminal helicase 1 (BRIP1 ) and partner and
localiser of BRCA2 (PALB2 ) (reviewed in [122]).
In conclusion, human cancers originate from complex interactions between environ-
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mental and genetic components. Environmental factors can be behavioural in nature,
such as alcohol drinking and smoking, occupational, such as exposure to asbestos or coal
tar, or naturally prevalent, such as solar radiation and outdoor air pollution. Although
the majority of cancers arise from environmental effects, it is estimated that up to a
quarter of all human cancers have a major genetic component. Genetic predisposition
to cancer can display Mendelian inheritance, when single genes account for the majority
of the inherited cancer risk. Autosomal dominant conditions require only one mutated
allele to confer an elevated cancer risk, and these can be caused by mutations in
tumour suppressor genes (e.g., TP53 or CDKN2A) or in proto-oncogenes (e.g., RET
and CDK4 ). Autosomal recessive cancer-predisposing conditions also exist, such as A-
T, NBS, BS and WS. However, the majority of the genetic risk for cancer is thought to
arise from the additive or multiplicative effects of many genes with small effects, and in
support of this hypothesis, polygenic models of cancer predisposition have been found
to explain observations made in population-based series.
In the remaining sections of this introduction, I focus on the particular cancer I
studied during my PhD, melanoma. I cover its biology, classification and presentation,
its risk factors, the melanoma genome, and unanswered questions in melanoma genetics.
1.4 Melanoma: Facts, origin and biology
Melanoma is a malignancy arising from melanocytes, the pigment-producing cells in our
skin. Even though it accounts for less than 2% of all dermatological cancer cases, it
causes more than 75% of skin cancer-related deaths [202]. Over the last thirty years,
its incidence has increased more rapidly than that of any other common cancer in the
UK (Fig. 1.5) [110]. Some of this effect is perhaps due to better surveillance and
improved detection methods and diagnosis criteria, but the majority is thought to be
real and linked to changes in sun-related behaviour, and has been reflected, for example,
in the increase in popularity of holiday packages in lower latitudes and sunbed usage
[110]. This increase means that malignant melanoma is now the fifth most commonly
diagnosed cancer in the UK, and is projected to become as common in the US by 2030
[203, 204].
The great majority of melanomas are diagnosed at an early stage, in which case
the 5-year survival rates are high (~95% for young adults and ~90% for older people)
[206, 207]. However, melanoma diagnosed at a metastatic stage is highly aggressive and
resistant to chemotherapeutic treatment [208, 209], and the 5-year survival rates decline
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to ~60% and ~15% for regional and distant metastatic disease, respectively [202]. These
effects are thought to arise from particular melanocyte biology properties, which I review
in the next subsection.
1.4.1 Melanocytes: How they originate, where they reside, what
they do
Melanocytes are specialised cells that synthesise melanin, a biopolymer that has various
roles in cellular protection against damaging stimuli. Almost all melanocytes are derived
from the neural crest, which is a transient embryonic cell population that can migrate
extensively and give rise to numerous cell types, including much of the peripheral nervous
system (reviewed in [210]). The exception are those melanocytes that constitute the
retinal pigment epithelium (RPE), which are derived from the neuroepithelium [211].
The neural crest is formed during the embryonic process of neurulation, when the
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neuroectoderm (at the outermost of the three germ cell layers) is transformed into the
neural tube (Fig. 1.6a). Cells at the border between the neural and non-neural ectoderm
dissociate and induce the epithelial-mesenchymal transition (EMT), allowing them to
migrate out of the neuroepithelium [210]. These migrating cells are initially multipotent
but they become gradually lineage-restricted depending on anatomical location (reviewed
in [212]). The moment at which neural crest cells become committed to the melanocytic
lineage (after which point they are called melanoblasts) is open for discussion [213],
but they do so before reaching their final destination in the developing embryo [214].
Melanoblasts migrate mainly dorsolaterally, and settle principally in the epidermis,
dermis, hair follicles and the inner ear cochlea [215].
During their migration process, melanoblasts rely on the Notch and Wnt signaling
pathways for lineage commitment [212], and express several genes essential for their
survival, such as paired box 3 (PAX3 ), sex determining region Y-box 10 (SOX10 ),
microphthalmia-associated transcription factor (MITF ) and v-kit Hardy-Zuckerman 4
feline sarcoma viral oncogene homolog (KIT ) [217, 218] (Fig. 1.6b). In line with their
functions in the developing melanocyte, defects in these genes underlie piebaldism and
the Waardenburg and Tietz syndromes, which have in common pigmentation defects
(reviewed in [219]).
Having reached their target site, melanoblasts differentiate into melanocytes by up-
regulating genes important for the production of melanin, such as tyrosinase (TYR),
tyrosinase-related protein 1 (TYRP1 ) and dopachrome tautomerase (DCT ), mainly
driven by MITF (reviewed in [214]) (Fig. 1.6b). Although the production of melanin
(known as melanogenesis) is widely considered to be the most important function of
melanocytes, it is by no means the only one, as these cells also have important sensory
and immunological roles [220, 221]. They also participate in eye organogenesis and
vision, hearing and possibly cardiac functions, depending on their anatomical location
[211]. As such, melanocytes can be described as “classical”, which are those found in the
skin and contribute to its pigmentation, and “non-classical”, which are those found in all
other parts of the body [211].
1.4.1.1 Classical melanocytes
The skin is divided into three layers: The hypodermis, which consists of fatty tissue
and connects the skin with underlying tissues, the dermis, which consists of connective
tissue and fibroblasts and houses the lymphatic, neural, vascular and secretory systems
in the skin, and the epidermis, the outermost layer [222]. The epidermis can be further
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divided into four layers, which, in order from innermost to outermost, are known as the
basal, spinous, granular and cornified layers [222]. Classical melanocytes can be found
in the dermis or in the basal layer of the epidermis (Fig. 1.7).
Epidermal melanocytes are dynamic cells, with dendritic projections that they use to
communicate with keratinocytes and Langerhans cells, thus mediating their pigmenta-
tion and immune functions [211, 224]. The interactions between epidermal melanocytes
and keratinocytes constitute the basis of the epidermal melanin unit, a complex that
coordinates the production and distribution of melanin and is capable of responding
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rapidly to a large array of environmental stimuli [222]. It has been calculated that each
epidermal melanocyte is in contact with about 30 keratinocytes [211], thus being able
to distribute melanin upon a large area when required.
Within the epidermis, melanocytes can be located in the papillary bulbs of hair
follicles or can be distributed in inter-follicular space. Inter-follicular melanocytes rarely
undergo cell division [225], but those in hair follicles are able to proliferate and are in-
volved in hair pigmentation and in the purging of toxic byproducts of melanin production
[211].
Dermal melanocytes do not interact with keratinocytes, as they are surrounded by
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fibroblasts. They are present in very small numbers, and although they are capable of
producing melanin, little is known about their function [211].
1.4.1.2 Non-classical melanocytes
Non-classical melanocytes are present in many different locations, such as the eye, the
inner ear, the heart, the brain and in adipose tissues, and do not generally contain large
amounts of melanin, although some exceptions exist [211]. Melanocytes in the eye can
be part of the RPE, in which case they play an essential role in retinal function and
visual acuity, or be located in the uvea, where they contribute to its development and are
responsible for iris coloration [211]. Melanin produced by the RPE is crucial for neural
retina development, and can protect it from ROS, thus preventing age-related macular
degeneration, whereas that produced by uveal melanocytes contributes to protection
from oxidative damage related to their location in a densely vascularised section of the
eye [211]. Otic melanocytes can be found in the cochlea or the vestibular organ, in which
they are necessary for normal hearing functions and might also participate in balance
perception [211, 226]. Cardiac melanocytes have only recently been described [227]; they
do not appear to transfer melanin to surrounding cells [228] and are not essential for
normal cardiac function, so their contribution in the heart remains unclear [211]. Brain
melanocytes are mainly located in the leptomeninges, which are the innermost tissue
layers that cover the brain [229]. It has been suggested that these melanocytes may aid
in sequestering toxic compounds from the circulation and participate in neuroendocrine
functions, although their physiological role has not been clarified [211, 226]. Melanocytes
that reside in adipose tissue have been found to synthesise melanin at much higher levels
in obese people than in controls, and it is thought that they might help to neutralise
ROS and cellular fat deposition present in these patients [211].
In summary, the majority of melanocytes originate from the neural crest, a multi-
potent embryonic cell population that also gives rise to much of the peripheral nervous
system; however, melanocytes in the RPE differ in that they originate from the neur-
oepithelium. Melanocytes can be classified according to their anatomical location,
with “classical” melanocytes being those that populate the skin (and thus have been
extensively studied) and “nonclassical” melanocytes being those residing in all other parts
of the body. Melanocytes contribute importantly to organ development and function,
but melanin biosynthesis is widely considered to be their most important task. In the
next paragraphs, I review the melanin biosynthetic pathway, as well as the specialised
organelles in which it takes place, the melanosomes.
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1.4.1.3 Melanosomes and melanin biosynthesis
Melanins are important biopolymers that determine the most obvious phenotypic char-
acteristic in human and other vertebrates, skin colour, and have an essential role in
protecting the body against harmful UV radiation and other environmental challenges
[222]. Melanins can be divided in two main groups: eumelanins, which are dark brown
or black, and phaeomelanins, which are lighter or yellowish. Eumelanins are insoluble
and participate in various protective functions, being able to oxidise and reduce other
molecules, bind diverse metal ions, and absorb the most hazardous components of solar
radiation (reviewed in [230]). Phaeomelanins have poor protective properties as they
are photolabile at physiological conditions, and thus might even increase phototoxicity
[231].
The pathway for melanin synthesis is the same for all melanocytes, although some
types of melanocytes display particularities. For example, although melanin synthesis
generally occurs in specialised organelles called melanosomes, it happens in the cytosol of
melanocytes that reside in adipose tissue [211]. Additionally, dopaminergic neurons are
able to synthesise a pigment related to melanin, termed neuromelanin, that appears to
have similar properties but may arise from a different non-enzymatic synthesis pathway
[232]. Also, the timing of melanosome generation and melanin biosynthesis can differ
significantly, for example, skin melanocytes produce melanosomes throughout life but
the RPE synthesises melanin only during embryonic and early post-natal life [211]. Non-
etheless, the majority of melanocytes carry out the synthesis of melanin in melanosomes
and express a common set of catalysing enzymes.
Melanosomes are membrane-bound, lysosome-related organelles that possess the
conditions and proteins required for melanin synthesis, and that prevent toxic byproducts
associated with its production from harming other cellular components [233]. Melano-
some development is generally divided into four stages, termed I-IV (Fig. 1.8). Stage
I melanosomes probably originate from the endoplasmic reticulum, and possess an
amorphous matrix and internal vesicles. Premelanosome protein (encoded by PMEL)
is then transferred to stage I melanosomes and aids in transforming them into fibrillar,
elongated organelles with TYR activity, now termed stage II melanosomes. Pigment
synthesis starts in stage III melanosomes, which accumulate melanin in their fibrillar
matrix. Finally, when they become fully pigmented they are termed stage IV melano-
somes, at which point they are ready for transfer to neighbouring cells (reviewed in
[226, 233, 234]).
Proteins necessary for melanosome structure and function are delivered to these
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Figure 1.8: Stages of melanosome maturation. a) Diagram of a portion of
a melanocyte body and dendrite. All stages of melanosome maturation are shown,
alongside other relevant organelles. The degree of melanisation is indicated by black.
b) Electron micrograph of melanosomal stages II, III and IV are shown. Reprinted
by permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell Biology
[235], copyright (2001).
organelles throughout their maturation process, PMEL early and TYR, TYRP1 and
DCT during the late stages [233]. The last three enzymes are required for melanin
production, and therefore their malfunction or absence underlies distinct oculocutaneous
albinism syndromes [222].
Biosynthesis of both eumelanins and phaeomelanins start with the hydroxylation
of L-tyrosine to form L-3,4-dihydroxyphenylalanine (L-dopa), a reaction catalysed by
TYR, and which is the rate-limiting step in melanin synthesis. The same enzyme then
is able to oxidise L-dopa to L-dopaquinone, the last common step in the synthesis of
dark and light pigments (see proximal phase, Fig. 1.9).
In eumelanin synthesis, L-dopaquinone yields L-dopachrome in a series of spontan-
eous chemical reactions, which then can form different precursors of dark pigments,
such as 5,6-dihydroxyindole (DHI) and DHI-2-carboxylic acid (DHICA). These com-
pounds then undergo spontaneous polymerisation reactions to form black and insoluble
eumelanin (DHI-melanin) and brown, somewhat soluble eumelanin (DHICA-melanin).
DCT and TYRP1 participate in the processing of L-dopachrome to these eumelanin
precursors (reviewed in [236]) (see distal phase, Fig. 1.9).
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Phaeomelanin synthesis is preferred if compounds such as L-cysteine or reduced
glutathione are present. In this case, L-dopaquinone reacts with the thiol group in
these compounds to form a complex mixture of intermediates, of which 5-cysteinyldopa
is thought to be the most abundant. This compound then is hypothesised to un-
dergo dehydration and several structural rearrangements to yield an alanyl-hydroxy-
benzothiazine monomer, which is thought to be the monomeric subunit of phaeomelanin
(Fig. 1.9). However, the phaeomelanin synthesis pathway is poorly understood, and thus
could proceed via different and more complex intermediaries [236].
Figure 1.9: Melanin biosynthesis pathway. For simplicity, the pathway can be
divided into the proximal phase, that contains the tyrosinase (TYR)-catalysed reactions,
and the distal phase, that contains the subsequent reactions. In eumelanin synthesis, L-
dopaquinone may form L-cyclodopa before this compound is spontaneously oxidised to
L-dopachrome. IQ: 5,6-indolequinone and IQCA: indole-2-carboxylic acid-5,6-quinone
are oxidation products from DHI and DHICA, respectively, and can be precursors for
eumelanins. The silver locus, named after the mouse phenotype, encodes in humans
the PMEL protein. Reproduced by permission from John Wiley & Sons, ref. [236],
copyright (2011).
Melanocytes respond to different environmental challenges by producing melanin.
Upon UV radiation, both melanocytes and keratinocytes increase their expression of
the proopiomelanocortin (POMC) protein, which is then processed to different pep-
tides, including α-melanocyte stimulating hormone (α-MSH) and adrenocorticotropin
(ACTH). These peptides can bind the melanocortin 1 receptor (MC1R) on the surface of
melanocytes and increase MITF expression through a pathway involving cyclic adenosine
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monophosphate (cAMP), protein kinase A (PKA) and the cAMP response element
binding protein (CREB) [222, 237]. The epidermal melanin unit can also respond to
other environmental stimuli such as physical pressure, growth factors or cytokines [222,
238]. Keratinocytes also produce and secrete other factors that stimulate melanocyte
dendricity and melanin synthesis, such as endothelin 1 (EDN1), colony-stimulating factor
2 (CSF2), prostaglandins E2 and F2α, leukaemia inhibitory factor (LIF), KIT ligand
(KITLG), fibroblast growth factor 2 (FGF2) and the hepatocyte and nerve growth
factors (HGF and NGF respectively) (reviewed in [222, 225]). These factors bind to
different receptors in the surface of melanocytes and signal down different but cross-
talking biological pathways, stimulating melanogenesis, dendrite formation, proliferation
and differentiation [222] (Fig. 1.10).
1.4.1.4 Implications of the melanocyte lineage in melanoma treatment
The embryonic origin of melanocytes and their function offer some clues as to the
aggressiveness and resistance of melanoma. For example, it has been shown that human
primary melanocytes become metastatic when transfected with a specific set of genes,
but not other cell types, indicating that at least a part of the characteristic aggressiveness
of melanoma can be attributed to melanocyte lineage-specific factors [240]. In human
benign naevi, the transcription factor snail family zinc finger 2 (SNAI2), that strongly
contributes to EMT during neural crest migration [241], has been shown to be expressed
along with other neural crest cell migration-associated genes [240]. Additionally, other
studies have shown that melanoma cells exploit lineage-specific RTKs or transcription
factors to promote their plasticity and metastatic potential [242, 243]. These observa-
tions might indicate that melanocytes are predisposed to acquiring invasive properties,
thus necessitating fewer alterations to metastasise than other tissue types.
Additionally, melanocyte function may help explain why melanoma is highly resistant
to chemotherapeutic treatment. Many chemotherapeutic drugs approved or being tested
for treating melanoma, such as dacarbazine [244], temozolomide [245] and cisplatin [246],
exert at least part of their function by inducing DNA damage and thus triggering cell
cycle arrest or cell death [247, 248]. Given the crucial role that melanocytes have in pro-
tecting our skin against damage caused by UV radiation, they have developed powerful
anti-apoptotic mechanisms that contribute to their intrinsic resistance to DNA damage
and cell death [215]. Lineage-specific factors, such as MITF and KIT, are thought to play
a role in activating anti-apoptotic genes such as B-cell chronic lymphocytic leukaemia
(CLL)/lymphoma 2 (BCL2 ), although the mechanisms of melanoma chemoresistance
48 Introduction
II
III IV
MC1R
TYR
TYRP1
TYRP2
L-tyrosine
L-tyrosine
L-phenylalanine
Melanosome
Actin
Survival
Apical
cap
KITLG
EDNRB
ER
Golgi
c-KIT
Dendrite
KITLG
EDN1
EDN1 POMC
ACTH & -MSH
Keratinocyte
Melanocyte
DNA
damage
UV radiation
I
MITF
TYR
Bcl-2 SOX10 CREBPAX3
TYRP1
TYRP2
MITFMITF
PP
P
Figure 1.10: Interactions between keratinocytes and melanocytes. Schematic
diagram of a melanocyte (left) and a keratinocyte. Upon UV radiation, keratinocytes
produce factors that stimulate melanin production in melanocytes. These factors can,
via signalling pathways, stimulate the trascription of genes important for survival and
melanin synthesis. These gene products are then shipped to melanosomes, which upon
maturation are transferred to keratinocytes where they contribute to DNA protection.
Figure reproduced, with some modifications, from ref. [239].
remain controversial [215, 249]. Some authors have described melanocytes as cells
that are “born to survive” [249, 250], and indeed, this seems to be the case given the
low success rate of treatments for metastatic melanoma, making it one of the most
challenging cancers to treat [251].
But how can a benign melanocyte give rise to one of the most aggressive and resistant
human cancers? In the following paragraphs, I address the different models and theories
that attempt to explain the transition from a benign melanocyte to malignant melanoma.
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1.4.2 From melanocytes to melanoma: Different models of dis-
ease progression
It has been estimated that about three quarters of all melanomas arise from de novo
melanocyte transformation, and the rest from pre-existing naevi [215, 252]. In both of
these distinct paths to malignancy, changes in skin morphology are associated with a
series of underlying molecular events.
1.4.2.1 The Clark model: Naevi become malignant
In 1984, Wallace Clark Jr. and colleagues described a step-wise model for the devel-
opment of malignant melanoma from common naevi [253]. Naevi in the skin normally
have an activating mutation in either v-raf murine sarcoma viral oncogene homolog
B (BRAF ) or neuroblastoma RAS viral (NRAS ), which promotes growth by hyper-
activation of the MAPK signalling pathway [254, 255] (Fig. 1.11). However, naevi
rarely progress towards cancer, as oncogene-induced senescence is triggered and tumour
suppressors such as INK4A (Fig. 1.3) and PTEN are up-regulated [256, 257]. However,
this oncogene-induced senescence can be overridden by additional mutational events,
sometimes in INK4A or PTEN themselves, and thus benign naevi can progress towards
a dysplastic state (Fig. 1.11). As discussed in Paragraph 1.3.2.1.6, families with
inactivating mutations in INK4A are predisposed to familial melanoma, perhaps because
naevi progress more easily to the dysplastic state, whereas in sporadic cases the loss of
PTEN is a more common alteration [258].
Additional mutational events might then affect MITF, although its role in melanoma
progression is varied. In 10-20% of samples, MITF is found amplified, an event that
is associated with worse prognosis. Although MITF is associated with melanocyte
differentiation, it is thought that it confers a growth advantage to cells by cooperating
with BRAF activation to transform them, thus being able to function as an oncogene
[259]. Other samples have been found where MITF and its targets are down-regulated,
suggesting that there are different subsets of melanoma with different MITF activities
(reviewed in [260]). Amplification of cyclin D1 (encoded by CCND1 ) is also a marker of
some acral melanomas, in which its inhibition has been shown to cause apoptosis [258]
(Fig. 1.11). This phase, referred to as the radial growth phase, is characterised by an
ability of melanocytes, now immortalised, to proliferate intradermally. The transition
to the vertical growth phase, in which melanocytes gain the ability to invade the dermis
and form tumours, is characterised by a loss of cell adhesion markers and the expression
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Figure 1.11: The Clark model for the progression from naevi to malignant
melanoma. The hyperplastic and dysplastic phases (originally described as separate
stages) are drawn together in this figure. Molecular events associated with each stage
are in the bottom panel. Figure adapted from ref. [258].
of integrin αVβ3, baculoviral inhibitor of apoptosis domain repeat containing 5 (BIRC5)
and matrix metallopeptidase 2 (MMP2), which contribute to survival and degradation
of the collagen in the basal layer of the epidermis (reviewed in [258]). It has been also
observed that the level of telomerase activity correlates well with tumour clinical stage,
with higher levels of tumour cell penetration having higher telomerase activity [261].
Finally, melanocytes that have gained the ability to colonise other tissues, thus giving
rise to malignant melanoma, commonly have a reduction or absence of expression of
transient receptor potential cation channel, subfamily M, member 1 (TRPM1), a target
of MITF. Although its function is not completely clear, this gene has been hypothesised
to function as a tumour suppressor by comparison to other members of its family [262]
(Fig. 1.11).
Many models of melanoma progression have been based on Clark’s initial description
of the melanoma stages, and thus is widespread in melanoma research community [263].
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However, this view has been challenged by the observation that melanocytes within a
naevus are not monoclonal as the Clark model would suggest, and the realisation that
most melanomas arise in normal skin, not in association with an existing naevus [263].
Thus, an alternative model for the origin of malignant melanoma, aiming to explain how
the majority of these cancers arise, has recently been put forward.
1.4.2.2 De novo progression from melanocytes to melanoma
Recently, Minoru Takata and colleagues proposed an alternative model for melanoma
progression that does not pass through the dysplastic naevus stage and thus is different
from Clark’s [263]. They proposed that a yet unidentified hit might cooperate with the
inactivation of INK4A or over-expression of cyclin D1 or CDK4, therefore allowing the
cell to bypass oncogene-induced senescence. The acquisition of an activating mutation in
BRAF would come after this first hit, resulting in clonal proliferation and thus yielding
the BRAF mutation heterogeneity observed in naevi. Activation of telomerase and
additional hits in late stages might be similar to those in cancers arising from benign
naevi. Therefore, the order of mutational events might determine whether a melanoma
arises from a pre-existing naevus or de novo [263]. This hypothesis is supported by
observations made in acral and mucosal melanoma, in which cyclin D1 amplification
arises frequently as a founder event, followed by oncogene activation, normally KIT
[263].
At least one mouse model has been developed in an effort to recapitulate de novo
disease progression. Mayuko Kumasaka and colleagues achieved de novo malignant
melanoma formation in endothelin receptor B (Ednrb)-heterozygous mice constitutively
expressing the RET oncoprotein [264]. This model could reproduce some characteristics
of the human disease, such as the late age of onset, poor prognosis and high percentage of
metastases, and, coupled with the observation that melanoma risk is increased in patients
with EDNRB loss-of-function mutations [265], could provide a molecular rationale for
the development of de novo malignant melanoma.
In summary, there seem to exist different paths to malignancy, with the majority of
melanomas arising de novo but some arising from pre-existing naevi. This distinction
might arise from the order in which important players for melanoma progression are
somatically altered, but the lesions involved in both cases (e.g. senescence bypass, on-
cogene and telomerase activation and down-regulation of adhesion markers) are thought
to be similar.
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1.4.3 Clinical classification and staging systems
The models described above attempt to describe how melanocytes progress from a
benign to a malignant state. Researchers have also classified melanoma in different types
depending on the microscopic growth patterns of these lesions and have created diverse
staging systems to aid treatment choice when diagnosing patients. In this Subsection,
I review the recognised types of melanoma and the diverse systems used in diagnostic
settings.
1.4.3.1 Types of melanoma
Clark not only defined the stages that a benign naevus had to progress through to
become a malignant tumour, but also classified melanoma according to the microscopic
growth patterns of these lesions [266]. He and his team divided it into four broad
main types: superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM),
nodular melanoma (NM) and acral lentiginous melanoma (ALM) [263, 267] (Fig. 1.12).
A B
C D
Figure 1.12: Types of melanoma. a) Superficial spreading melanoma, b) Nodular
melanoma, c) Lentigo maligna melanoma and d) Acral lentiginous melanoma. Panels a,
b and d reproduced from ref. [209] under a Creative Commons CC BY-NC 4.0 license.
Panel c taken from the Skin Cancer Foundation, and reproduced by [268].
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SSMs constitute about 70% of all invasive melanomas, and are characterised by
melanocytes expanding upward within the epidermis and radially in its basal layer. They
display variation in pigmentation and the majority occur de novo [267, 269]. LMMs
evolve from lentigo maligna, a lesion that occurs on sun-exposed skin of older patients,
although the progression is rare and slow. They are considered to be at the earliest
stage of melanoma (see Paragraph 1.4.3.2.3), and are characterised by a proliferation of
abnormal melanocytes along the basal layer of the epidermis [267, 270]. NMs are the
second most common subtype of melanoma, comprising 10-15% of cutaneous melanomas,
and are more aggressive than SSMs. They occur more commonly in sun-exposed areas of
the skin, and present as expanding, darkly pigmented nodular lesions [271, 272]. ALMs
present in palms and soles, and are the most common manifestation of melanoma in
people of Black ancestry. They are highly aggressive, and present as darkly pigmented
patches with varying degrees of pigmentation that expand rapidly [267, 273, 274].
Other types of melanoma have been identified that do not conform to the typical
classification system. The IARC recognises, apart from the types mentioned above, des-
moplastic melanoma (DM), melanoma arising from blue naevi (BN), melanoma arising
from giant congenital naevi (GCN), childhood melanoma, naevoid melanoma and per-
sistent melanoma [275]. DMs are superficial melanocytic lesions in which malignant cells
are separated by fibrous stroma or collagen fibres, and can present cellular abnormalities.
Melanomas arising from BN, which owe their colour to their deep position within the
epidermis, are exceedingly rare and seem to be highly metastatic. GCN are large lesions
that commonly cover more than 2% of the body surface, and are direct precursors to
melanoma. Indeed, about 6% of GCN progress to malignancy, and the tumours are
commonly sharply demarcated and characterised by asymmetry. Childhood melanoma
comprises melanomas that develop in individuals before they reach puberty. Their
incidence is quite low, and their clinical features are similar to melanomas arising in
adults. Naevoid melanomas are also rare, and are distinctive because they resemble
common intradermal naevi, but with the potential to metastasise. Persistent melanomas
are those that grow out of primary lesions that have been excised, and normally have
the same epidemiological and etiological characteristics as the primary tumour they are
derived from [275].
Because of the heterogeneity in melanoma lesions and the existence of tumours
that do not conform to the above classification system, John Curtin and colleagues
proposed in 2005 an alternative classification in which melanoma types could potentially
be distinguished not by histological characteristics but by molecular signatures [276]. As
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such, characteristics such as the number of DNA copies, gains in the CCND1 locus or
mutations in BRAF or NRAS in a sample were able to accurately distinguish among
acral melanomas, mucosal melanomas or melanomas on skin with or without chronic
sun-induced damage [276]. Melanomas with and without chronic sun-induced damage
roughly correspond to LMM and SSM, respectively, and acral melanoma to ALM in
Clark’s classification [263].
These distinct types of melanoma and their associated molecular events reveal a
glimpse of the complexity of melanoma aetiology, indicating that diverse biological
pathways can be altered in different ways in melanoma development, depending on
characteristics such as anatomical site, amount of sun exposure, age and ancestry.
1.4.3.2 Melanoma staging systems
Different staging systems have been developed to describe tumour depth and the amount
of spreading to other parts of the body. These are routinely utilised by medical doctors
and researchers when diagnosing a patient and recommending treatment procedures.
1.4.3.2.1 Clark levels Tumour depth had been known to inversely correlate with
prognosis, which inspired Clark to propose, in 1969, a 5-level classification system to
score tumour depth [277] (Table 1.1).
Table 1.1: Clark levels used to score tumour depth.
Clark level Description
Level I All tumour cells are above the basal layer of the epidermis
(melanoma in situ)
Level II Tumour cells have broken into the papillary dermis
Level III Tumour cells have reached the junction between the papillary and
reticular dermis
Level IV Tumour cells have invaded the reticular dermis
Level V Tumour cells have spread into the subcutaneous tissue
Clark levels were used as the main tumour staging determinant in the American
Joint Committee on Cancer (AJCC) staging system of 1997, but following studies that
demonstrated that they only held independent predictive value for thin melanoma lesions
(T1 stage, see Table 1.2), the AJCC revised their classification system in 2001 to restrict
their assessment to this type. This recommendation has stayed the same for the last
release of their classification system, in 2009 [278, 279].
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1.4.3.2.2 Breslow thickness Around the same time that Clark published his clas-
sification system, the pathologist Alexander Breslow also published a paper arguing that
melanoma lesions had to be scored on tumour thickness as this factor, along with Clark’s
level, seemed to correlate well with prognosis [280]. Tumour thickness is measured by
determining the depth of invasion from the skin surface to the farthest malignant cell,
usually by a pathologist examining a lesion under the microscope. Breslow thickness
is still used as the main determinant of tumour staging, according to the 2009 AJCC
melanoma staging system [279] (Table 1.2).
Table 1.2: Breslow thickness measurements used by the 2009 AJCC melanoma
tumour staging system. Tis stands for tumour in situ, where cells are confined to
the top layer of the epidermis. Modified from ref. [279].
Tumour stage Breslow thickness (millimetres)
Tis Not applicable
T1 ≤ 1.00
T2 1.01-2.00
T3 2.01-4.00
T4 > 4.00
1.4.3.2.3 TNM scale The TNM classification is the main cancer staging system
in use, and the most recent guidelines for melanoma were published by the AJCC in
2009 [279]. T stands for tumour size, N for the number of metastatic nodes, and
M for the number of distant metastases. Each of these can be further subdivided
to indicate characteristics such as whether ulceration is present, the amount of nodal
metastatic burden and the site where metastases are present (Table 1.3). As such, this
system utilises the Clark levels and Breslow thickness to aid in defining tumour stage
and prognosis. The TNM stages include the most important parameters that retain
individual prognostic value, and thus are the most important indicator of probability of
survival [279] (Fig. 1.13).
1.4.3.2.4 Melanoma diagnosis: The ABCDE acronym In 1985, the mnemonic
“ABCD” was created and published by three medical doctors to aid both healthcare
professionals and the public in the early diagnosis of malignant melanoma [281]. Its
main idea is that naevi that present the ABCD criteria should be examined closely;
A stands for asymmetry, B for border irregularity, C for colour variegation and D for
diameter larger than 6 millimetres (mm). More recently, a fifth criterium, E (evolving),
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Table 1.3: Most recent pathologic stage categories for cutaneous melanoma as
determined by the AJCC. Tumour thickness (T) stages are as described in Table 1.2,
with the letters a and b indicating the absence and presence of ulceration, respectively.
The number of metastatic nodes (N) are scored as follows: N0, not applicable, N1, 1
metastatic node, N2, 2 or 3 metastatic nodes, and N3, 4 or more. The letters a, b and c
indicate micrometastases, macrometastases and in transit metastases, respectively. M0
and M1 refer to the absence and presence of distant metastases, respectively. Reprinted
with permission from ref. [279]. © (2009) American Society of Clinical Oncology. All
rights reserved.
Stage T N M
0 Tis N0 M0
IA T1a N0 M0
IB T1b N0 M0
T2a N0 M0
IIA T2b N0 M0
T3a N0 M0
IIB T3b N0 M0
T4a N0 M0
IIC T4b N0 M0
IIIA T1-4a N1a M0
T1-4a N2a M0
IIIB T1-4b N1a M0
T1-4b N2a M0
T1-4a N1b M0
T1-4a N2b M0
T1-4a N2c M0
IIIC T1-4b N1b M0
T1-4b N2b M0
T1-4b N2c M0
IV Any T Any N M1
was added to recognise the dynamic nature of melanoma and to aid in identifying lesions
that might not conform to the ABCD rule, such as NMs [282]. The ABCD rule has been
found useful in recognising early lesions [283, 284], and due to its simplicity, continues
to be widely used and promoted.
As described in this Section, the different types of melanoma, their progression
through different disease stages and their resistance mechanisms are associated with
genomic lesions such as activation of KIT, NRAS or BRAF, or inactivation of CDKN2A
or PTEN, among others. In the next section, I review the current knowledge regarding
the human melanoma genome, including known driver mutations (i.e., those that confer
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Figure 1.13: Survival curves from the AJCC Melanoma Staging Database
grouped by TNM stage. The AJCC analysed data from 30,946 patients with Stage
I-III melanoma, survival curves grouped by TNM stage over a 20-year period are shown.
a) Stages I and II. b) Stage III. Reprinted with permission from ref. [279]. © (2009)
American Society of Clinical Oncology. All rights reserved.
a fitness advantage to the carrier cell) and mutational signatures.
1.5 The human melanoma genome
Since the discovery of BRAF-activating mutations in almost 70% of human melanomas
[285], somatically-acquired aberrations in the MAPK signalling pathway have been
intensely studied. Overall, the great majority of melanomas have MAPK pathway
dysregulation, with 15% of melanomas acquiring activating RAS mutations in a BRAF
mutually-exclusive manner [258, 286]. Curtin and colleagues found that activating
mutations of the MAPK pathway seemed to be less common in melanomas with chronic
sun damage and non-cutaneous melanomas, and in general, that distinct subsets of
genetic alterations were present depending on the type of melanoma [276]. Additionally,
traditional BRAF or NRAS activating alterations are not C-to-T transitions, which are
typically induced by UV radiation (see Subsection 1.3.1.5) [287]. These observations
indicate that UV exposure significantly affects melanoma progression, possibly through
the mutation of other oncogenic pathways.
In the last five years, the human melanoma genome has been intensely investigated
using WGS, WES and exon capture methodologies. Two large studies analysing the
somatic mutation frequency in more than 25 cancer types agreed that melanoma has
the highest mutational burden across all of them, principally due to the ubiquitous
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presence of C-to-T transitions [288, 289] (Fig. 1.14). This elevated mutational rate
therefore can act as a confounding factor when attempting to uncover melanoma driver
mutations.
Despite these difficulties, several studies have described many genomic events con-
tributing to melanomagenesis or tumour progression. The majority of these mutations,
that have been classified as drivers according to different criteria (e.g., mutation fre-
quency across samples, reduction of tumour fitness upon gene silencing or tumour
progression upon ectopic gene expression), affect signalling pathways important for cell
proliferation and migration. As such, somatically-aquired mutations resulting in MAPK
pathway activation other than BRAF or RAS have been identified, such as gain-of-
function events in glutamate receptor metabotropic 3 (GRM3 ) [290], MAPK kinase 1
(MAP2K1 ), MAP2K2 [291], and v-erb-b2 avian erythroblastic leukaemia viral oncogene
homolog 4 (ERBB4 ) [292]. Additionally, loss-of-function events in MAPK kinase kinase
9 (MAP3K9 ) and MAP3K5 have been found to decrease MAPK signalling but increase
drug resistance [293].
The PI3K pathway also plays a key role in melanoma progression. Activating
mutations in NRAS and loss of function on PTEN, which result in activation of this
signalling pathway, have been found in 15% and 20-30% of melanomas, respectively,
in a mutually-exclusive manner [294]. Other significantly mutated loci might also
activate the PI3K pathway, such as phosphatidylinositol-3,4,5-trisphosphate-dependent
Rac exchange factor 2 (PREX2 ) [295], phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha (PIK3CA) [287], v-akt murine thymoma viral oncogene homolog
3 (AKT3) [294], and KIT (which also signals down the MAPK pathway) [287, 296].
Expectedly, other common somatic alterations involve pathways important for cell
cycle control and genome maintenance. Copy-number gains or somatic activation of
the telomerase reverse transcriptase (TERT ) gene are a frequent event in melanoma,
as point mutations in its core promoter leading to increased telomerase expression were
found in about 70% of examined tumours [297, 298]. These mutations were all found
to be C-to-T transitions, providing a mechanism for UV radiation-induced tumourigen-
icity. Additionally, copy-number gains in CCND1 are common in the acral subtype
of cutaneous melanoma [299, 300], where its encoded product cyclin D1 contributes to
tumour development by binding the CDK4/6 complex and by phosphorylating RB1 (see
Paragraph 1.3.2.1.6). Recently, two independent studies identified protein phosphatase
6, catalytic subunit (PPP6C ) as frequently mutated exclusively in melanoma samples
with BRAF or RAS mutations [287, 301]. PPP6C encodes a protein able to block entry
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Figure 1.14: Frequency and type of somatically-acquired mutations in
melanoma genomes. a) Prevalence of somatic mutations in human cancers. Each
dot represents one sample, and the red line represents the median number of mutations
per cancer type. The vertical axis is log-scaled and shows the number of somatic
mutations per megabase (Mb), whereas the horizontal axis has the cancer types ordered
by the number of mutational events. Melanoma is the type of cancer with the highest
mutational burden overall. b) The contributions of somatic signatures to individual
cancer types. Bars represent selected samples from each cancer type whereas the vertical
axis denotes number of mutations per Mb. Whereas other cancer types have distinct
contributions from different mutational processes, melanoma tumours are dominated by
C-to-T transitions (Signature 7) and temozolomide-induced mutations in treated cases
(Signature 11). Signature 1B has been linked to ageing, and is present across different
cancer types. Reprinted by permission from Macmillan Publishers Ltd: Nature [288],
copyright (2013).
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into S phase, suppress the levels of cyclin D1 and reduce RB1 phosphorylation [302].
However, the two studies did not agree on the nature of the mutations: One identified
probable loss-of-function events [301], whereas the other one identified clusters of variants
in highly conserved residues that might represent oncogenic mutations [287].
Although the majority of cancers inactivate the P53 pathway at the level of TP53
itself, mutations in TP53 are not too frequent in melanoma, generally found in less
than 20% of samples [209, 287, 301]. However, loss of this pathway’s functions seems to
be achieved, in a mutually-exclusive manner, by mutating RB1 or the INK4A-coding
region of CDKN2A, or amplifying CDK4 or MDM2 [209, 287, 303] (see Paragraph
1.3.2.1.6). Interestingly, more than half of the mutations in TP53 in one large systematic
review could be attributed to UV stress, implicating this locus in UV-induced disease
progression [304]. Another study identified a synonymous C-to-T somatic mutation in
the BCL2-like 12 (BCL2L12 ) gene, which caused accumulation of its messenger (m)RNA
and protein product due to differential miRNA targeting [305]. This accumulation was
found to cause increased binding to P53, decreased induction of UV-induced apoptosis,
and a reduction in the transcription of endogenous P53 target genes.
Other pathways that might be commonly targeted for somatic alterations are those
important in melanocyte development. The MITF pathway is altered in about 20% of
metastatic tumours, with MITF amplification being a frequent event [259, 306]. Copy-
number gains in MITF, in conjunction with oncogenic BRAF, were shown to be able to
transform melanocytes [259], and the MITF regulator SOX10 was found to be mutated
in about 10% of primary melanomas and to be inactivated in some metastatic tumours
[306].
Recently, the glutamate receptor pathway has also been found to be somatically
deregulated in melanoma cells. Mutations in GRM3 not only activate the MAPK
signalling pathway, but also alter glutamate receptor function [290]. Additionally, muta-
tions in the glutamate receptor, ionotropic, N-methyl D-aspartate 2A (GRIN2A) have
been found in about a quarter of melanomas, and phospholipase C, beta 4 (PLCB4 ), a
downstream effector from GRIN2A, has also been found to be recurrently mutated [307].
Glutamate receptor dysfunction has been noted in neuronal tumours, with gliomas that
have high glutamate release being more aggressive [308]. Given the neural crest origin
of melanocytes, it might indicate that shared molecular mechanisms between neurons
and melanocytes allow melanoma cells to take advantage of neurophysiological receptors
[209]. Although it is unclear from the pattern of mutations if GRIN2A acts as a tumour
suppressor or an oncogene, mutant GRM3 was found to harbour a mutation hotspot and
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to confer increased anchorage-independent growth and migration, possibly indicating
that it acts as an oncogene [290, 307].
Many other significantly mutated loci have been described. Recently, ras-related
C3 botulinum toxin substrate 1 (RAC1 ) was described as a new oncogene in two
independent studies, as both found UV-induced recurrent mutations affecting the same
codon [287, 301]. RAC1 is an important player in cell proliferation and cell migration,
and when mutated, it could provide a migratory advantage to melanocytes through
ERK activation [301]. Other candidate genes include deleted in colorectal carcinoma
(DCC ), dynein cytoplasmic 1 intermediate chain 1 (DYNCI1I ), RPTOR independent
companion of MTOR, complex 2 (RICTOR), AT rich interactive domain 2 (ARID2 ),
serine/threonine kinase 19 (STK19 ), sorting nexin 31 (SNX31 ) and transforming acidic
coiled-coil containing protein 1 (TACC1 ) [287, 301].
Although somatic mutations are required to drive melanomagenesis, the acquisition of
mutations is facilitated by certain factors, such as induction of C-to-T transitions upon
UV radiation exposure, or having a preponderance of phaeomelanin over eumelanin,
which can generate oxidation-induced DNA damage. In addition, germline mutations
in some of the genes mentioned above have been found to predispose to melanoma with
high penetrance. In the next section, I discuss these and other risk factors for melanoma
development.
1.6 Risk factors for melanoma development
Several risk factors for the development of melanoma have been identified. These can
be environmental, such as exposure to UV radiation, physical characteristics, such as
having fair skin, eyes or hair, or genetic, such as carrying mutations in genes that
control melanogenesis or more general cell integrity processes. In this Section, I review
established risk factors for melanoma and their modes of action.
1.6.1 Environmental factors
1.6.1.1 UV radiation
It has been estimated that about 86% of all melanomas can be attributed to exposure to
UV radiation, whether from the sun or from UV-emitting devices such as sunbeds [110],
and as such, it is considered the main risk factor for developing melanoma (for mutagenic
mode of action, see Subsection 1.3.1.5). However, different patterns of sun exposure carry
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different risks. For example, a meta-analysis of 57 studies and a total of 38,671 patients
identified that intermittent and intense sun exposure significantly increased melanoma
risk when compared to chronic sun exposure [309]. Although a history of sunburn might
appear to increase melanoma risk, this effect may arise because people are more likely
to remember it, but a causal relationship cannot be excluded [309].
Additionally, the relationship between the use of sunbeds and melanoma has been
analysed in several studies, and at least two meta-analyses concluded that melanoma
risk was increased in individuals that had ever used sunbeds, with risk increasing if
the exposure was at a young age [310, 311]. As such, the IARC decided to raise
the carcinogenicity level of sunbed usage to the top category in 2009 [312]. In 2011,
legislation came into force in England and Wales that made it illegal for people under
18 years of age to use sunbeds [313], and other countries, such as France, Brazil, Austria
and Germany, have also taken steps to limit the exposure of younger individuals [314].
1.6.1.2 Other environmental factors
Diverse studies have identified other factors that might play a role, albeit probably
limited, in melanoma susceptibility. Melanomagenesis has been linked to arsenic expos-
ure [315], regular swimming (probably water chlorination) [316], exposure to residential
magnetic fields [317], and industries such as electronics, metal and transport and com-
munications [318]. However, these studies analysed only a limited number of people and
reported small odds ratios (ORs) with wide confidence intervals, so further research is
necessary to establish whether a causal relationship exists between these environmental
factors and melanoma formation.
1.6.2 Physical characteristics and medical history
1.6.2.1 Skin, hair and eye colour
Skin and hair colour are primarily determined by the amount and types of melanins
produced, although other pigments such as haemoglobin and dietary carotenoids also
contribute to them [319]. The absence of both eumelanin and phaeomelanin results
in white hair (albinism), higher eumelanin production results in dark hair and skin,
and higher phaeomelanin production results in blond or red hair and fair skin [319].
Therefore, given the crucial role of eumelanin in skin protection against UV radiation,
it is expected that individuals with darker skin and hair would be better protected than
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blond or red-haired individuals when exposed to UV radiation [226] (see Subsection
1.4.1.3).
Although the molecular details underlying hair and skin colour are still incompletely
understood, some important players have been elucidated. The switch between eu-
melanin and phaeomelanin production within a melanocyte is controlled by MC1R,
which is highly polymorphic in the human population [319]. Variants that impair MC1R
binding to α-MSH and/or subsequent cAMP production, and therefore affect eumelanin
production, are over-represented in redheads and fair-skinned people [320]. Furthermore,
MC1R mutation carriers are not only more susceptible to UV radiation-induced damage,
but may also have increased oxidation-induced DNA damage arising from phaeomelanin
synthesis, contributing to melanomagenesis [321].
MC1R variants play a role not only in red-haired individuals, but also account for
inability to tan in individuals without red hair [322], and increase the risk of developing
freckles independently of skin and hair colour [323]. As such, an inability to tan and
the presence of freckles represent independent melanoma risk factors [324, 325]. More
recently, a mutation altering KITLG expression levels was found to underlie classic blond
hair colour in Europeans [326], and given that this pathway seems to play an important
role in melanocyte number, size and dendricity [327], it will be interesting to see whether
this variant contributes to melanoma susceptibility in this population, and if so, whether
the mechanism involves the KIT pathway.
Eye colour is a polygenic trait, but two main contributing loci have been identified:
oculocutaneous albinism II (OCA2 ) and homologous to the E6-AP carboxyl terminus
(HECT) and regulator of chromosome condensation 1-like domain (RLD) containing E3
ubiquitin protein ligase 2 (HERC2 ) [328]. OCA2 is involved in melanosome transport
and maturation, and thus variations in this gene affect the type and quantity of melanin
produced [328]. Polymorphisms within HERC2 probably act in the same pathway,
as they have been found to affect OCA2 expression levels [329]. Therefore, eye colour
reflects genetic variants that affect melanin distribution, and therefore has been identified
as an independent melanoma risk factor [324, 330].
1.6.2.2 Presence of multiple naevi
The presence of an elevated number of naevi is considered one of the most important
risk factors for melanoma development. Naevi are benign melanocytic tumours, and
although the majority are stable and will not progress to melanoma, some will become
malignant (see Subsection 1.4.2.1). A meta-analysis carried out in 2005 identified a 7-
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fold higher melanoma risk in people with more than 100 common naevi compared with
those that have fewer than 15, and individuals with five dysplastic naevi presented a
6-fold higher risk compared with individuals with no dysplastic naevi [331].
Although the majority of melanomas arise de novo (see Subsection 1.4.2.2), it has
been calculated that around 20% of all melanomas originate from a dysplastic naevus
(reviewed in [332]), and, at least within CDKN2A mutation-carrier families, individuals
with dysplastic naevi are more likely to carry the mutant gene compared with family
members without dysplastic naevi [333]. Therefore, the presence of multiple common
or dysplastic naevi might indicate the presence of genetic or environmental factors that
favour melanoma progression, such as carrying a mutation that accelerates melanocyte
proliferation, or having a history of sun exposure.
1.6.2.3 Presence of a previous melanoma
Individuals with a previous diagnosis of melanoma have a 8-12-fold increased risk of
developing a subsequent melanoma if they do not have a family history of melanoma,
and 300-500-fold increased risk if they do and have dysplastic naevi when compared
to population incidence rates [334, 335]. As is the case with dysplastic naevi, the
development of a single melanoma might be indicative of the presence of underlying
risk factors, but it can also happen that cells from a primary tumour that failed to be
surgically excised proliferate and originate a secondary tumour. This event is referred
to as local recurrence or persistent melanoma (discussed in Subsection 1.4.3.1).
1.6.2.4 Other medical conditions
Immunocompromised patients, such as organ transplant recipients, are at an increased
risk of developing many types of cancer, with skin cancer including melanoma being
one of the most common [336, 337]. Additionally, Parkinson’s disease patients also
seem to have a significant increase in melanoma incidence, although the reason remains
unknown [338]. Perhaps not surprisingly, individuals with other types of cancer, such as
non-Hodgkin’s lymphoma, leukaemia and renal and gastrointestinal tumours also have
increased melanoma risk [339–342]. Additionally, several studies have reported that
retinoblastoma patients that survive their disease are also at high risk of developing
melanoma [209, 343, 344].
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1.6.3 Genetic risk factors
Another important melanoma risk factor is having a family history of the disease, which
could be indicative of underlying genetic alterations that predispose to its formation.
Meta-analyses have shown a ~2-fold increase in risk for individuals with a family history
compared to those without [345, 346]. Several loci have been discovered, through
methodologies such as linkage studies, WGS, WES or GWAS, to influence cutaneous
melanoma risk (Fig. 1.15). These genes participate in cell cycle control or genome
stability, and have varying degrees of penetrance.
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risk. The dotted line indicates where the highest emphasis is when searching for
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1.6.3.1 High-penetrance loci
The biological function of the two classical high-penetrance melanoma susceptibility loci,
CDKN2A and CDK4, is discussed in Paragraph 1.3.2.1.6. About 40% of melanoma-prone
families carry mutations in CDKN2A, whereas very few kindreds with pathogenetic
CDK4 mutations have been described worldwide [350, 351]. For familial cases, the
overall penetrance of CDKN2A mutations has been estimated at 30% by 50 years of age
and 67% by 80 years of age, although it can be modified by residence location [352]. For
sporadic cases, it has been calculated at 14% by 50 years of age and 28% by 80 years
of age [353], indicating that other shared environmental or genetic risk factors might
influence familial melanoma risk.
RB1 mutation carriers that survive retinoblastoma (see Paragraph 1.3.2.1.1) are
at a 4-80-fold risk of developing melanoma when compared to population incidence
levels [209]. Other genes have been reported recently that might be highly penetrant,
although estimating their penetrance has been hampered by the small numbers of carrier
individuals identified. In 2011, Thomas Wiesner and his team identified deleterious
mutations in BRCA1-associated protein 1 (BAP1 ) co-segregating with melanocytic
tumours in two families, with tumours showing loss of heterozygosity of the wild-type
allele [354]. Two years later, Susanne Horn and colleagues identified a mutation in
the promoter of TERT co-segregating with the disease in a large melanoma-prone
German family [297]. This mutation was found to increase TERT expression levels,
and since then, similar somatically-acquired mutations have been found in a variety of
other cancers [355].
1.6.3.2 Medium-penetrance loci
As discussed in Subsection 1.6.2.1, individuals that carry variants inMC1R have a higher
risk of developing melanoma. ORs for different variants within the gene range from 1.42
to 2.45 [356]. More recently, a single nucleotide variant (SNV) affecting codon 318 in
MITF was found to disrupt a conserved small ubiquitin-like modifier (SUMO)-ylation
site, thus altering the spectrum of MITF target genes and leading to melanomagenesis.
The OR for this allele was calculated to be between 2.7 and 4.78, consistent with an
intermediate penetrance effect, but its allele frequency is much rarer than that of MC1R
variants [357, 358]. BRCA2 mutation carriers have more than 2.5-fold risk of developing
the disease when compared to population incidence levels [347].
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1.6.3.3 Low-penetrance loci
Many low penetrance loci, with high allele frequencies, have been identified through
GWAS. Many of these genes affect pigmentation functions or skin sensitivity to UV-
induced DNA damage [215]. For example, variants in agouti signalling protein (ASIP),
an antagonist of MC1R, TYR and TYRP1 have been associated with cutaneous melan-
oma with ORs ranging from 1.15 to 1.45 [359], and similar ORs were obtained for variants
in the naevus-associated genes methylthioadenosine phosphorylase (MTAP), phospholi-
pase A2, group VI (PLA2G6 ) and interferon regulatory factor 4 (IRF4 ) [360]. Variants
in epidermal growth factor (EGF ) and its receptor (EGFR) have also been associated
with melanoma and its progression [361, 362]. Other loci potentially implicated are
caspase 8 (CASP8 ), CCND1, solute carrier family 45, member 2 (SLC45A2 ), ATM,
OCA2, myxovirus resistance 2 (MX2 ), among others (reviewed in [194, 209, 215]).
As we can see from the above paragraphs, melanoma is a complex disease arising from
the interaction of diverse environmental factors, such as UV radiation and potentially
other carcinogens, with the underlying genetic make-up of an individual. It is possible
that dozens or maybe hundreds of genes, contributing to pigmentation, skin sensitivity,
cell cycle control and genome stability, influence the genetic risk of this disease. In the
next section, I discuss melanoma clustering in families, as the subject of study of this
dissertation.
1.7 Familial melanoma
The English general practitioner William Norris first reported a case of familial melan-
oma in 1820 [363]. He speculated, given that his patient’s tumour had originated from
a naevus, that his children and brothers had many naevi, and that his father had also
died of the disease, that melanoma was hereditary. This observation is notable because
it was made nearly half a century before Mendel published his treatise on genetics [1].
Familial melanoma can be characterised by multiple melanoma cases across several
generations on one side of the family, or by the presence of multiple primary melanomas
in a single individual, or by an early age of onset [209]. In 1978, Lynch coined the term
“familial atypical multiple mole-melanoma syndrome” (FAMMM) for families with a
clustering of multiple large, dysplastic naevi of variable colour with pigmentary leakage,
one of the main risks for the development of melanoma [364] (see Subsection 1.6.2.2).
However, tumours from individuals with FAMMM do not show any histopathologic
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differences when compared to sporadic cases, and they might not show all typical
FAMMM characteristics, so their analysis is not useful when diagnosing the familial
condition [365]. Individuals with FAMMM caused by mutations in CDKN2A also have
been found to have a higher incidence of other malignancies, especially pancreatic cancer
[365, 366].
Since Norris’s report, it has become clear that although the majority of melanomas
can be attributed to UV radiation exposure [110], about 10% of all melanoma cases have
a family history of the disease [194]. However, heritability of melanoma is high, as it has
been estimated that about 55% of variation in liability to melanoma is due to genetic
effects [367]. This discrepancy between high heritability and low familial melanoma rate
might indicate that a large proportion of the risk arises from common, low-penetrance
variation [368], although some rare high-penetrance loci might still remain undiscovered.
This could be because individual variants in a locus might have a very low allele frequen-
cies and/or might not be obviously disruptive, which precludes systematic identification
of potential candidates.
The definition of familial melanoma varies depending on geographical location, as
some regions, such as Australia, have a higher prevalence of melanoma and thus a
higher probability of seeing clusters of melanoma within a family caused by non-genetic
reasons [352, 369, 370]. In the UK and Europe, familial melanoma is generally defined
as a cluster of two or more first- or second-degree relatives with melanoma [370, 371],
whereas in Australia it constitutes a diagnosis of one invasive melanoma and two or
more other cancer diagnoses among first- or second- degree relatives [370]. Additionally,
patients might be referred for genetic testing if they live in a region with low melanoma
incidence and present with at least two primary tumours, or if they present with three
or more primary tumours and they live in a high melanoma incidence region [370].
1.8 Unanswered questions in melanoma genetics
Since the discovery of CDKN2A and CDK4 about 20 years ago [192, 199], only a handful
of other high-penetrance genes in very rare families have been described, namely BAP1,
RB1 and TERT (see Subsection 1.6.3.1). Collectively, these genes explain only about
50% of all familial melanoma cases. This fact begs the question: Are there any more
high-penetrance genes remaining to be discovered, or can all unexplained familial risk
be attributed to many lower-penetrance alleles?
Additionally, these known high-penetrance genes encode proteins that participate in
1.8 Unanswered questions in melanoma genetics 69
cell cycle control and genome maintenance pathways, with CDKN2A, CDK4, RB1 and
BAP1 participating in G1/S cell cycle progression ([372], see Paragraph 1.3.2.1.6), and
TERT having a paramount role in genome stability after each cell division [373]. If other
high-penetrance loci remain to be discovered, do these participate in the same biological
pathways, or are there any other processes important in melanoma predisposition?
During my PhD, I endeavoured to help answer these questions. The dramatic drop
in the costs in sequencing costs over the past decade [14] has allowed the use of this
technology to explore large numbers of affected individuals in the search for common
affected loci or biological pathways. When planning this project, we, as a team, decided
to use WES in multiple members of several melanoma-prone families for four main
reasons:
• Unbiased projects (i.e., assessing the whole genome or exome rather than sets of
candidate genes) to date studying genetic susceptibility to melanoma are very few,
and have been carried out in three or fewer individuals [354, 358]. This means
that the possibility of rare, high-penetrance alleles in coding regions has not been
properly addressed.
• The cost of sequencing an exome is ~20× less than that of sequencing a whole
genome, which would allow us to study multiple individuals from a greater number
of affected families. This is helpful when attempting to obtain statistical support
for the co-segregation of candidate mutations.
• Variation in protein-coding regions can be directly interpretable, e.g. causing an
amino acid change or introducing a premature stop codon in a protein, which then
can be assessed by functional, structural or conservation scores.
• The possibility that deep catalogues of human genetic variation would be developed
and made publicly available during the course of this project, which would allow a
better estimate of the allele frequency of candidate variants in human populations.
1.8.1 Overview of whole-exome sequencing as a tool for provid-
ing answers
In order to analyse the protein-coding regions of the genome, the WES method involves,
firstly, the enrichment of the DNA sample for exonic regions (or any other custom regions,
in the case of candidate gene sequencing). Generally, this is achieved by solid- or liquid-
phase hybridisation. In the first case, probes complimentary to the target regions are
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fixed in a solid surface, such as a microarray, which can then be washed and captured
regions eluted; in the second case they can be hybridised to biotinylated DNA or RNA
probes and captured with streptavidin beads [374, 375] (Fig. 1.16). Captured DNA
regions can then be massively sequenced, mapped onto the human genome reference
assembly, and potential variants can be called and filtered in the search for candidate
melanoma predisposition genes.
Figure 1.16: Hybridisation methods for target DNA capture. A) Solid-phase.
Baits complementary to the targeted sequence (blue with black stripes) are synthesised
on a microarray. Upon fragmentation, target DNA (blue) hybridises with the microarray
baits, the array is washed and the captured DNA is eluted. B) Liquid-phase. Baits
complementary to the targeted sequence (blue with black stripes) are synthesised and
biotinylated, indicated by an asterisk. Fragmented DNA hybridises with the baits, and
these are captured with streptavidin beads (black). The bead-bait complexes are washed
and the target DNA eluted. Target DNA is then sequenced. Reprinted from ref. [374]
by permission of Oxford University Press.
1.8.2 Overview of the methodology followed to study melanoma
predisposition genes
I have organised the chapters in this dissertation roughly according to the sequential
order in which I carried out the different steps in the study (Fig. 1.17). In order to
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search for high-penetrance melanoma susceptibility genes, I used three main familial
melanoma collections, originating from the UK, The Netherlands, and Australia. These
datasets were not all available at the start of the project and thus the initial analyses
were only performed with the UK and Dutch datasets (discovery and replication phases,
covered in Chapter 2). Then, with the availability of the Australian cohort, I could
perform an integrative analysis and identify candidate susceptibility genes (covered in
Chapter 3). Finally, I cover the mechanistic investigation of the mode of action of these
candidate genes in Chapter 4. Finally, in Chapter 5, I discuss the relevance of the results
presented here, as well as the future directions of this project.
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Figure 1.17: Methodology followed during my PhD to study melanoma
susceptibility genes. The chapter in which each step is covered is indicated at the
left. An arrow indicates a contribution of that dataset to the next analysis.

Chapter 2
Familial melanoma sequencing:
European phase
Some methods in this chapter have been published (ref. [376]). Some parts of the text
have been reproduced from this reference; I confirm I have ownership of copyright for
reproduction in this work.
In an attempt to identify high-penetrance germline variants that contribute to melan-
oma development, we exome-sequenced and analysed affected members from predisposed
families. For this phase, I had access to an extensive set of samples collected by clinicians
and scientists over past decades from families from the UK and The Netherlands. This
chapter explains the rationale for patient selection, the sequencing methodology, data
processing and the gene prioritisation analyses performed.
This phase is divided into two stages, discovery and replication. Briefly, we sequenced
whole exomes from high-priority families (i.e., those with a higher number of cases, early
age of onset and/or MPM) and compiled a list of candidate genes. For the replication
phase, we targeted these genes for sequencing in additional families to search for sup-
porting evidence of the involvement of the identified genes in melanoma predisposition.
Finally, we developed novel gene prioritisation strategies combining evidence from both
the discovery and replication phases in order to proceed to biological validation. An
overview of all the steps explained in this Chapter is depicted in Fig 2.1.
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Figure 2.1: Flowchart of analysis steps followed in the search for melanoma
susceptibility genes, European phase. Steps are colour-coded depending on the
place where these were done, green: Leeds or Leiden, blue: Sanger Sequencing Facility,
orange: Sanger Vertebrate Resequencing team, red: Sanger Experimental Cancer
Genetics team. Black indicates a ready dataset. Arrows indicate datasets entering
or exiting the pipeline. Details of each step are annotated at their right.
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2.1 Discovery phase
Initially, we decided to sequence the whole exomes of 41 patients from 24 melanoma-
prone families that did not harbour pathogenetic variants in previously known genes. We
then prioritised and captured resulting candidate genes from this phase in an extended
set of 94 patients.
2.1.1 Patient selection
The families selected for sequencing all had three or more cases of melanoma. Ad-
ditionally, families were preferentially sequenced if DNA was available from multiple
members, if they had members that presented with multiple primary melanoma (MPM)
or if melanoma presented at an early age (before the fourth decade of life) (Table 2.1 and
Figure A.1.1). The families sequenced were recruited to a UK Familial Melanoma Study
directed by the Section of Epidemiology and Biostatistics, University of Leeds (Leeds,
UK), and the Leiden University Medical Centre (LUMC, Leiden, The Netherlands). All
cases were found to be negative for pathogenetic variants in CDKN2A and CDK4 at
the institution of origin. Informed consent was obtained under the Multicentre Research
Ethics Committee (UK): 99/3/045 for the Leeds cases and Protocol P00.117-gk2/WK/ib
for Leiden cases. Genomic DNA was extracted from peripheral blood using standard
methods. This work was carried out by Prof. Julia A. Newton-Bishop, Prof. D. Timothy
Bishop and Dr. Mark Harland at the University of Leeds for Leeds cases, and by Assoc.
Prof. Nelleke A. Gruis at LUMC for Leiden cases.
2.1.2 Exome sequencing
DNA was supplied by the institutions of origin to the Sequencing Facility at the Wellcome
Trust Sanger Institute (hereinafter referred to as “Sanger”). DNA libraries were prepared
from 5 μg of genomic DNA, and exonic regions were captured with the Agilent SureSelect
Target Enrichment System, 50 Mb Human All Exon kit, which is a liquid-phase hybrid-
isation method. Paired-end reads of 75 base pairs (bp) were generated on the HiSeq
2000 platform and mapped to the reference GRCh37/hg19 human genome assembly
using the Burrows-Wheeler Aligner (BWA) [377] (for software versions and parameters
see Table A.1). Reads were duplicate-marked using Picard [378] and were recalibrated
and realigned around indels using the Genome Analysis Toolkit (GATK) package [379]
(Table A.1). Exome capture and sequencing resulted in an average of 90.8% of target
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Table 2.1: Pedigrees sequenced as part of the discovery phase. NL: The
Netherlands.
Pedigree
ID Origin
Num.
melanoma
cases in
pedigree
Num.
sampled
cases
Presence
of MPM
in
pedigree
Age of
diagnosis
of first
melanoma
UF1 Leeds, UK 4 2 Yes 28
UF2 Leeds, UK 5 1 Yes 57
UF3 Leeds, UK 4 1 Yes 37
UF4 Leeds, UK 5 1 Yes 27
UF5 Leeds, UK 4 1 Yes 25
UF6 Leeds, UK 4 1 Yes 42
UF7 Leeds, UK 4 2 Yes 36
UF8 Leeds, UK 4 1 Yes 34
UF9 Leeds, UK 5 1 Yes 25
UF10 Leeds, UK 3 3 Yes 35
UF11 Leeds, UK 4 1 Yes 18
UF12 Leeds, UK 4 1 Yes 44
UF13 Leeds, UK 4 1 Yes 42
UF14 Leeds, UK 4 2 Yes 35
UF15 Leeds, UK 8 2 No 22
UF16 Leeds, UK 4 2 Yes 50
UF17 Leeds, UK 6 1 Yes 16
UF18 Leeds, UK 5 1 Yes 25
UF19 Leeds, UK 6 2 Yes 27
UF20 Leeds, UK 5 3 Yes 21
UF21 Leeds, UK 3 2 Yes 41
NF1 Leiden, NL 4 3 Yes 25
NF2 Leiden, NL 4 2 No 42
NF3 Leiden, NL 5 4 Yes 27
bases being covered ≥10× across the autosomes and sex chromosomes. Genomic variants
were then called using SAMtools mpileup [380] (Table A.1). This work was done by the
Sequencing Facility and by pipelines written by the Vertebrate Resequencing Team at
Sanger.
2.1.3 Data processing
Under the rationale that potential disease-causing germline mutations are not commonly
found in human populations, I removed known variants in common variation datasets
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from further analyses. For this step, I used The 1000 Genomes Project, October 2011
release database [15], and The Single Nucleotide Polymorphism database (dbSNP),
release 135 [381]. Additionally, I also removed all variants found in 805 in-house control
exomes that belonged to either the 500 Exome Project, developed by the Metabolic
Disease Group, or a set of control exomes part of the Cancer Genome Project at Sanger.
One of the best-known problems of NGS and variant-calling algorithms is the high
false-positive rate of resulting variant calls [382, 383]. For this reason, it is important to
remove variants for which confidence is low, a concept that is captured by the base and
mapping quality scores assigned by the Illumina platform and the BWA algorithm, re-
spectively [377, 382]. These quantities are represented in the variant’s quality score, cal-
culated by SAMtools mpileup [384], and which is given by −10log10P(call is erroneous)
[385]. In an attempt to remove false positives but at the same time keep any potentially
disease-causing mutation that could be affected by low local coverage or alignment errors,
I decided to remove all variants with a quality below 10. This filter ensures that we keep
only those variants whose probability of being wrong is less than 1 in 10, but at the same
time, this low quality cut-off warrants subsequent confirmation by Sanger sequencing
before proceeding to biological validation.
Additionally, I applied other standard variant quality filters to control for known
causes of false positives, such as removing variants observed in one strand more than
expected by chance (P -value≤0.0001), variants called predominantly close to the end of
reads, where quality is known to drop (P -value≤0.0001), variants supported by two or
less reads, and variants with a root mean square mapping quality lower than 10. This
left a total of 316,097 mutations across all samples for further analyses (Fig. 2.2).
As we have sequenced only exonic regions, I decided to keep only variants resulting
in protein-altering changes. In order to predict the consequences of each variant, I used
the Ensembl project’s Variant Effect Predictor (VEP) tool, version 2.1 (Ensembl release
63) [386]. The types of consequences kept for further analyses are shown in Table 2.2.
The code I wrote to perform these analyses, with some modifications, has been published
[387].
Finally, when we sequenced more than one member of a pedigree, I retained only
variants co-segregating with melanoma that were unique to that pedigree, whereas I
considered all variants unique to an individual from pedigrees in which only one affected
family member was sequenced. We decided to keep only variants unique to a pedigree
in an effort to reduce any systematic biases arising from the sequencing, processing and
variant calling methodologies [388], but have also done a separate analysis examining
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Figure 2.2: Number of variants per exome remaining after filtering for common
variation and quality, discovery phase. Pedigree IDs are indicated below each set
of bars, each bar represents one exome. Colours are used only to distinguish between
different members within the same family. Similar numbers of variants were called across
all samples.
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Figure 2.3: Number of variants per pedigree remaining after filtering for
co-segregation and protein-altering changes, discovery phase. Pedigrees are
ordered from the highest to the lowest number of variants passing all filters. In general,
pedigrees with more members have less variants passing the filtering criteria due to the
co-segregation requirement.
variants that did not pass this filter (see Subsection 2.3.4.1). This left a total of 15,600
mutations for further analyses (Fig. 2.3).
2.1.4 Gene prioritisation for replication phase
In order to define a list of candidate genes for sequencing in additional melanoma families,
I decided to retain only those genes that were mutated in two or more pedigrees, which
revealed 344 recurrently mutated genes after manual removal of genes likely to be false
positives (see Subsection A.2.1). Genes mutated in 3 or more families for which co-
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Table 2.2: Consequences of variants kept for further analyses, discovery phase.
Table reproduced from refs. [389, 390]
Ensembl 63 term Sequence Ontology term Sequence Ontology description
Essential splice site splice_donor_variant A splice variant that changes the 2
base region at the 5’ end of an
intron
splice_acceptor_variant A splice variant that changes the 2
base region at the 3’ end of an
intron
Stop gained stop_gained A sequence variant whereby at
least one base of a codon is
changed, resulting in a premature
stop codon, leading to a shortened
transcript
Frameshift
coding frameshift_variant A sequence variant which causes adisruption of the translational
reading frame, because the
number of nucleotides inserted or
deleted is not a multiple of three
Stop lost stop_lost A sequence variant where at least
one base of the terminator codon
(stop) is changed, resulting in an
elongated transcript
initiator_codon_variant A codon variant that changes at
least one base of the first codon of
a transcript
Non synonymous
coding inframe_insertion An inframe non synonymousvariant that inserts bases into in
the coding sequence
inframe_deletion An inframe non synonymous
variant that deletes bases from the
coding sequence
missense_variant A sequence variant, that changes
one or more bases, resulting in a
different amino acid sequence but
where the length is preserved
Splice site splice_region_variant A sequence variant in which a
change has occurred within the
region of the splice site, either
within 1-3 bases of the exon or 3-8
bases of the intron
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segregation information exists are shown in Table 2.3, and the full list can be seen in
Table A.1.2.
Table 2.3: Top recurrently mutated genes, discovery phase.
Gene name Num. families (num.
members per family)
Coding length in
kilobases (kb)
Number of
mutations per kb
RNF213 5 (3, 2, 2, 2, 1) 24.435 0.204624514
C10orf93 5 (2, 2, 1, 1, 1) 10.638 0.47001316
SMG1 4 (3, 2, 2, 1) 16.112 0.248262165
ADAMTS7 4 (3, 2, 1, 1) 5.497 0.727669638
ARID1A 4 (2, 1, 1, 1) 9.225 0.433604336
PRUNE2 4 (2, 1, 1, 1) 14.81 0.270087779
NPHP4 4 (2, 1, 1, 1) 13.136 0.304506699
EP400 4 (1, 1, 1, 1) 13.501 0.29627435
PLEC 4 (1, 1, 1, 1) 16.941 0.236113571
ANKK1 3 (4, 1, 1) 2.589 1.158748552
KIF26B 3 (3, 2, 1) 8.091 0.370782351
FAT2 3 (3, 1, 1) 14.514 0.206696982
ZFC3H1 3 (3, 1, 1) 9.636 0.311332503
NEBL 3 (2, 2, 1) 13.683 0.219250164
AGBL1 3 (2, 2, 1) 3.294 0.910746812
SH3TC2 3 (2, 2, 1) 15.027 0.199640647
MPHOSPH9 3 (2, 2, 1) 8.663 0.346300358
XDH 3 (2, 1, 1) 5.999 0.500083347
MYO5C 3 (2, 1, 1) 10.002 0.299940012
FN1 3 (2, 1, 1) 17.274 0.173671414
SYTL5 3 (2, 1, 1) 4.876 0.615258409
ANKRD17 3 (2, 1, 1) 12.001 0.249979168
DGKQ 3 (2, 1, 1) 4.945 0.606673407
SCN7A 3 (2, 1, 1) 8.164 0.367466928
SLC26A8 3 (2, 1, 1) 6.017 0.498587336
KIF26A 3 (2, 1, 1) 6.741 0.445037828
NCKAP5 3 (2, 1, 1) 9.681 0.309885342
PRKG1 3 (2, 1, 1) 7.637 0.392824407
RP1L1 3 (2, 1, 1) 8.875 0.338028169
To recapitulate all filtering steps so far, these 344 genes present with at least two
different variants in at least two different pedigrees. Each of these variants is shared by
all sequenced members of the pedigree and is absent from all other pedigrees, and is also
likely to affect protein function based on its predicted consequences. We reasoned that
these criteria ensure that the variant segregates with the disease while discarding any
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systematic mapping errors or SNPs not present in the common variation filtering sets.
Next, we reasoned that we should investigate whether there were any overrepresented
biological pathways in these 344 candidate genes, and if there were, include all pathway
gene members in the subsequent screening in additional families as they would represent
plausible candidates. In order to do this, I ran hypergeometric tests on the list of
candidates against all biological pathways in the curated gene sets in the Molecular
Signatures Database (MSigDB), version 3.0, from the Gene Set Enrichment Analysis
(GSEA) [391]. The hypergeometric test is a statistical tool that is able to calculate the
probability of drawing k successes, out of n total draws without replacement, from a
specified population of size N containing exactly K successes. Therefore, it is able to
assign a P -value to the event of observing k genes belonging to a pathway of size K
in n = 344 draws (our list of recurrently mutated genes) from N = the total number
of human genes. The 833 biological pathways taken as reference were annotated either
by the Kyoto Encyclopaedia of Genes and Genomes (KEGG) [392] (186 pathways),
Reactome [393] (430 pathways) or BioCarta [394] (217 pathways) databases, and the
reference gene universe were all annotated genes in the Ensembl database, release 65
[395] (N = 19,975 genes).
I performed the hypergeometric tests with a custom R script, facilitated by Dr.
Alistair G. Rust, from the Experimental Cancer Genetics team at Sanger, and which
uses functions from the package HTSanalyzeR, version 2.8.0 [396]. After correcting for
multiple tests (using Benjamini and Hochberg’s method [397]), three pathways remained
with an adjusted P -value≤ 0.05: the ABC transporters and the pantothenate and
coenzyme A biosynthesis pathways, annotated by KEGG, and the linkage to MAPK
signalling for integrins, annotated by Reactome (Table 2.4, refer to Table A.1.3 for
the full list of pathways). The number of GSEA-annotated genes belonging to these
pathways is 64 in total, which were added to the set of genes to capture in the replication
set.
In addition to the 344 recurrently mutated genes (Table A.1.4, “direct evidence”)
and the 64 genes belonging to overrepresented pathways in these (Table A.1.4, “ABC
transporter ”, “Pantothenate and CoA biosynthesis pathway”, “Linkage to MAPK sig-
nalling for integrins”), we also decided to include all genes that presented with obviously
disruptive consequences (essential splice site, stop gained and frameshift-coding, Table
2.2), regardless of the number of pedigrees in which these were found (202 genes) (Table
A.1.4, “disruptive consequence”). Additionally, 91 genes that had been found previously
involved in melanoma or cancer development were also included for further screening
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Table 2.4: Significantly overrepresented biological pathways in set of
recurrently mutated genes, discovery set. For all these comparisons, n = 344
and N = 19,975.
Biological
pathway name
Pathway
size (K)
Expected
hits
Observed
hits (k)
P -value Adjusted
P -value
Human
gene
names
ABC
transporters
(KEGG)
44 0.7577 6 9.37E-06 0.0061 ABCB6,
ABCA12,
ABCA6,
ABCA1,
ABCC3,
ABCA7
Pantothenate
and CoA
biosynthesis
(KEGG)
16 0.2755 3 0.0001 0.0219 ENPP3,
PANK4,
BCAT1
GRB2 and SOS
provides linkage
to MAPK
signalling for
integrins
(Reactome)
15 0.2583 3 0.0001 0.0219 FN1,
FGG,
FGB
P130CAS
linkage to
MAPK signalling
for integrins
(Reactome)
15 0.2583 3 0.0001 0.0219 FN1,
FGG,
FGB
(Table A.1.4, “previous evidence for involvement in melanoma/cancer ”). Therefore, the
gene set to be captured in the replication cohort was composed of a total of 701 genes.
2.1.5 Custom probe design
Having the list of genes to be evaluated in additional samples, I then made a design to
capture these regions by liquid hybridisation (Figure 1.16). For this step, I extracted the
genomic coordinates of all exons per gene as annotated in Ensembl release 65, adding
100 bp on each side to capture potential variants in splice regions, and sent this design
to Dr. Bram Herman, from Agilent Technologies, who ran scripts to generate efficient
complementary probe sequences. The finished design targeted ~5.6Mb of the human
genome and covered ~99.23% of the target exons. After manufacturing and sending
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back to Sanger, these probes were ready to be used in an extended set of melanoma
patients for assessment.
2.2 Replication phase
DNA from an additional 94 cases, each from a different melanoma pedigree without
CDKN2A or CDK4 variants, was sent to the Sanger for targeted exon sequencing.
These families constituted the remaining pedigrees with two or more melanoma cases in
the Leeds and Leiden collections.
2.2.1 Targeted sequencing and data processing
Samples from the replication phase were exon-captured using the Agilent SureSelect XT
custom kit, and sequenced on the Illumina HiSeq 2000 platform generating 75bp paired-
end reads. Alignment, duplicate marking, recalibration, indel realignment and variant
calling were done by the Sanger Sequencing Facility and Vertebrate Resequencing Team
as described above (see Subsection 2.1.3; for specific parameters see Table A.1).
In order to capture the familial relationships in all samples to corroborate that
sample exchanges had not occurred, a pairwise identity-by-descent (IBD) analysis was
performed on the 135 melanoma samples (41 from the discovery phase and 94 from the
replication) based on the polymorphic sites on these 701 genes, as annotated in dbSNP
135 [381] (14,820 positions). The rationale behind this analysis is that pairs of first-
degree relatives, such as parents and offspring or siblings, are expected to share about
50% of their genome (meaning a pairwise IBD score of 0.5, approximated by the amount
of shared SNPs); second-degree relatives are expected to have a pairwise IBD score of
0.25, and so on, and thus this score is able to discriminate between related and unrelated
samples. So, after keeping only positions with allelic frequency > 0.05 and r2 < 0.05 (an
estimator of pairwise linkage disequilibrium [LD]), only 722 SNPs remained for further
analyses. These filters are necessary to satisfy assumptions of the distribution of allele
frequencies in the population, and thus to calculate accurate IBD results. All expected
familial relationships, which were all anticipated to have a pairwise IBD score of 0.25
or higher, were captured with a cut-off value of 0.14. This low value might be due to
the small number of SNPs used for the analysis, as this fact is expected to increase
background noise (Fig. 2.4). With this analysis, we were able to detect contamination
in one sample. This sample and another one that was found during the course of this
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analysis to be an unaffected sibling from a melanoma patient were excluded, leaving 92
samples in the replication phase. The IBD analysis was performed by Jimmy Z. Liu at
the Sanger, using the genome-wide complex trait analysis (GCTA) tool [398].
Figure 2.4: Distribution of pairwise IBD values for samples in the discovery
and replication sets. The x-axis shows pairwise IBD values, whereas the y-axis shows
counts of pairwise comparisons (out of
(
135
2
)
). Values are centered around 0.45 for
first-degree relatives, around 0.25 for second-degree relatives, and around 0 for unrelated
individuals. The wide distributions observed are due to the low number of SNPs used
for the analysis.
I then applied the same variant filtering steps as in the discovery set analysis ex-
plained above (common variation, quality and variant consequence filters).
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Table 2.5: Control cohorts used in the melanoma gene prioritisation stage,
European phase. Explanations are taken from the UK10K website (www.uk10k.org).
Cohort name Description Number of
samples
UK10K Neuro
Muir
Sample consists of subjects with
schizophrenia, autism, or other psychoses
all with mental retardation (learning
disability)
167
UK10K Neuro
IOP Collier
Sample consists of samples from subjects
with schizophrenia, psychotic symptoms, or
bipolar disorder. Set is of UK origin.
112
UK10K Neuro
Aberdeen
Sample set comprises cases of schizophrenia
with additional cognitive measurements,
collected in Aberdeen, Scotland.
267
2.3 Gene prioritisation strategy
2.3.1 Gene ranking methodology
We then decided to devise a method to prioritise genes based on the likelihood of
observing the number of mutations found in melanoma patients when compared to a set
of controls. The resulting strategy takes into account the number of non-synonymous
variants detected, the coding length of the gene and the exonic capture efficiencies in
both the discovery and replication phases and the controls.
2.3.1.1 Choice of control exomes
As controls, we decided to use all samples from three neurodevelopmental cohorts from
the UK10K Sequencing Project [399], release 14/03/2012, consisting of a total of 546
exomes (Table 2.5). These samples were chosen because, in addition to presenting with
a phenotype unrelated to cancer, they were captured with the same Agilent SureSelect
exome probes as those used for the melanoma cases described above, and were also
sequenced on the Illumina HiSeq 2000 platform.
Control exomes were aligned, filtered for duplicates, recalibrated and realigned around
indels as described above. I then called variants and filtered for common variation,
quality and consequences with the same tools and parameters as the melanoma cohort.
As there were three pairs of siblings across the three cohorts, I decided to keep one index
case from each of these, thus ensuring the samples were not related. This left 543 exomes
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for further analyses.
2.3.1.2 Principal component analysis to ensure that cases and controls are
matched by ancestry
Before being able to compare allele frequencies in cases and controls, it is necessary to
ensure that these two groups are matched by ancestry. Not accounting for population
structure is a frequent source of false-positive results and reduced power in genetic studies
[400]. In order to ensure this, I decided to perform a principal component analysis (PCA)
on the melanoma cases and the UK10K controls to group individuals on the basis of their
genomic variation. For this, I obtained a set of SNPs, with an allelic frequency higher
than 1% in The 1000 Genomes Project dataset, that were shared between the sequenced
melanoma cases (discovery and replication sets) and the UK10K controls. This allele
frequency filter is necessary, as otherwise populations can be grouped on particular
chromosomal segments instead of on genome-wide population structure [400]. This filter
left 2,434 bi-allelic positions spread across the 701 genes that were captured.
Then, with a custom R script supplied by Mamunur Rashid at the Experimental
Cancer Genetics team at Sanger, I was able to plot the cases and controls according to
their genetic variation. Briefly, the program converts genotypes to 0 if the individual is
homozygous for the reference allele, 1 if heterozygous, and 2 if homozygous for the variant
allele, and then normalises the resulting matrix. Then, it obtains the pairwise covariance
matrix and estimates its eigenvalues and eigenvectors. It obtains the loadings for each
SNP based on The 1000 Genomes dataset, and then applies them to the melanoma cases
and controls. The resulting plot shows that, to the best resolution we could obtain with
the small number of shared SNPs, cases and controls are ancestry-matched as they are
all European (Fig. 2.5).
2.3.1.3 Gene prioritisation
Having shown that cases and controls are matched by ancestry, I was able then to
compare the number and types of germline variants detected in both datasets. I thank
Drs. Jeroen de Ridder from the Delft University of Technology and Kees Albers, from
the Sanger, for very useful discussions in devising the following prioritisation strategy.
For each gene g we calculate µ¯nucg , which is the average per-nucleotide variant rate for
gene g in the control set. µ¯nucg is calculated by counting the number of non-synonymous
variants detected in an individual, and then dividing it by the number of exonic bases
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Figure 2.5: Principal component analysis plot showing that cases and controls
are matched by ancestry, European phase. Plot showing the first and second
principal components. Ancestry was estimated using the 1000 Genomes Project
individuals and then projected onto the melanoma (black) and UK10K control (pink)
cohorts.
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in that individual that were captured with a coverage of at least 2. Therefore,
µ¯nucg =
1
n
k=n
∑
k=1
mg,k
bg,k
,
where n is the number of control individuals (n= 543 in this case), mg,k is the number
of non-synonymous mutations detected in gene g in individual k, and bg,k is the number
of bases with a coverage of at least 2 in gene g in individual k.
We can then use µ¯nucg to calculate µg,s, which may be interpreted to be the rate at
which we find at least one nucleotide variant in gene g in study phase s, if the mutation
events are independent:
µg,s = 1− (1− µ¯nucg )Lg,s,
where Lg,s is the average captured coding length of gene g in nucleotides in study
phase s, and s ∈ S where S= {discovery, replication}. The length of gene g is not taken
as a constant, as it can change across different study phases because of variations in
target capture efficiency. Then, the probability that at least Xg,s out of Ys individuals
have at least one variant in gene g is:
if Xg,s ̸= 0,
P -valueg,s = 1−
j=Xg,s−1
∑
j=0
(
Ys
j
)
µ jg,s(1−µg,s)Ys− j,
else,
P -valueg,s = 1.
Finally, we obtain a P -value for gene g as
P -valueg =∏
s∈S
P -valueg,s.
The P -value calculated from the steps above attempts to capture the likelihood
of observing as many variants as we detect in the melanoma exomes, or more, when
compared to a control dataset, and utilise an index case from each pedigree in the
calculations as we are assuming that mutation events are independent (which means
that Ydiscovery = 24 and Yreplication = 92). However, it does not capture any co-segregation
information. In order to take into account this information, we then decided to correct
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this P -value for the likelihood that multiple members in a pedigree share each variant
in gene g:
scoreg = P -valueg×∏
p∈P
Cp,
where Cp is the co-segregation coefficient for pedigree p, and P is the set of all
pedigrees where gene g was found with at least one mutation in the discovery phase. Cp
captures the probability that, given a pedigree structure, a given pair of relatives share
a variant. Therefore, Cp = 0.5 for a pair of first-degree relatives, Cp = 0.25 for a pair of
second-degree relatives, and so on. In general, Cp = 12m , where m is the highest number
of meioses separating any two members of pedigree p.
The above methodology will assign scoreg = 0 to genes that only have one detected
mutation in either the replication or the discovery phase if no mutations are detected in
the control exomes. So while they might be interesting, we regard genes with only one
detected variant as uninformative. The top 30 genes resulting from this ranking after
removing uninformative genes are shown in Table 2.6, and the full list can be consulted
in Table A.1.5.
Before proceeding to biological validation, it is of paramount importance that the
variants detected in these genes are confirmed as real. This is because we decided to
keep variants that have a probability of being wrong of up to 1 in 10 given sequencing
data (discussed in Subsection 2.1.3).
2.3.2 Validation of next-generation sequencing-detected variants
In order to validate detected variants in candidate melanoma susceptibility genes, poly-
merase chain reaction (PCR) primers were designed against all variants in the top 83
genes according to the ranking in Table A.1.5 (the top 30 genes are shown in Table 2.6).
Genomic DNA from carriers was amplified and capillary-sequenced in order to confirm
the presence or absence of NGS-detected germline variants. An overall confirmation rate
of almost 86% was achieved, as 522 out of 608 putative tested variants were detected
in the original sample (Fig. 2.6). The PCR validation work was done by Dr. Mark
Harland at the University of Leeds.
It would seem that a lower-than-expected confirmation rate was achieved, as only
about ~18% and 45% of the variants with quality scores between 10 and 20 and those
between 20 and 30 were confirmed, respectively. However, it is important to take into
account that the quality score gives the likelihood of observing the reported genotype
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Table 2.6: Top 30 genes after prioritisation, European phase. P-values were not
corrected for multiple tests as we did not use them to assess significance of mutational
events but for producing a ranked list of candidates.
g P -valueg scoreg
MAGEB1 0 0
SPINK2 0 0
LCN1 0 0
BEST1 1.32E-06 6.62E-07
NFE2L3 3.98E-06 1.99E-06
NEBL 4.03E-05 5.04E-06
CACNA1E 1.25E-05 6.27E-06
WBP11 6.44E-05 8.05E-06
C1orf93 1.08E-05 1.08E-05
PASK 3.03E-05 3.03E-05
ZNF160 0.000290599 3.63E-05
CTSA 0.000154824 3.87E-05
SOX17 0.000316849 7.92E-05
MPHOSPH9 0.001369208 8.56E-05
SYTL5 0.000205992 0.000102996
KLHDC8A 0.001758527 0.000109908
C6orf25 0.000529058 0.000132264
NECAB3 0.000154336 0.000154336
BIN1 0.000164977 0.000164977
NBR2 0.000178824 0.000178824
RNF213 0.026272146 0.000205251
TMC2 0.000875866 0.000218967
CRIP2 0.000228709 0.000228709
NAT10 0.000275362 0.000275362
PCDH15 0.000700415 0.000350207
SMG1 0.023773426 0.00037146
ITIH5 0.000390115 0.000390115
PDZD7 0.000858102 0.000429051
AGAP3 0.00044007 0.000440073
SCLT1 0.00046525 0.000465246
given the sequencing data and their quality, and that no systematic biases are considered
in its calculation. Therefore, it is unable to predict the experimental validation rate.
Based on the experimental validation rate, a modified prioritisation list was compiled
from Table 2.6. This re-ranked list takes as basis the methodology performed above,
as only variants in previously highly-ranked genes were tested. Additionally, we were
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Figure 2.6: Percentage of variants confirmed by PCR to be real grouped by
quality score. Overall, 608 variants were tested, and 522 were confirmed to be real.
able to test for co-segregation in additional members of several pedigrees, that were
not sequenced in the discovery or replication phases. The final candidate list from this
prioritisation strategy, ranked by the number of variants co-segregating in pedigrees, is
shown in Table 2.7, along with the Gene Ontology terms from each gene.
2.3.3 Development of a visualisation tool for germline variants
The gene ranking methodology described above takes into account the number and types
of mutations detected in a gene, the likelihood of seeing as many as those mutations
in a control dataset, and the probability that those variants co-segregate in a given
pedigree. However, it does not take into account the positions within a protein where
these mutations lie, or if they are found in other common variation datasets that we did
not use in the filtering steps. For example, a gene with three different variants disrupting
one functional domain might be more biologically relevant than one with five mutations
scattered throughout the protein.
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In order to take these concerns into account, I wrote a programme capable of taking
a list of genomic variants (specifying only chromosome, variant position, base change
and strand) and outputting a schematic diagram showing where these mutations lie in
protein context. The programme plots all translatable transcripts per gene along with
their functional domains, and shows variants alongside a colour code indicating whether
they are found in any user-specified variation datasets (specified in variant call format
[VCF] when running the program). Optionally, the user can specify distinct variation
files for distinct study phases, which the programme draws in different colours.
I wrote this piece of software in the Perl programming language, using the Graphic
Design (GD) module for plotting [401], the Ensembl VEP for variant prediction [386] and
the Ensembl Perl Application Programme Interface (API) [395] for obtaining information
about transcripts and protein structure. An illustrative example can be seen in Fig. 2.7.
With this tool, I could easily and quickly generate plots for manual inspection, for
all 701 genes. Examination of PCR-validated variants in the top 25 genes, however,
revealed no evident mutational patterns.
2.3.4 Other analyses
2.3.4.1 Founder mutation analysis
In the discovery phase and subsequent gene prioritisation, we only considered genes
that had two or more variants in different pedigrees. Additionally, we required these
variants to be unique to a pedigree. We reasoned that this strategy would highlight
genes with multiple, rare and potentially causal variants in the melanoma cohort while
discarding any systematic biases arising from the sequencing, processing and variant
calling methodologies [388].
However, it can also be the case that a causal variant that would normally be rare has
become more common with small population isolation and interbreeding, as has been
shown for variants in BRCA1 and BRCA2 [403]. Such variants would have been missed
from the above analysis. In order to address this issue, we performed the same filtering
steps described above but we lifted the requirement for the variant to be unique, as well
as the filter requiring it to co-segregate with melanoma in more than one pedigree.
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Figure 2.7: Example of a protein plot showing NGS-detected variants. The
NEBL gene was chosen for illustrative purposes. For brevity, only two transcripts are
shown, although the original plot depicts five. The gene name and associated Ensembl
ID are shown at the left, followed by a list of domains (in this case, from the Pfam
database [402]). Types of consequences are shown at the right, along with the colour
code for different phases in the study. Four common variation datasets were fed into
the program (shown at the top right corner in different colours). The four squares next
to a variant indicate whether it is found in any of the variation datasets: If it is, the
square is filled with the colour corresponding to that dataset, otherwise it is blank. One
variant (Ex. 2 S.S.) is found in the NHLBI GO ESP dataset [17] (represented by a green
square). The three variants detected in the discovery phase (Table 2.3) are depicted in
blue, whereas two variants detected in the replication phase are shown in red. Ensembl
transcript IDs are indicated at the left of each plot. Versions of software used to run the
programme are indicated at the bottom. Ex: Exon, SS: Splice site.
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Table 2.7: Gene prioritisation after validation of NGS-detected variants. The
numbers of variants that were found to co-segregate and not co-segregate in melanoma-
prone pedigrees are indicated, as well as the number of variants successfully tested.
These variants include those detected in the replication phase. Note that some pedigrees
might have additional members that were not sequenced but were PCR-tested. Some
variants failed at the confirmation stage and could not be assessed. Only genes from
The Gene Ontology (GO) terms in this table are representative from the full list, and
were extracted from Ensembl release 65.
Gene Number of
pedigrees with
confirmed
co-segregating
variants
(number of
members in
each pedigree)
Confirmed
variants
not co-
segregating
Variants
success-
fully
tested
GO terms
SMG1 4 (4, 3, 3, 2) 0 6 DNA repair, response to
stress, nucleotide binding,
nuclear-transcribed mRNA
catabolic process,
nonsense-mediated decay,
protein serine/threonine
kinase activity, protein
binding, ATP binding
RNF213 4 (3, 3, 2, 2) 5 9 Nucleotide binding, protein
binding, ATP binding, zinc
ion binding,
nucleoside-triphosphatase
activity
PDZD7 3 (3, 2, 2) 2 6 Protein binding, nucleus,
cilium
NFE2L3 3 (2, 2, 2) 0 3 Sequence-specific DNA
binding transcription factor
activity, transcription from
RNA polymerase II promoter
CTSA 3 (2, 2, 2) 0 3 Serine-type carboxypeptidase
activity
KLHDC8A 2 (3, 3) 0 2 Protein binding
C6orf25 2 (3, 3) 0 2 Receptor activity, endoplasmic
reticulum, heparin binding
ZNF160 2 (3, 2) 0 2 DNA binding, regulation of
transcription, zinc ion
binding, hemopoiesis
MPHOSPH9 2 (3, 2) 0 2 M phase of mitotic cell cycle,
Golgi membrane
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CACNA1E 2 (2, 2) 0 3 Behavioural fear response,
regulation of heart rate,
voltage-gated calcium channel
activity, visual learning,
sensory perception of pain,
sperm motility
WBP11 2 (2, 2) 0 2 Single-stranded DNA binding,
RNA processing, protein
phosphatase type 1 regulator
activity
PCDH15 2 (2, 2) 0 2 Photoreceptor outer segment,
startle response,
morphogenesis of an
epithelium, calcium ion
binding, cell adhesion, visual
perception, locomotory
behavior
NECAB3 1 (4) 0 1 Calcium ion binding, Golgi cis
cisterna, oxidoreductase
activity, antibiotic
biosynthetic process,
regulation of amyloid
precursor protein biosynthetic
process
BEST1 1 (2) 0 3 Chloride channel activity,
visual perception
NEBL 1 (2) 1 2 Structural constituent of
muscle, regulation of actin
filament length
PASK 1 (2) 0 3 Nucleotide binding, protein
kinase activity, signal
transducer activity, ATP
binding
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SOX17 1 (2) 0 3 Negative regulation of
transcription from RNA
polymerase II promoter,
angiogenesis, vasculogenesis,
cardiogenic plate
morphogenesis, negative
regulation of Wnt receptor
signalling pathway involved in
heart development,
sequence-specific DNA
binding transcription factor
activity
SYTL5 1 (2) 0 1 Intracellular protein
transport, Rab GTPase
binding, metal ion binding
We found 60 variants predicted to affect protein sequence that were present in more
than one pedigree for which co-segregation information was available (Table A.1.6).
Unsurprisingly, many of these seem to be systematic errors after removal of common
SNPs in common variation databases, especially those found in multiple pedigrees (see
Subsection 2.1.3) (Fig. 2.8). Consistent with these types of error, almost all of these
variants are insertions or deletions, with only two missense variants not involving these
types of mutational events (Table A.1.6). These two variants are located in WAS protein
family homolog 6 pseudogene (WASH6P) and Golgin A6 family-like 10 (GOLGA6L10 ).
WASH6P was found mutated in pedigrees UF15, UF16 and UF19 (Fig. A.1.1), and
is located in chromosome X. So far, although somatic inactivation of X-linked tumour
suppressors has been demonstrated (e.g., for forkhead box P3 [FOXP3 ] and APC mem-
brane recruitment protein 1 [AMER1 ]), no examples of germline inactivation of X-linked
tumour suppressors have been found. This might be because these genes seem to be
homozygous lethal (reviewed in [404]). That it acts as a proto-oncogene cannot be
discarded; however, this is unlikely given that WASH6P is classified as a pseudogene
[405]. There are no reports for the function of GOLGA6L10, although its annotation
has disappeared from the most current Ensembl database release (76), indicating that
the gene model has changed dramatically from the Ensembl version used to call variants
(65).
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GRCh37 position (chr 2)
Reference sequence
Consensus sequence
Reads [Read direction]
Low quality read
Figure 2.8: Example of a putative founder variant found in melanoma
pedigrees. This variant is found co-segregating in 10 different melanoma pedigrees,
the same or more than any other variant detected in this analysis. The position of
the variant is indicated in orange. Dots indicate that the base matches the reference,
asterisks indicate deletions. Note that the variant is found in a low-complexity region
(a long stretch of GT repeats). These variants are probably mapping errors, as
three different genotypes are observed (four or two bases deleted, and no deletion).
Chromosome position, genome assembly, consensus sequence as calculated by SAMtools
(before variant calling), and read orientation are indicated. Note there are only forward
reads in this region; a low-quality read is indicated. Sequence data is displayed with
SAMtools’ tview tool [380].
There were 441 variants found to co-segregate in only one pedigree, corresponding
to 318 genes that were absent from the prioritisation stage (Table A.1.7). Some of these
might represent interesting candidates, but additional information is needed to assess
their significance (such as biological function). Some of these are covered in more detail
in the Discussion.
2.3.4.2 Mutations in known loci
During the course of these analyses, we were also interested to see whether these families
had any novel variants in other known melanoma susceptibility genes that were not
assessed at the institution of origin. As explained in Subsection 2.1.1, patients recruited
to this study were previously found to be negative for any pathogenetic variants in
CDKN2A and CDK4, and we were able to corroborate this when examining their
NGS data. However, other high- and medium-penetrance susceptibility genes have been
described, such as RB1 , BAP1 , the promoter of TERT , BRCA2 , MITF and MC1R
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(discussed in Subsection 1.6.3).
BAP1 was part of the genes captured in the replication set, however, no missense,
essential splice site, frameshifts or gains of stops were detected in any family in the
whole cohort (representing a total of 116 pedigrees). One variant in BRCA2, encoding a
proline to leucine change at position 2107 (P2107L), that passed our filters, was detected
in one individual part of the replication dataset. This variant seems to be novel, as
it is not found in the Universal Mutation Database for BRCA2 [406] or the Leiden
Open Variation Database (LOVD), from the IARC [407]. RB1 was not captured in the
replication dataset, and no germline variants passing our filters were found in any of the
pedigrees in the discovery dataset.
To analyse variants in the TERT promoter that were not captured in the exome
dataset, Mia Petljak from the Sanger and Dr. Mark Harland from the University of Leeds
PCR-amplified and capillary-sequenced the genomic region described in the original
study in all families, using the same primers [297]. We were able to identify one family,
UF19, carrying the same germline variant in both members for whom DNA was available
(Fig. A.1.1). An analysis of SNPs within the haplotype comprising this region in both
the German family described originally and UF19 suggested that this variant arose
independently, as no common variants were found (data not shown).
As the MITF medium-penetrance variant E318K was found not to co-segregate
perfectly with melanoma [358], we decided to lift the co-segregation requirement when
searching for this variant in the melanoma pedigrees. All three members of family UF10
and one member of family UF16 were found to be carriers (Fig. A.1.1), as well as three
individuals from the replication dataset.
Three different variants in MC1R were found in individuals from the discovery set:
The individual part of UF4 is heterozygous for R213W, a polymorphism that has been
observed in previous melanoma studies, although no concrete association exists between
this variant and melanoma risk [408, 409]. Other variants we identified in the discovery
phase were R109W, in one member of the four-member pedigree NF3, and the frameshift
variant F179ins c.537_538insC in one member of UF1, that has been observed previously
but for which no risk association has been found [410]. The variants found in samples
from the replication set are shown in Table 2.8. These have been found previously to be
risk factors for melanoma development [411, 412].
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Table 2.8: List of MC1R variants found in samples from the replication
dataset.
Genomic variant Protein change Number of samples
16:89985750, C/CA c.85_86insA 4
16:89985844, G/T V60L 22
16:89985918, C/A D84E 4
16:89985940, G/A V92M 14
16:89986091, G/A R142H 5
16:89986117, C/T R151C 30
16:89986130, T/C I155T 2
16:89986135, A/C T157P 2
16:89986144, C/T R160W 18
16:89986154, G/A R163Q 7
16:89986252, T/C F196L 1
16:89986546, G/C D294H 11
2.4 Summary and conclusion
During this phase of the study, we tested different methodologies in order to reduce
vast amounts of genomic data into a set of plausible melanoma susceptibility candidate
genes for biological testing. We considered diverse criteria, such as the number and
types of mutations found in a gene, the allelic frequency of these, the likelihood of
finding those variants in a matched control population, the probability that members
within an affected pedigree share the variant, the occurrence of different mutations
within functionally-relevant portions of a protein, and the biological function of the
gene (as given by GO terms). We reasoned that a high score in these attributes might
be predictive of the involvement of a gene in familial susceptibility to melanoma. We also
developed novel gene prioritisation strategies, including a software tool to graphically
assess the impact and novelty of variants detected by NGS on protein structure.
The gene at the top of our list, SMG1 phosphatidylinositol 3-kinase-related kinase
(SMG1 ), was found to have rare variants co-segregating in four different pedigrees, one
with four tested members. This is the main reason why this gene is the first candidate in
our ranking, as not all variants detected in genes scoring higher (Table 2.6) were validated
by PCR and capillary sequencing (Table 2.7). Additionally, it is a biologically plausible
candidate given that it participates in DNA repair and response to UV-induced DNA
damage [413]. Follow-up experiments on SMG1 are described in Chapter 4. Various
variants in known melanoma loci were also detected, especially a novel variant in BRCA2,
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a recently reported causal variant in the promoter of TERT, and several variants in the
medium-penetrance loci MITF and MC1R.
During the course of this phase of the study, an extensive set of samples from
Australian pedigrees became available for analysis. The number of individuals in this
dataset more than doubles the number of UK and Dutch samples used in this phase, and
therefore, we performed a different set of analyses to study them. This new, integrative
phase, is described in the next chapter.
Chapter 3
Familial melanoma sequencing:
Integrative phase
Methods and results of this chapter have been published or are accepted for publication
(refs. [376] and [414]). Some parts of the text have been reproduced from these
references; I confirm I have ownership of copyright for reproduction in this work.
While I was studying the European samples discussed in Chapter 2, a large dataset
of multi-case Australian samples became available for analysis, which more than doubled
the initial dataset. This Chapter describes the clinical characteristics of the pedigrees
and samples in this new dataset and explores the integrative analysis rationale we fol-
lowed, as well as the potential melanoma susceptibility candidates that were uncovered.
An overview of the steps followed in this phase is depicted in Fig. 3.1.
3.1 Patient selection
Australia is the country with the highest melanoma incidence in the world [369]. For this
reason, criteria for the collection of melanoma families in the UK and Australia vary, as
melanoma risk factors such as the presence of atypical naevi are much more common in
the Australian population [415]. This suggests that sunlight-induced phenocopies occur-
ring in melanoma-predisposed families might confound the search for high-penetrance
susceptibility genes.
To account for this factor, the great majority of pedigrees sequenced for this phase
had five or more melanoma cases, which reduces the probability that the aggregation of
cases observed within families was due to clustering of sporadic cases. The additional
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Figure 3.1: Flowchart of analysis steps followed in the search for melanoma
susceptibility genes, integrative phase. Steps are colour-coded depending on
the place where these were done, purple: QIMR Berghofer, yellow: Macrogen, Inc.,
green: Leeds or Leiden, blue: Beijing Genomics Institute, orange: Sanger Vertebrate
Resequencing team, red: Sanger Experimental Cancer Genetics team, pink: Leeds and
QIMR Berghofer. Black indicates a ready dataset. Arrows indicate datasets entering or
exiting the pipeline. Details of each step are annotated at their right.
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samples included in this study were recruited to the Queensland Familial Melanoma
Project (QFMP) [416], and informed consent was obtained from the Human Research
Ethics Committee of the QIMR Berghofer Medical Research Institute. Genomic DNA
was extracted from peripheral blood using standard methods. This work was done by
Lauren G. Aoude, Antonia L. Pritchard, Jane M. Palmer, Judith Symmons and Prof.
Nicholas K. Hayward at QIMR Berghofer, Queensland, Australia.
In addition to this dataset, we decided to sequence the whole exomes of 45 additional
samples from Leeds: 31 that had a family history of the disease and 14 single cases.
Twenty-one of the samples with a family history had been already included in the
replication set, but we only had sequence for 701 genes in these samples. Single cases
were selected for sequencing if they presented with either MPM or an early age of onset
(≤40 years of age), which strongly suggests a genetic component to their disease.
Therefore, our new, integral dataset comprises 184 samples in which the whole
protein-coding genome has been sequenced: 41 from the discovery set, 98 Australian
samples, and 45 additional Leeds samples, belonging to a total of 105 pedigrees. These
samples were processed in different institutes and sequencing centres (Tables 3.1 and
A.1.8).
3.2 Exome sequencing and data processing
Sixteen samples from the Australian cohort underwent whole genome sequencing, and
the rest were whole exome-sequenced (Table A.1.8). In both cases, DNA libraries were
prepared from 5μg of genomic DNA. For whole exomes, exonic regions were captured
with the Agilent SureSelect Target Enrichment System, 50 Mb Human All Exon kit,
and for whole genomes, libraries were prepared using the standard Illumina library
preparation protocol. Then, 100bp paired-end reads were generated on the Illumina
HiSeq2000 platform. These samples were processed at Macrogen, Inc. The additional
samples from the Leeds cohort were sequenced at the Beijing Genomics Institute (BGI),
and were also captured with the Agilent SureSelect Target Enrichment System, 50 Mb
Human All Exon kit and sequenced in the Illumina HiSeq2000 platform, generating 90bp
paired-end reads. Finally, both sample sets were mapped to the reference GRCh37/hg19
human genome assembly using the Burrows-Wheeler Aligner (BWA) [377], and Leeds
samples were further recalibrated and realigned around indels using the GATK package
[379].
For Leeds samples, exome capture and sequencing resulted in an average of almost
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Table 3.1: Summary of pedigrees sequenced by Institute and sequencing
centre, integrative phase. Cases marked with an asterisk were selected for an absence
of phenotypic risk markers (self-reported sun sensitivity and/or low mole count). The
case marked with two asterisks was selected because they presented with three different
primary cancers, one of which was melanoma. BGI: Beijing Genomics Institute.
Institutes Leeds (UK) Leiden
(NL)
QFMP
(Australia)
Total
Sequencing
centres
Sanger BGI Sanger Macrogen
Familial pedigrees
5+ cases 8 0 1 25 34
4 cases 11 1 2 5 19
3 cases 2 12 0 3 17
2 cases 0 18 0 2 20
Total 21 31 3 35 90
Single cases
MPM* 0 4 0 0 4
Early age of
onset* (≤40
years of age)
0 10 0 0 10
Different
primaries
0 0 0 1** 1
Total 0 14 0 1 15
Total by
Institute
66 3 36 105
78% of target bases being covered by ≥10× across the autosomes and sex chromosomes,
rising to 82% when the whole set of exomes, including the Australian samples, were
considered. Whole genomes were sequenced to at least 27× mapped coverage. Variants
were then called using SAMtools mpileup [380] and filtered for quality. Then, we removed
common variants found in the 1000 Genomes Project, October 2011 release [15] and the
dbSNP 135 release [381] (as described in Subsection 2.1.3).
We also decided, as before, to take forward only protein-changing consequences.
However, as we used an updated version of the Ensembl database (70) and the VEP (2.8),
we also updated the consequences kept for further analyses (Table 3.2). We also kept
only variants co-segregating in all affected members of a pedigree, while considering all
variants called in pedigrees for which a single individual was sequenced. The processing
of the Australian samples was done by Peter Johansson and Mitchell S. Stark, based
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at the Oncogenomic Laboratory in QIMR Berghofer. Leeds samples were aligned, im-
proved and variant-called by pipelines written by the Vertebrate Resequencing group at
Sanger, while I performed all the variant filtering steps as described in Subsection 2.1.3.
After these filtering steps, 23,051 non-polymorphic variants private to a single pedigree
remained for downstream analysis, which were filtered for quality, co-segregation in all
affected members, and were predicted to affect protein structure or function.
3.3 Gene prioritisation strategy
With the addition of the Australian families, we now had access to a much more extensive
set of pedigrees in which multiple members have been sequenced (Table A.1.8). There-
fore, we decided to search for genes that had variants, passing the above filtering criteria,
co-segregating with melanoma in pedigrees for which we had sequence information for
3 or more members. We found 320 such genes (Table A.1.9); however, we only found
5 genes that had variants co-segregating with melanoma in more than one of these
pedigrees (Table 3.3).
It would seem that there is a discrepancy between this list and the one presented
in Table 2.7, as genes RNF213, KLHDC8A and C6orf25 were found to harbour co-
segregating variants in two or more pedigrees for which information was available for
3 or more members in the European phase of this study. However, the list compiled
in Table 2.7 included capillary sequencing of additional members that were not exome-
sequenced. In particular, RNF213 had co-segregating variants in UF10, UF14, UF21
and NF2, of which only UF10 had three members sequenced by NGS (Fig. A.1.1).
Similarly, C6orf25 had co-segregating variants in UF10 and one individual from the
replication cohort, for which two additional family members were available for testing.
As such, these genes are included in Table A.1.9. KLHDC8A, however, was found with
co-segregating variants in two pedigrees that had only two members sequenced by NGS,
with an additional member per pedigree available for PCR testing (UF15 and UF16)
(Fig. A.1.1). A novel variant in SMG1 was found to co-segregate with melanoma in an
Australian pedigree for which 3 members were sequenced (discussed in Chapter 4).
This prioritisation strategy, which adds additional weight to variants co-segregating
in multiple pedigrees for which we have more information, identified two genes with
similar biological roles (as indicated by GO terms) in telomere maintenance, protection
of telomeres (POT1 ) and adrenocortical dysplasia homolog (ACD) (also known as TPP1,
TINT1, PTOP and PIP1 ) (Figs. 3.2a,b and 3.3, and Table 3.3). We then extended our
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Table 3.2: Consequences of variants kept for further analyses, integrative
phase. Table reproduced from refs. [389, 390]
Sequence Ontology term Sequence Ontology description
transcript_ablation A feature ablation whereby the deleted region includes a
transcript feature
splice_donor_variant A splice variant that changes the 2 base region at the 5’ end
of an intron
splice_acceptor_variant A splice variant that changes the 2 base region at the 3’ end
of an intron
stop_gained A sequence variant whereby at least one base of a codon is
changed, resulting in a premature stop codon, leading to a
shortened transcript
frameshift_variant A sequence variant which causes a disruption of the
translational reading frame, because the number of
nucleotides inserted or deleted is not a multiple of three
stop_lost A sequence variant where at least one base of the terminator
codon (stop) is changed, resulting in an elongated transcript
initiator_ codon_variant A codon variant that changes at least one base of the first
codon of a transcript
inframe_insertion An inframe non synonymous variant that inserts bases into
in the coding sequence
inframe_deletion An inframe non synonymous variant that deletes bases from
the coding sequence
missense_variant A sequence variant, that changes one or more bases,
resulting in a different amino acid sequence but where the
length is preserved
transcript_amplification A feature amplification of a region containing a transcript
splice_region_variant A sequence variant in which a change has occurred within
the region of the splice site, either within 1-3 bases of the
exon or 3-8 bases of the intron
incomplete_terminal_
codon_variant
A sequence variant where at least one base of the final codon
of an incompletely annotated transcript is changed
mature_miRNA_variant A transcript variant located with the sequence of the mature
miRNA
TFBS_ablation A feature ablation whereby the deleted region includes a
transcription factor binding site
TFBS_amplification A feature amplification of a region containing a transcription
factor binding site
TF_binding_site_variant A sequence variant located within a transcription factor
binding site
feature_elongation A sequence variant that causes the extension of a genomic
feature, with regard to the reference sequence
feature_truncation A sequence variant that causes the reduction of a genomic
feature, with regard to the reference sequence
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Table 3.3: Genes with co-segregating variants in more than one pedigree
with three members sequenced. The number of co-segregating pedigrees is shown
alongside their pedigree IDs and number of sequenced members. GO terms are extracted
from Ensembl release 70.
Gene name Pedigrees with
co-segregating
variants
GO terms
NEK10 2 (NF1: 3, AF11: 4) Protein serine/threonine kinase activity,
ATP binding, protein phosphorylation,
transferring phosphorus-containing groups,
metal ion binding
POT1 2 (UF20: 3, AF1: 3) Telomere maintenance via telomerase,
nuclear telomere cap complex,
single-stranded DNA binding, positive
regulation of DNA strand elongation,
protein binding
ACD 2 (AF19: 3, AF10: 3) Telomere maintenance, nuclear telomere
cap complex, negative regulation of
telomere maintenance via telomerase,
positive regulation of single-stranded
telomeric DNA binding
MPDZ 2 (AF19: 3, AF4: 3) Tight junction, cell adhesion, protein
C-terminus binding, postsynaptic density,
apical plasma membrane, virus-host
interaction, myelination
SMG1 2 (UF20: 3, AF3: 3) DNA repair, response to stress, nucleotide
binding, nuclear-transcribed mRNA
catabolic process, nonsense-mediated
decay, protein serine/threonine kinase
activity, protein binding, ATP binding
search for other variants falling within these genes in the remaining pedigrees that were
not considered in the prioritisation strategy. We identified an additional two pedigrees in
which we had sequenced only one individual, UF23 and UF31, also harbouring missense
variants in POT1 (Fig. 3.2c,d), and a single case that presented with MPM carrying
a predicted splice site variant (UN4) (Table A.1.8). We could not identify other co-
segregating variants in ACD (Table 3.4). All of these variants were confirmed by
capillary sequencing by Dr. Mark Harland, for Leeds samples, and Lauren G. Aoude,
for Australian samples.
In order to obtain a bioinformatic estimation for the pathogenicity of the variants
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Figure 3.2: Pedigree structure for families with POT1 variants. These pedigrees
were sequenced as part of the European phase of this study (UF20), or were additional
Australian (AF1) or Leeds (UF23 and UF31) pedigrees included in the integrative
phase of the study. Individuals that had their whole exome sequenced are shown
with a red outline. Types of cancers are indicated under each symbol, along with the
number of primaries and the age of onset (if known) in parenthesis. Circles represent
females, squares represent males, diamonds represent individuals of undisclosed sex.
A line through the symbol means the individual is deceased. Filled symbols represent
individuals with cutaneous malignant melanoma (CMM), and other cancers are indicated
by half-filled symbols. All melanomas were confirmed by histological analysis, with the
exception of two cases (marked by asterisks). Note that pedigrees have been adjusted
to protect the identity of the families without loss of scientific integrity. a) Pedigree
UF20, carrying the Y89C variant. b) Pedigree AF1, that was found to carry the splice
acceptor variant. c) Pedigree UF31, that was found to be a carrier of the Q94E variant.
d) Pedigree UF23, which carries the R273L variant.
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Figure 3.3: Pedigree structure for families with ACD variants. These pedigrees
were additional Australian pedigrees included in the integrative phase of the study.
Individuals that had their whole exome sequenced are shown with a red outline. Types
of cancers are indicated under each symbol, along with the number of primaries and
the age of onset (if known) in parenthesis. Circles represent females, squares represent
males, diamonds represent individuals of undisclosed sex. A line through the symbol
means the individual is deceased. Filled symbols represent individuals with cutaneous
malignant melanoma (CMM), and other cancers are indicated by half-filled symbols.
All melanomas were confirmed by histological analysis, with the exception of the cases
marked by asterisks. Unaffected siblings are indicated by a diamond with the number
of siblings shown in the centre of the symbol. Note that pedigrees have been adjusted
to protect the identity of the families without loss of scientific integrity. CML: Chronic
myeloid leukaemia. a) Pedigree AF19, that was found to be a carrier of the Q320X
variant. b) Pedigree AF10, which carries the N249S variant.
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Table 3.4: Variants in POT1 and ACD identified in melanoma pedigrees.
Pedigrees are shown with the number of individuals that were sequenced. The reference
transcripts are ENST00000357628 for POT1 and ENST00000393919 for ACD, which
are the only ones per gene for which both the Ensembl automated annotation and the
manual Havana team annotation agree.
Gene Pedigree Genomic position Consequence
prediction
SIFT [417] PolyPhen-2
[418]
POT1 UF20 (3) 7:124503684, T/C Y89C Deleterious Probably
damaging
POT1 AF1 (3) 7:124465412, C/T Splice acceptor
variant
- -
POT1 UF23 (1) 7:124493077, C/A R273L Deleterious Probably
damaging
POT1 UF31 (1) 7:124503670, G/C Q94E Tolerated Probably
damaging
POT1 UN4 (1) 7:124467262, A/C Splice variant - -
ACD AF19 (3) 16:67692665, G/A Q320X - -
ACD AF10 (3) 16:67693137, T/C N249S Tolerated Benign
identified in this study, I used the Sorting-Intolerant-From-Tolerant (SIFT) [417] and
PolyPhen-2 [418] algorithms. These tools utilise sequence conservation in protein fam-
ilies and multiple-sequence alignments to determine the functional impact that a given
substitution is likely to have. Almost all the variants identified in these genes are either
obviously disruptive or are predicted to have a high functional impact (Table 3.4).
Using the visualisation tool described in Subsection 2.3.3, I could analyse the po-
sitions where these variants lie in the protein structures (Fig. 3.4). None of the
variants detected in POT1 are found in the common variation datasets that I used
in this study, and are also not found in the set of ~6,500 exomes released by NHLBI
GO ESP [17]. Of the two variants predicted to affect splicing, one falls in a splice
acceptor site and the other one affects a base in close proximity to a splice donor
site, both in the intron between exons 17 and 18, between amino acids 562 and 563
(Fig. 3.4). Interestingly, all missense variants in POT1 lie within two repeats of a
functional domain annotated in the SUPERFAMILY database [419] as a nucleic-acid
binding, oligonucleotide/oligosaccharide-binding (OB) fold (Fig. 3.4).
Of the variants identified in ACD, one is obviously disruptive, introducing a prema-
ture stop codon, and the other one affects an amino acid in a functional domain. This
second variant, N249S, was found at an allelic frequency of 0.0012 in the 500 Exome
Project from the Metabolic Disease Group at Sanger, and at an overall frequency of
3.3 Gene prioritisation strategy 111
Figure 3.4: Plot of the POT1 and ACD variants found in familial melanoma
pedigrees. This image shows the variants detected in melanoma pedigrees in protein
context. The programme was amended to display Sequence Ontology terms, as per the
new terminology of Ensembl release 70. The "300/500 exome dataset" label refers to
the 805 in-house exomes used in filtering steps during the European phase of the study.
"WashU ESP dataset" refers to 6,500 exomes released by the NHLBI GO ESP [17].
Domains in POT1 were retrieved from the SUPERFAMILY database [419] and those in
ACD from Pfam [402]. SS: Splice site, SAV: Splice acceptor variant.
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0.0002 in the set of exomes released by NHLBI GO ESP [17]. The functional domain,
annotated in the Pfam database [402], is described as having POT1-binding function
[420, Note: The Pfam entry for PF11509, which is the domain in the figure, was recently
merged with PF10341.].
3.4 Frequency of POT1 and ACD variants in a con-
trol dataset
In order to gather further evidence for an association between variants in POT1 and ACD
and familial melanoma, I compared the representation between variants in our familial
melanoma cases with variants in controls. The controls chosen for this comparison were
the same three neurodevelopmental cohorts from the UK10K Project [399] described
in Subsection 2.3.1.1 (546 exomes) (Table 2.5). Previous to making this comparison,
however, it was necessary to ensure that cases and controls are matched by ancestry, as
was performed in Subsection 2.3.1.2. It is necessary to perform this step again, because
we have now both an extended set of cases and increased resolution to determine ancestry
(with whole genomes instead of a small targeted capture).
To ensure that the controls were matched by ancestry to the melanoma cohort, I
performed a PCA using 1,092 individuals across 14 populations from the 1000 Genomes
Project, October 2011 release dataset [15]. I took forward for analysis a subset of high-
quality variant positions (quality score >10, minimum mapping quality >10, strand
bias P -value >0.0001, end distance bias P -value >0.0001) that were common to the
melanoma cohort and the UK10K controls, as well as the 1000 Genomes Project data
set. I also excluded SNPs with a minor allele frequency <0.05 or that were in linkage
disequilibrium with another SNP (pairwise r2 > 0.1) in the 1000 Genomes Project data
set, or that had a Hardy-Weinberg P -value <1× 10−5 in the UK10K controls. After
filtering, 7,196 SNPs remained that were spread across all autosomes. Then, using the
R package SNPRelate [421], I estimated the first ten principal components using the
1000 Genomes Project individuals and then projected them onto the melanoma cohort
samples and UK10K controls. I then removed controls lying greater than 2 standard
deviations (s.d.) from the mean scores for principal component 1 or 2, calculated using
only European individuals in the 1000 Genomes Project data set (n = 20). This left a
total of 523 individuals in the control set, and the result of this analysis is shown in
Fig. 3.5. I thank Jimmy Z. Liu, from the Sanger, for his time and valuable advice on
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performing this analysis.
Finally, to ensure that individuals within the UK10K cohort were not related, an IBD
analysis was performed using the PLINK toolset [422] and the same set of variants that
were used for the PCA. For each pair of individuals with an estimated IBD >0.2, one
individual was removed at random (n= 3). This filtering left 520 exomes for comparison
against the melanoma cohort. The IBD analysis was done by Jimmy Z. Liu, from the
Sanger.
I then filtered variants in this collection of 520 UK10K control exomes as described
above (keeping positions within exonic regions and removing all variants in Phase 1 of
the 1000 Genomes Project, October 2011 release [15] and the dbSNP 138 release [381]).
I then predicted and filtered consequences as described above.
3.4.1 Variants in POT1
Because I used an updated version of dbSNP (138) for the UK10K filtering step, I
assessed whether the POT1 variants found in this phase of the study passed this filter.
After ensuring that they did, I counted variants that passed our filters in the UK10K
cohort. I found three variants in POT1 in different individuals of the UK10K cohort:
two predicted to affect splice regions falling in introns and one rare, missense variant
outside the OB domains (Q539H).
To estimate the probability of observing as many variants as I found in the melanoma
cohort, I performed a two-tailed Fisher’s exact test comparing the 4 out of 105 families
with melanoma, excluding a discovery pedigree, to three individuals out of 520 controls
carrying rare variants in POT1, yielding a P -value of 0.01703. The detected variants in
POT1 are also not found in the 805 in-house control exomes (Fig. 3.4).
The low P -value obtained by this comparison suggests that we find rare POT1
variants in our melanoma cohort at a higher-than-expected frequency when compared
to a control population matched by ancestry. Additionally, this P -value is likely to be
an underestimate, as it does not consider the fact that some of these variants are shared
across multiple individuals within a pedigree.
We also decided to search for these variants in 2,402 population-matched controls
belonging to the Leeds Melanoma Case-Control study. This control set includes 499
population-matched control DNA samples, 370 family controls (family members of melan-
oma cases without a diagnosis of melanoma) and 1,533 DNA samples from the Wellcome
Trust Case Control Consortium. All 2,402 samples were wild-type for the POT1 vari-
ants. Moreover, when we genotyped 1,739 population-based melanoma cases that were
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Figure 3.5: Principal component analysis plot showing that cases and controls
are matched by ancestry, integrative phase. Plot showing the first and second
principal components. Ancestry was estimated using the 1000 Genomes Project
individuals and then projected onto the melanoma (gray) and UK10K control (orange)
cohorts. Note that controls lying greater than 2 s.d. from the mean principal component
1 or 2 scores, calculated using only European individuals in the 1000 Genomes Project
data set, are not shown in this plot and were not considered in subsequent analyses. I
did not depict three individuals from the QFMP cohort for whom the zygosity of the
called genotypes was not available.
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recruited from across Yorkshire, UK, as part of the same study, we found one case who
carried the R273L variant. This individual presented with MPM with early onset (at 48
years of age), similar to the phenotype presented by the familial cases. This variant was
confirmed by PCR sequencing. The genotyping work I describe here was performed by
Dr. Mark Harland at the University of Leeds.
DNA was available from two individuals that were not whole-exome sequenced, one
from pedigree UF20 (predicted to be an obligate carrier, individual III-2, Fig. 3.2a)
and another one from pedigree UF23 (individual III-1, Fig. 3.2d). Unsurprisingly, the
obligate carrier tested positive for the presence of the variant, whereas the additional
member from pedigree UF23 did not. I explore the implications of this fact in Chapter
4 and in the Discussion.
Overall, we found that all nine POT1 variant carrier individuals identified through
whole-exome sequencing or by targeted PCR resequencing of additional family members
(4 from UF20, 3 from AF1, one from UF23 and one from UF31) had developed melan-
oma, presenting from one primary (four cases) to eight melanomas at 21 to 80 years
of age (Fig. 3.2). One variant carrier from these familial cases also developed breast
cancer at 63 years of age, and another developed small cell lung cancer at 47 (pedigree
UF20). Other malignancies in the untested first- or second-degree relatives of variant
carriers included melanoma (pedigrees UF20 and UF31), endometrial cancer (pedigree
UF20) and brain tumours (pedigrees UF20 and UF23). I cover follow-up experiments
on these variants, as well as the role of POT1 in familial cancer predisposition, in the
next Chapter, as well as in the Discussion.
3.4.2 Variants in ACD
Because I used an updated version of dbSNP for the UK10K filtering step, I assessed
whether the ACD variants found in this study passed this filter. The N249S variant is
annotated in dbSNP 138, having been submitted by the NHLBI GO ESP [17], in which
it is found at an overall allele frequency of 0.0002 (Fig. 3.4). The Q320X variant passed
this filter. I then counted the number of individuals in the UK10K control set that
carried rare variants in ACD and found a single, missense variant, resulting in an amino
acid substitution (A72E) that does not occur in any functional domains. A Fisher test
would not be informative in this case, as just one variant has been found in each cohort.
The QIMR Berghofer team, headed by Prof. Nicholas K. Hayward, led an investiga-
tion on the prevalence and haplotype of the ACD N249S variant. Briefly, they genotyped
an additional 4 cases or obligate carriers of pedigree AF10, and found that all of them
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harboured the variant (7 out of 7 tested cases or obligate carriers) (individuals III-3,
III-5, III-7, IV-3, IV-6, IV-7 and IV-8, Fig. 3.3b). Other carriers are individuals III-9,
III-11, IV-1 and IV-9. Individual III-4 tested negative for the variant. They also studied
the whole exomes of 7 families from Copenhagen, Denmark (recruited by the Danish
project of hereditary malignant melanoma) and discovered one family harbouring the
ACD N249S variant, segregating in 3 out of 4 members tested. This family was found
to share the ACD haplotype with the Australian family. They also performed linkage
analysis of both families and calculated a logarithm (base 10) of odds (LOD) score of
1.14.
They also searched for the N249S variant in Australian population-based case-control
panel, but did not find it in 1,669 cases or 1,590 controls. The variant was also absent
from 1,000 Danish diabetes cases and 1,000 metabolically healthy controls.
Overall, we found that ACD variant carriers presented with zero, one or two primar-
ies, at 26 to 58 years of age (Fig. 3.3). Other malignancies, such as lung and breast
cancer, are present in ACD variant carrier individuals, and brain cancer and chondrosar-
coma are also present in untested first- or second-degree relatives of variant carriers (Fig.
3.3). I cover the implications of these results in the Discussion.
3.5 Summary and conclusion
In this phase of the study, I had access to exome sequences from a much larger set
of familial melanoma pedigrees, recruited in Australia as part of the QFMP [416],
totalling 98 exomes from 36 pedigrees. We also obtained whole exome sequences from an
additional 45 Leeds patients, that were either familial cases (31 patients) or were single
cases that presented with MPM or an early age of onset (14 patients) (Table 3.1). With
this extended set of patients, an analysis of genes mutated in more than one pedigree with
multiple members was more informative than when we performed a similar analysis in the
European phase (shown in Table 2.3). We observed only five genes with co-segregating
variants in more than one pedigree for which we had sequence for 3 or more members,
and while all of them represent plausible candidates, we found it interesting that two
of these genes seem to have very similar biological functions (telomere maintenance).
These genes are POT1 and ACD. Therefore, we decided to pursue these candidates and
attempt to establish their role, if any, in melanoma predisposition.
Interestingly, POT1 and ACD directly interact with each other, as ACD recruits
POT1 to telomeres, where they belong to the six-protein complex shelterin [423, 424].
3.5 Summary and conclusion 117
Shelterin has a paramount role in protecting telomere ends from the DNA damage
response, as well as controlling telomerase access to telomeres [423]. The location of
the mutations is also interesting, as missense variants fall within the OB folds of POT1,
which allows it to bind to single-stranded (ss) DNA, or the POT1-interacting domain of
ACD [423] (Fig. 3.4). The rest of the variants found in these genes are predicted to be
disruptive, introducing a premature stop codon or affecting mRNA splicing.
A search for variants in these genes in a set of control exomes matched by ancestry
to the melanoma cases suggested that germline mutations in POT1 are rare, whereas
results were inconclusive for variants in ACD. These hypotheses were further supported
by genotyping of population-matched case control series for the particular variants found
in this study. Therefore, we decided to further investigate the molecular mechanism by
which these variants might increase melanoma risk in carriers, as well as their biological
consequences.
I describe experiments investigating the function of these variants, as well as other
genes detected in the European phase of this study, in the next Chapter. In the
Discussion, I address the involvement of the protein complex to which POT1 and ACD
belong, shelterin, in melanoma and generally in cancer predisposition.

Chapter 4
Biological validation of candidate
melanoma susceptibility genes
Methods and results of this chapter have been published or accepted for publication
(refs. [376] and [414]). Additionally, a review I wrote on sections covered by this
chapter has also been accepted for publication (ref. [425]). Some parts of the text
have been reproduced from these references; I confirm I have ownership of copyright for
reproduction in this work.
In previous chapters, I have discussed the different methodologies we followed to
pinpoint genes that might have a role in melanoma susceptibility. We found several genes
with rare variants that co-segregate with melanoma in all affected members sequenced
from each carrier family. These genes have roles in DNA repair upon UV irradiation or
telomere protection, and the detected variants are predicted to alter protein structure
or function. Therefore, these genes represent plausible candidates given their biological
roles, and moreover, some of them are mutated at a higher-than-expected frequency in
the melanoma cohort than in controls matched by ancestry.
However, in silico predictions of the consequences of these variants are insufficient
to establish the causality of these genes in melanoma susceptibility, if any, and thus
it is necessary to experimentally demonstrate their biological relevance. This Chapter
explains the experimental procedures we performed to test the effect of these variants,
and the consequences they may have in variant carriers.
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4.1 SMG1, the top candidate gene from the European
phase of the study
SMG1 was the highest-ranked candidate in the European phase of this study, and it also
had a rare variant co-segregating with melanoma in multiple members of an Australian
pedigree, which made this gene one of the top candidates of the integrative phase as
well (Table 3.3). In order to investigate the role of SMG1 in melanoma origin and
progression, we attempted to assess whether SMG1 had any influence on melanocyte
transformation, to determine if changes of expression had any effect on cell cycle or
proliferation.
4.1.1 Summary of variants found in SMG1
During the discovery phase of this study (Section 2.1), we had identified four variants
in SMG1 that segregated with the disease in four different families (Table 2.3). After
PCR validation of these variants and testing of additional pedigree members, all of these
with the exception of one were found to be real and co-segregate in all available affected
members (Table 2.7). The variant that could not be confirmed due to poor sequencing
traces, an insertion of one amino acid at position 18, was however detected by NGS in
the two sequenced cases in that pedigree. Three variants in three different pedigrees
were detected in the replication phase; however, two of these were found not to be real
after PCR validation (see Table 2.7, these are the two variants that were successfully
tested but that gave a negative result). During the integrative phase of this study,
an additional rare variant in SMG1 was found to co-segregate in all members of an
Australian pedigree (Table 3.3). This variant was also confirmed by PCR. The PCR
confirmation work and co-segregation assessment was performed by Dr. Mark Harland
for Leeds samples and Lauren G. Aoude for Australian variants. All this information is
summarised in Table 4.1.
We can appreciate, from visual inspection of the variants in a protein plot (generated
by the tool discussed in Subsection 2.3.3), that all confirmed missense variants cluster
in the C-terminus of the protein, outside any functional domains (Fig. 4.1). Two of
these variants, S3047N and H3234Q, are found at a very low frequency in the set of
exomes released by the NHLBI GO ESP [17] (1 out of 11,790 and 1 out of 12,146 alleles,
respectively), but are found to co-segregate with melanoma in all three members of the
pedigrees tested (Table 4.1). The two variants involving insertions or deletions, found
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Table 4.1: Summary of all variants found in SMG1. The study phases in which
each variant was identified is indicated. The number of individuals tested and that were
found to carry the variant is shown in parentheses.
Study
phase
Pedigree Genomic
position
(GRCh37)
Protein PCR SIFT [417] PolyPhen-
2
[418]
Discovery UF20 (4) 16:18840781,
G/A
H3144Y Real Tolerated Benign
Discovery UF16 (3) 16:18841071,
C/T
S3047N Real Tolerated Benign
Discovery UF17 (3) 16:18823187,
C/A
V3602L,
splice
variant
Real Tolerated Probably
damaging
Discovery NF2 (2) 16:18937311,
-/CGC
G18GG Poor - -
Replication RP1 (1) 16:18937327,
CGT/-
S11- Real - -
Replication RP2 16:18880434,
G/T
T942K Not
real
Tolerated Probably
damaging
Replication RP3 16:18903640,
G/A
S150L Not
real
Deleterious Benign
Integrative AF3 (3) 16:18839392,
A/T
H3234Q Real Tolerated Benign
in pedigrees NF2 and RP1, are in a repetitive region at the N-terminal portion of the
protein that consists of two serines followed by six glycines.
4.1.2 Biological function of the SMG1 protein
SMG1 belongs to the PI3K-related kinase (PIKK) family of proteins, which includes
ATM, ATR, MTOR and the DNA-dependent protein kinase, catalytic subunit (DNA-
PKcs, encoded by PRKDC ). These proteins have important roles in the response to
DNA damage, mitogenic signalling, and DNA break repair [426, 427]. Similarly to these
proteins, SMG1 has been found to participate in DNA damage response, being activated
upon UV or ionising radiation and participating in P53 phosphorylation and stabilisation
[413]. It also participates in the nonsense-mediated mRNA decay (NMD) pathway,
a process that monitors and destroys transcripts with premature termination codons
(reviewed in [428]). In this pathway, it phosphorylates UPF1 regulator of nonsense
transcripts homolog (UPF1), an essential helicase that is recruited to mRNA molecules
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Figure 4.1: Summary of variants detected in the SMG1 protein. The variants
we detected in familial melanoma pedigrees are shown in protein context, the transcript
in the picture belongs to the consensus coding DNA sequence (CCDS45430). The four
variants identified in the discovery part of the European phase are depicted in blue (Table
2.3), variants identified in the replication part are shown in red. The variant found co-
segregating in an Australian pedigree is shown in green (Table 3.3). Subsequent PCR
confirmation determined that two of the variants identified in the replication phase,
S150L and T942K, were not real (see Table 2.7, these were the variants successfully
tested but with a negative result). All other variants were confirmed as real with the
exception of the 1 aminoacid insertion at position 18, as sequence in the trace was poor
and could not be confirmed. However, this variant was found in two members of the
same family by NGS. All variants co-segregate perfectly with melanoma in all members
tested.
upon recognition of stop codons by the translation machinery (reviewed in [428]). This
phosphorylation is central to the NMD pathway, as over-expression of a kinase-mutant
form of SMG1 was found to suppress NMD, whereas that of wild-type SMG1 enhances
it [429].
Additionally, SMG1 has been found to have roles in other biological processes. It
has been implicated, for example, in the cellular response to low oxygen levels and in
tumour necrosis factor (TNF)-α-induced apoptosis. In the first case, SMG1 was shown
to be activated by hypoxia and its depletion augmented the activity of hypoxia inducible
factor 1, alpha subunit (HIF1A), a master regulator of cellular responses to low oxygen
levels [430]. In the second case, SMG1 depletion, but not that of other proteins part of
4.1 SMG1, the top candidate gene from the European phase of the study 123
the PIKK family, was shown to rapidly increase the rate of apoptosis induced by TNFα
activity [431].
SMG1 was recently found to have a role in adipogenesis, possibly via its participation
in another mRNA decay pathway, mediated by staufen double-stranded RNA binding
protein 1 (STAU1) [432]. This pathway targets higher-order structures in the 3’ untrans-
lated region (3’UTR) of mRNAs, and is more active than NMD during adipogenesis.
SMG1 down-regulation was found to delay adipogenesis possibly by phosphorylating
UPF1, an enzyme that participates in both NMD and STAU1-mediated mRNA decay
(SMD) [432]. Additionally, SMG1 might have a role in the regulation of brain phos-
phorylated α-synuclein (p-syn) levels, which are involved in neurodegenerative disorders
such as Parkinson’s disease with dementia. SMG1 knockdown was found to significantly
increase the levels of p-syn levels in the brain, and its low expression correlated with
higher levels of this phosphoprotein [433].
More intriguingly, SMG1 has also been linked to telomere maintenance, and inde-
pendently, to cancer predisposition. Depletion of SMG1 was shown to induce loss of
entire telomere tracts, as well as to induce chromosome and chromatid breaks [434].
It can localise to telomeres in vivo and antagonise the association of telomeric re-
peat–containing RNA (TERRA), which is the product of telomere transcription, with
chromatin. By preventing TERRA association with telomeres, it might aid efficient
telomere capping and cell cycle progression [435]. Although Smg1 is homozygous lethal
in mice, animals heterozygous for a knockout allele of Smg1 were found to be predisposed
to different cancers, such as lymphomas and lung adenocarcinomas, as well as having
chronic inflammation [436]. These mice did not have any defects in the NMD machinery,
but displayed tissue oxidative damage and low-level inflammation prior to the develop-
ment of tumours. These conclusions are supported by human data, as SMG1 has been
found to be significantly mutated in lung adenocarcinoma [437], and mutations in this
gene have been found in more than 5% of all assessed samples of cervix, stomach and
intestine cancers in the Catalogue of Somatic Mutations in Cancer (COSMIC) database
[438]. However, it may have a different role in myeloma and acute myeloid leukaemia,
in which it could contribute positively to cancer progression [439, 440].
In conclusion, SMG1 has been found to play a role in many diverse biological path-
ways, namely NMD, SMD, hypoxia response, adipogenesis, TNFα-induced apoptosis,
inflammation, DNA damage response upon UV and ionising radiation and telomere
maintenance. Perhaps it is the last two, together with the observation that Smg1+/- mice
are predisposed to cancer, those which are most relevant for the melanoma phenotype
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in these families with SMG1 variants. In the next subsection, I describe the different
experiments that were attempted in order to prove the role of SMG1 and these variants
in melanoma formation.
4.1.3 Description of biological assays
The experiments detailed in this section were performed by Drs. Jessamy C. Tiffen
and James Hewinson, from the Experimental Cancer Genetics team at the Sanger, in
the course of a year. The first experiment attempted was a colony formation assay in
soft agar, using a melanocyte cell line, referred to as pmel*, that already carries the
activating BRAF V600E mutation [259]. Cells that only have activated BRAF do not
spontaneously transform in soft agar, possibly due to oncogene-induced senescence [441].
The rationale behind this experiment was that if SMG1 functions as a tumour suppressor
in melanocytes (as it may be assumed given the biological roles discussed above), then
cells might transform and form colonies upon its knockdown. However, although a
stable knockdown of SMG1 was achieved via the use of lentiviral vectors, various
technical problems prevented us from completing this experiment. Mainly, mycoplasma
contamination before cells were shipped from the laboratory of origin meant that results
obtained thus far had to be repeated, and spontaneous transformation of control cells
(i.e., those not treated with a SMG1 knockdown vector) prevented us from deriving any
conclusive results. Given these difficulties, a different strategy was attempted.
The second experiment that was tried was a knockdown or over-expression of SMG1
in the melanoma cell lines A375 and Mel-ST [240, 442]. The first of these was derived
from a 54-year-old female with malignant melanoma, and the second one is a human
melanoma cell line that is immortalised but not transformed. The idea was to address
whether SMG1 expression changes had any effect on on apoptosis, cell cycle progression
and proliferation upon UV or ionising radiation. Interestingly, Mel-ST cells that had
been depleted of SMG1 via short hairpin (sh)-RNA interference showed an increase in
the proportion of cells in the S and G2/M phases of the cell cycle upon UV irradiation
when compared with irradiated controls (Fig. 4.2), in accordance with previous reports
[413]. This result might indicate that SMG1 -deficient cells have checkpoint signalling
defects upon UV-induced DNA damage, but there might be another mechanism in place
to arrest them at the S phase of the cell cycle (Fig. 4.2). This might indicate that cells
depleted for SMG1 need additional hits to progress towards malignancy. However, the
behaviour of these cells could not be reproduced in A375 cells, as these did not show
any changes in cell cycle profile upon UV irradiation.
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Figure 4.2: Cell cycle profile for Mel-ST melanoma cells with a SMG1
knockdown. Top panel, cell cycle profiles. Gray line, Mel-ST with the anti-SMG1
shRNA vector; black line, Mel-ST with a non-targeting vector. Two different UV
intensities were assessed, note that only one is shown in the top panel. Bottom panel,
bar chart showing the proportion of cells in each condition. PI: propidium iodide. I
thank Drs. Jessamy C. Tiffen and Gabriel Balmus for this image.
Finally, site-directed mutagenesis is being attempted to assess whether the particular
variants detected in melanoma pedigrees have any effect in SMG1 stability. So far,
mutants have been generated in a cDNA expression vector (from ref. [429]), and have
been confirmed to have the correct sequence. This experiment is on-going.
4.1.4 Conclusion
SMG1 is an attractive candidate for a melanoma susceptibility gene given the diverse
biological roles it plays in the cell, among them, response to UV-induced DNA damage
and P53 phosphorylation. We have attempted several different experimental methodo-
logies to assess its role in melanocytes, namely SMG1 knockdown, over-expression and
site-directed mutagenesis in melanoma cell lines. However, studying SMG1 has proven
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difficult for several reasons, among them, cell contamination and irreproducibility of
results between cell lines. We hope that we can address these concerns with further
experiments.
4.2 Candidate genes from the integrative phase
During the integrative phase of this analysis, we prioritised a list of five genes, because
they were found to have co-segregating variants with melanoma in two or more pedigrees
for which we had sequences available for three or more affected individuals (Table
3.3). Of these, POT1 and ACD were of special interest because they participate in
telomere maintenance, and furthermore, interact with each other as part of the six-
protein complex shelterin [423]. The location of the detected variants is also noteworthy,
as all of the missense variants detected fall within functional domains in the protein
structures, within the ssDNA-binding OB folds in the case of POT1 and in the POT1-
binding domain in the case of ACD (Fig. 3.4). The rest of the detected variants
are predicted to be disruptive, introducing premature stop codons or affecting mRNA
splicing. Additionally, we found variants in POT1 at a statistically higher frequency in
the melanoma pedigrees when compared with controls, even when co-segregation with
melanoma was not considered, and genotyping of a case-control series identified a case
that carried one of the familial POT1 variants. This makes POT1 and ACD attractive
candidates for being melanoma susceptibility genes. This Section details the experiments
carried out to test the involvement of the detected variants in melanoma susceptibility.
4.2.1 The biological role of POT1, ACD and the shelterin com-
plex
Telomeres are structures at the ends of linear chromosomes that consist of double-
stranded DNA repeats followed by a short ssDNA protrusion. They play an essential role
in regulating genomic stability by allowing the cell to distinguish between chromosome
ends and double-stand DNA breaks, and as such, they need to be replicated each cell
cycle and protected from DNA-processing enzymes [443, 444]. The shelterin complex,
a large macromolecular structure to which POT1 and ACD belong, binds telomeres
and has a paramount role in their protection [423]. Shelterin displays a wide range of
functions that not only include telomere length maintenance and protection from DNA
repair mechanisms, but also the regulation of diverse signalling cascades from telomeres
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Figure 4.3: The shelterin complex and its biological functions. The shelterin
complex, shown at the left of the figure, binds telomeres to protect them and regulate
diverse signalling cascades. Chromosome ends can fold into T-loops and D-loops,
which form when the 3’ ssDNA protrusion invades the double-stranded telomere.
Signalling cascades that shelterin regulates, and their biological effects, are shown at
the right. SIAH2: Siah E3 ubiquitin protein ligase 2, CBX3: Chromobox homolog 3,
RTEL1: Regulator of telomere elongation helicase 1, Tnk: Tankyrase, XPF: ERCC4,
excision repair cross-complementation group 4, WRN: Werner syndrome, RecQ helicase-
like, BLM: Bloom syndrome, RecQ helicase-like, MRN: MRE11-RAD50-NBN complex,
OBFC1: oligonucleotide/oligosaccharide-binding fold containing 1, Ub: Ubiquitination,
ADPr: ADP ribosylation, NHEJ: Non-homologous end joining.
[444] (Fig. 4.3).
The other components of shelterin are telomeric repeat-binding factors 1 and 2
(TERF1 and TERF2, also known as TRF1 and TRF2), TERF1-interacting protein 2
(TINF2, also known as TIN2) and TERF2-interacting protein 1 (TERF2IP, also known
as RAP1) [423]. Although these proteins are fast-evolving, with the architecture of
the complex being different in organisms such as ciliates and yeast when compared to
mammals, the overall functionality of shelterin is highly conserved [445, 446].
TERF1 and TERF2 are double-stranded DNA-binding proteins that recognise telo-
meric repeats with high affinity upon homodimerisation, while POT1, the most evol-
utionarily conserved member of shelterin, can specifically recognise telomeric ssDNA
[423, 447–449]. Therefore, the presence of several TTAGGG-binding domains in the
complex gives shelterin its exquisite specificity for telomeric sequence. ACD binds to
POT1, recruiting POT1 to telomeres and enhancing its recognition ability, whereas
TERF2IP localises to telomeres via its interaction with TERF2 [423, 450]. TINF2 is
able to bind TERF1, TERF2 and the ACD/POT1 sub-complex, therefore bringing all
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the shelterin components together [451, 452].
The importance of the shelterin complex is evidenced by the fact that null mutations
in the majority of its components result in embryonic lethality in mice [453–456]. One of
the most important functions of shelterin is to protect chromosome ends from DNA repair
nucleases, which it achieves by inhibiting six DNA damage signalling pathways: ATM-
and ATR-signalling, classical non-homologous end joining (NHEJ), alternative NHEJ,
homologous recombination, and resection [457]. Shelterin also has an important role in
regulating telomere structure and length. TERF1 and TERF2 have DNA remodelling
activities, being able to bend DNA and contributing to T-loop formation, whereas POT1
is able to regulate telomere length by contributing to the nucleolytic processing of the
telomeric 5’ end and control telomerase access to the end of chromosomes [423, 447,
458, 459]. The absence of functional shelterin therefore leads to polyploidization, fragile
telomeres and sister chromatid exchanges, among other chromosomal aberrations [457].
In particular, POT1 can function both as a negative and a positive regulator of
telomere length. In support of the former role, its knockdown has been shown to elicit
telomere lengthening in HTC75 cells [424], and so does a mutant form lacking the DNA-
binding domain [460], or the ACD-binding domain [461]. Additionally, point mutations
affecting the ability of POT1 to bind to ssDNA in CLL cells were shown to lead to
telomere lengthening, as well as various types of chromosomal aberrations [462]. In
support of the latter role, POT1 has been found to enhance the processivity of telomerase
when found in a complex with ACD [463], and its exogenous expression in telomerase-
positive HT1080 cells led to telomere elongation, albeit with some variability [464].
In order to explain these seemingly contradictory results, Feng Wang and colleagues
proposed a three-state model for the role of POT1 at telomeres [463]: First, when
POT1 is bound to the 3’ overhang as part of the shelterin complex, it blocks access to
telomerase by sequestering the telomere, thus acting as a negative regulator of telomere
length. Second, the POT1-ACD complex is removed from chromosome ends, possibly
by disruption of the shelterin complex. Third, the POT1-ACD complex is recruited
to telomeres to serve as a telomerase processivity factor. The cycle is restarted as the
telomere is elongated, as it can bind shelterin complexes and the 3’ overhang can be
re-bound by the POT1-ACD complex. POT1 depends on ACD for its recruitment to
telomeres, as ACD knockdown has been shown to reduce POT1 localisation to the ends
of chromosomes and to promote telomere dysfunction [445].
Additionally, knockdown of POT1 in tumour cells has been shown to elicit a transient
DNA damage response and to alter the sequence of chromosome termini, thus also
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determining telomere structure [459]. In this study, tumour cells depleted for POT1
displayed telomere dysfunction, yet they could proliferate as well as control cells without
the POT1 knockdown vector. In contrast, human primary fibroblasts responded to
POT1 depletion by inducing senescence and reducing cell division, but proliferation was
partially restored upon abrogation of the P53 and the INK4A/RB1 pathways. This
observation is interesting, as it could mean that additional mutations are necessary
in order for POT1-deficient cells to progress to tumourigenesis. Several studies have
also shown that a single POT1 allele that is unable to bind ssDNA is enough to exert
a dominant-negative effect, indicating that abrogation of a single copy of the gene is
sufficient to inhibit POT1 function [460, 462, 465]. This effect might be due to disrupted
interactions at the telomere, as TERF2 has reduced association with its binding partners
in the shelterin complex upon mutant POT1 expression [465].
In conclusion, POT1, ACD and the other shelterin components play an essential role
in telomere length regulation and protection, and their malfunction might predispose
cells to malignancy via telomere uncapping and length dysregulation, which then could
lead to chromosomal abnormalities. In the next subsection, I describe the studies we
performed to investigate the biological effect of the POT1 and ACD variants detected
in melanoma pedigrees.
4.2.2 The effect of POT1 variants found in melanoma pedigrees
In total, we identified five pedigrees carrying different POT1 variants, two predicted to
affect mRNA splicing and three missense (Fig. 3.4, Table 3.4). We performed different
analyses to study the function of these two types of mutations.
4.2.2.1 Investigation of the variants predicted to affect mRNA splicing
There were two variants predicted to affect POT1 mRNA splicing detected in familial
melanoma pedigrees, one falling in an intronic splice acceptor site and another one falling
6bp away from a splice donor site (Fig. 3.4, Table 3.4). In order to computationally
predict whether these variants were likely to be deleterious, I used the MaxEntScan
algorithm [466] to compare the sequences of the variant and wild-type splice sites. This
algorithm was shown to be able to accurately discriminate real splice acceptor and donor
sites from decoys, and works by supplying only a short sequence at the intron-exon
boundary. It then assigns a score reflecting the likelihood that the sequence functions
as a splice donor or acceptor. The scores for the region with the splice acceptor variant
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were 5.53 (wild-type) and -3.32 (with variant), whereas for the splice donor region these
were 7.96 (wild-type) and 4.7 (with variant).
To put these scores in context, I retrieved 10,000 sequences at random from the
human genome, using the Ensembl API release 70, and obtained their MaxEntScan
scores. Subsequently, I retrieved 10,000 real splice acceptor sites and 10,000 real splice
donors from human genes chosen at random, but always choosing the second exon. I then
obtained a distribution of all of their MaxEntScan scores. The splice acceptor variant
lowered the score of the wild-type sequence from the 9.2th to the 0.57th percentile
when compared to the score distribution of real splice acceptors, while the splice donor
variant lowered it from the 33.67th to the 12.31th percentile when compared to the
score distribution of real splice donors (Fig. 4.4). Therefore, the splice acceptor variant
is predicted to be highly deleterious, whereas the splice donor variant still falls well
within the scores of real splice sites.
We then decided to test whether these variants had any effect in POT1 mRNA
splicing. To do this, RNA extracted from the whole blood of two carriers of the splice
acceptor variant (pedigree AF1) was converted to cDNA using SuperScript III Reverse
Transcriptase (Invitrogen). RT-PCR was then performed to confirm that this variant
was indeed disruptive to splicing. M13-tagged forward and reverse primers were designed
to flank the spliced region. The product was visualised on a 3% NuSieve Agarose gel,
and the sequence was verified using standard Sanger sequencing methods. This work
was done by Lauren G. Aoude, at QIMR Berghofer. This experiment showed that this
splice acceptor variant affects transcript splicing, as it leads to a frameshift and the
introduction of a premature stop codon 11 amino acids downstream of the intron-exon
boundary (Fig. 4.5).
As we failed to see any effect of the splice donor variant on transcript splicing by
PCR, we decided to perform whole blood RNA sequencing from the carrier to see whether
we could find traces of any aberrant POT1 transcripts. However, we could not detect
anything abnormal (data not shown). The RNA extraction was performed by Marcela
Sjöberg and the transcriptome analysis was done by Martin del Castillo, at Sanger.
These analyses support that the splice acceptor variant carried by pedigree AF1 is
disruptive to the POT1 transcript, causing a frameshift and introducing a premature
stop codon. However, we did not find evidence to support that the splice donor variant
is deleterious to the carrier.
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Figure 4.4: MaxEntScan scores for the splice acceptor and splice donor variants
detected in familial melanoma pedigrees. The location of the scores for the wild-
type (black) and variant (red) sequences for the splice acceptor (solid) and splice donor
(dotted) sequences are shown against score distributions for real splice donors, real splice
acceptors and random genomic sequences.
4.2.2.2 Investigation of the three missense variants detected in melanoma
pedigrees
4.2.2.2.1 Evolutionary conservation of variant positions In order to assess
the evolutionary conservation of the residues where we detected variants in POT1, I
gathered amino acid sequences for the encoded protein in evolutionarily diverse species
(i.e., human, mouse, cow, armadillo, elephant, opossum, platypus, chicken, frog and
zebrafish) from the National Centre for Biotechnology Information (NCBI) and aligned
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a b
Figure 4.5: The POT1 splice acceptor variant affects transcript splicing. a)
Rationale for the effect of the splice acceptor variant. The splice acceptor signal sequence
(AG) is underlined, and the variant is indicated. This variant is predicted to cause a
one-base shift of the splice acceptor signal. b) Sequencing of the POT1 product in a
control with wild-type POT1 (top) and a carrier of the splice acceptor variant (pedigree
AF1, individual IV-1, Fig. 3.2) (bottom). The boundary between exons 17 and 18 is
marked with a dotted red line. The wild-type sequence, in nucleotides and in amino
acids, is indicated in black, and the sequence the variant results in is indicated in red.
The mutant sequence leads to the introduction of a premature stop codon 11 amino
acids downstream of the exon 17-exon 18 boundary.
them using Clustal Omega [467]. All of the missense variants we identified in POT1
disrupt amino acids that are completely conserved through eutherians (Fig. 4.6).
To estimate the number of substitutions per site in this amino acid alignment, I used
the ProtPars routine from the PHYLIP package of programmes [469]. This routine is
able to infer an unrooted phylogeny from the sequences supplied by counting the number
of mutations required to span all the amino acids observed at each site of the alignment,
while being consistent with the genetic code. Synonymous variants are omitted from the
final count, as it is assumed that they are not under selection. As such, it is capable of
estimating the number of substitutions, at the DNA level, that occurred in the amino
acid alignment shown in Fig. 4.6. This analysis showed higher conservation for the three
altered amino acids (2, 2 and 0 substitutions at positions 89, 94 and 273, respectively)
than the average for the OB folds (2.42 substitutions per site) and, in fact, the whole
protein (3.49 substitutions per site) across ~450 million years of evolutionary history
(since the divergence of the zebrafish and human lineages). If we only consider sequences
from eutherian organisms, then no substitutions have occurred in any of these three
residues, compared to 0.8 substitutions per site in the OB folds and 1.39 substitutions
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Figure 4.6: Highly conserved residues of POT1 are altered in familial
melanoma. Shown are the positions of the missense variants on a multi-species amino
acid alignment. More conserved amino acids through evolution are shown in a darker
colour. The alignment is displayed using Jalview v2.7 [468].
per site in the whole protein. I defined the OB fold regions as amino acids 8-299 in the
human sequence, according to the annotation in SUPERFAMILY [419].
4.2.2.2.2 Structural modelling and characterisation of POT1 variants Hav-
ing corroborated that the positions where these variants lie are highly conserved, we then
proceeded to structurally characterise the residues in which we find germline variants.
To do this, we examined the structure of the POT1 protein bound to a telomere-like
polynucleotide (dTUdAdGdGdGdTdTdAdG), obtained from the Protein Data Bank
(PDB), id: 3KJP [470, 471]. According to this model, all three altered residues (Y89,
Q94 and R273) were among 24 residues located in close proximity (<3.5 Ångströms)
to the telomeric polynucleotide [462] (Fig. 4.7a). R273 interacts with the oxygen at
position 2 of telomeric deoxythymidine 7, whereas Q94 and Y89 both interact with the
G deoxynucleotide at position 4. Remarkably, the POT1 codon for Q94 has been found
to be a target for recurrent somatic alteration (Q94R) in CLL, where ~5% of cases carry
POT1 mutations that cluster in the sequences encoding the OB folds [462]. Therefore,
the POT1 variants we identified are expected to weaken or abolish the interaction of
POT1 with telomeres.
The list of 24 residues located in close proximity to the telomeric polynucleotide,
based on this crystal structure, was defined by Andrew J. Ramsay et al. in a previous
publication [462]. These residues are 31, 33, 36, 39–42, 48, 60, 62, 87, 89, 94, 159,
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Figure 4.7: Missense variants in POT1 disrupt the interaction between POT1
and single-stranded DNA. a) Shown are the locations of the POT1 Y89, Q94 and
R273 residues in the two N-terminal OB folds (green). A telomere-like polynucleotide
sequence is shown in orange. Interacting nucleotides in the telomeric sequence are labeled
in gray. All three substitutions are predicted to disrupt the association of POT1 with
telomeres. This image was generated by Víctor Quesada, at the University of Oviedo,
Spain, and was rendered with PyMOL v0.99 [472]. b) Mutant Y89C, Q94E and R273L
POT1 proteins are unable to bind telomeric (TTAGGG)3 sequences as shown by an
electrophoretic mobility shift assay. The Y223C POT1 mutant was used as a positive
control representing a known disruptive alteration [462].
161, 223, 224, 243, 245, 266, 267, 270, 271 and 273. In order to assess the statistical
significance of finding amino acid substitutions affecting these residues in the population,
I searched 6,503 exomes released by the NHLBI GO ESP [17] for substitutions at any
of the bases that would cause a change in these amino acids. The genomic positions
that encode these 24 residues are shown in Table 4.2. In summary, a minimum of
6,498 exomes had all bases covered at a minimum average coverage of 59×. The variant
encoding N224D was found at an overall allele frequency of 1 in 13,005. No other amino
acid–changing variants were found. I then compared the number of variants found in
these 24 OB domain residues in controls (1 in 6,498) to the number of variants found in
all analysed pedigrees (3 in 105), obtaining a P -value of 1.54×10−5 using a two-tailed
Fisher’s exact test. This comparison indicates that our melanoma cohort is enriched for
rare variants in DNA-interacting residues of POT1 when compared to the population.
The in silico analyses above point to these variants being deleterious, as not only are
4.2 Candidate genes from the integrative phase 135
Table 4.2: Genomic location of bases encoding the 24 OB domain residues in
close proximity to telomeres
Amino acid Genomic position (GRCh37)
31 g.124532351-124532353
33 g.124532345-124532347
36 g.124532336-124532338
39 g.124532327-124532329
40 g.124532324-124532326
41 g.124532321-124532323
42 g.124532320 and g.124511094-124511095
48 g.124511076-124511078
60 g.124511040-124511042
62 g.124511034-124511036
87 g.124503689-124503691
89 g.124503683-124503685
94 g.124503668-124503670
159 g.124503473-124503475
161 g.124503467-124503469
223 g.124499044-124499046
224 g.124499041-124499043
243 g.124493166-124493168
245 g.124493160-124493162
266 g.124493097-124493099
267 g.124493094-124493096
270 g.124493085-124493087
271 g.124493082-124493084
273 g.124493076-124493078
they predicted to be so by bioinformatic algorithms (Table 3.4), but variants in amino
acids that participate in protein-DNA interactions seem to be extremely rare. The
positions at which these variants are found are also highly conserved through evolution,
and the variants themselves have the potential to impair POT1 binding to telomeres.
Therefore, we decided to formally test whether the variants we identified disrupt POT1
function.
4.2.2.2.3 In vitro translation and G strand binding assays To test the ef-
fect of these variants on POT1 function, we assessed the ability of in vitro-translated
POT1 proteins carrying the Y89C, Q94E and R273L variants to bind to (TTAGGG)3
sequences. Human POT1 in a T7 expression vector (Origene) was mutated by site-
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Figure 4.8: 35S gel showing the in vitro translation products of POT1 wild-
type (WT) and OB domain mutants. This gel confirms that each in vitro
translation reaction successfully produced protein for the electrophoretic mobility shift
assay shown in Fig. 4.7b. The Y223C variant was somatically acquired in CLL and has
previously been shown to be unable to bind to telomeric DNA [462]. The DNA-protein
complexes shown in 4.7b were visualised by [32P]-labeling of (TTAGGG)3 ssDNA.
directed mutagenesis to generate cDNAs encoding the POT1 Y89C, Q94E and R273L
variants. Mutant and control T7 expression vectors were used in an in vitro transla-
tion reaction using the TNT coupled reticulocyte lysate kit (Promega) following the
manufacturer’s instructions. A 5-μl fraction of each reaction was analysed by SDS-
PAGE; proteins were visualised and relative amounts were quantified using the FLA
7000 phosphorimager system (Fujifilm) (Fig. 4.8). DNA binding assays were performed
as described previously with minor modifications [473]. Protein-DNA complexes were
analysed by electrophoresis on a 6% polyacrylamide Tris-borate-EDTA gel run at 80 V
for 3 h. Gels were visualised by exposure to a phosphorimager screen (Fig. 4.7b). DNA
mutagenesis, in vitro translation reactions and DNA binding assays were performed by
Andrew J. Ramsay, at the University of Oviedo, Spain.
Electrophoretic mobility shift assays showed a complete abolition of POT1-DNA
complex formation with mutant POT1 (Fig. 4.7b). Notably, other similar variants
that abolish the binding of POT1 with telomeres have been described to be somatically
acquired in CLL [462]. The variants found in CLL, in particular Y36N and Y223C,
promote uncapping of telomeres, telomere length extension and chromosomal aberrations
and thereby promote tumourigenesis.
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4.2.2.2.4 Analysis of telomere length in POT1 variant carriers Given these
observations, and the important role of POT1 in telomere length maintenance, we next
asked whether melanoma cases from pedigrees with mutated POT1 had telomere lengths
that differed from those of non-carrier melanoma cases. Therefore, using exome sequence
from the 41 cases that belong to the discovery phase (in which the three members of
UF20 were sequenced), telomere length of each subject was estimated from NGS data.
The algorithm used, called TelSeq and written by Zhihao Ding at the Sanger [474],
estimates telomere length by counting TTAGGG sequences in unmapped reads in NGS
data, and takes into account factors such as GC composition and read length in order to
give an accurate estimation. The algorithm was shown to correlate with Southern blot
measurements of telomere lengths, so it is a useful tool to compare telomere lengths in
melanoma patients with and without POT1 variants. Only the discovery phase cohort
could be used because the exomes sequenced by BGI, to which the Q94 and R273 carriers
belong, did not contain any unmapped reads and thus could not be assessed by TelSeq.
The telomere length measurement was performed by Zhihao Ding, who was blinded to
the POT1 status of all samples.
After calculation of relative telomere length, I adjusted the 38 samples without
germline POT1 variants for age at blood draw and sex using a linear model (Fig. 4.9).
I then estimated the corresponding values for POT1 variant carriers on the basis of
the same adjustment. I did these calculations with a custom R script, using the Hmisc
library [475].
This analysis showed that all three members of pedigree UF20 had telomeres that
were significantly longer than those in melanoma cases with wild-type POT1. I per-
formed a Wilcoxon rank-sum test comparing the telomere lengths of the three Y89C
cases to that for the 38 non-carrier controls (P -value <0.0002, Fig. 4.10a).
Because not all samples with missense variants could be included in the bioinformatic
measurement, we decided to measure telomere lengths by PCR in all missense variant
carriers, as well as other members of their families (both carriers and non carriers) and
a panel of melanoma cases that did not carry POT1 variants at these positions. These
individuals had been genotyped for the detected variants before (see Subsection 3.4.1).
Therefore, in this measurement, we included cases from the Leeds Melanoma case-control
study, seven POT1 missense variant carriers (pedigrees UF20, UF31 and UF23 and the
carrier individual from the Leeds Melanoma cohort) and two non-carrier family controls
(UF23, individual III-1 and UF20, individual III-1, Fig. 3.2). Relative mean telomere
length was ascertained by SYBR Green RT-PCR using a version of the published
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Figure 4.9: Linear model used to adjust bioinformatically calculated telomere
lengths for age at blood draw and sex. Residuals were used as the adjusted relative
telomere lengths. Dark circles represent male samples, and light circles represent females.
The sex variable is coded as 0=female, 1=male. Note that only two dimensions (relative
telomere length and age) are shown.
4.2 Candidate genes from the integrative phase 139
−6 −4 −2 0 2 4
0.0
0.1
0.2
0.3
0.4 Y89C
Q94E
R273L
Non-carrier 
family controls
D
en
si
ty
R
el
at
iv
e 
ad
ju
st
ed
te
lo
m
er
e 
le
ng
th
Pedigree UF20
POT1 Y89C
Cohort
POT1 WT
0.0
0.2
0.4
0.6
0.8
1.0
Adjusted mean −∆Ct values
IV-2III-4II-2
a b
longer telomeres
P<0.0002
Figure 4.10: Missense variants in POT1 lead to elongated telomeres. a)
Calculation of telomere length from exome sequence data. Relative adjusted telomere
lengths for the three sequenced members of pedigree UF20 are shown alongside the
mean telomere length of 38 (all other) melanoma cases that were sequenced alongside
them but were wild type for POT1. All values are shown relative to the largest sample
measurement. Error bars, 1 s.d. b) PCR-based estimate of telomere length. Adjusted
mean -ΔCt values, which correlate positively with telomere length, for POT1 missense
variant carriers and non-carrier family controls are shown against a distribution of values
from 252 melanoma cases recruited from the Leeds Melanoma cohort that are wild type
at the above-mentioned positions. All measurements have been adjusted for age at blood
draw and sex. The black line represents a Gaussian kernel density estimate for this set
using Silverman’s rule of thumb [476] for bandwidth smoothing. Orange dots, members
of pedigree UF20; pink dots, members of pedigree UF31; blue dots, members of pedigree
UF23; red dots, individual from the Leeds Melanoma case control study carrying the
R273L variant. The number of biological replicates for each individual ranged from one
to four, each with two technical replicates, for the POT1 missense variant carriers and
non-carrier family controls. Two technical replicates were performed for the 252 POT1
non-carrier cases. Error bars, standard error of the mean.
quantitative PCR protocols [477, 478] that was modified as described previously [479].
In brief, genomic DNA was extracted from whole blood, and telomere length was
ascertained by determining the ratio of detected fluorescence from the amplification of
telomere repeat units (TEL) relative to fluorescence for a single-copy reference sequence
from the HBB (β-globin) gene (CON). Telomere and control reactions were performed
separately. For each assay, the PCR cycle at which each reaction crossed a predefined
fluorescence threshold was determined (Ct value). The difference in the Ct values,
∆Ct = CtTEL−CtCON, was the measure of telomere length used in the analysis, as
in other published data generated using this assay [479, 480].
For the analysis, samples with CtCON < 18, CtCON > 27 or CtCON > 2 s.d. away
from the mean were removed and considered to represent failed reactions. This filtering
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left 252 samples from the Leeds Melanoma cohort for further analyses, with no missense
variant carriers or non-carrier family controls removed. All samples had between two
and eight technical replicates. The telomere length estimation by PCR was performed
by Karen A. Pooley and Alison M. Dunning, at the University of Cambridge, UK, who
were blinded to POT1 status of all samples.
I then estimated mean ∆Ct values for each sample from all replicates. I then adjusted
the estimated mean values of ∆Ct obtained from melanoma cases without germline
POT1 variants for age at blood draw and sex using a linear model (Fig. 4.11). The
corresponding values for POT1 variant carriers were estimated on the basis of the same
adjustment. In Fig. 4.10b, adjusted mean ∆Ct values are plotted with the histogram
showing the non-carrier melanoma cases compared to the missense variant carriers and
the non-carrier family controls plotted above. I then performed a Wilcoxon rank-sum
test comparing the adjusted mean ∆Ct values for the 252 non-carrier melanoma cases
with those for the 7 missense variant carriers, yielding a P -value of 3.62×10−5.
Both the bioinformatic estimation and the PCR measurements of telomere lengths
agree that all POT1 variant carriers have significantly longer telomeres than individuals
without these variants, even when compared to members of the same family (Fig. 4.10b).
Thus, missense variants in the OB domains of POT1 not only abolish telomere binding,
but are also associated with increased telomere length. Interestingly, the melanoma
case in pedigree UF23, who does not carry the R273L variant, has shorter telomeres
than her carrier relative, with length comparable to non-carrier cases or the disease-free
individual from pedigree UF20. I elaborate on this observation, as well as the potential
tumourigenesis mechanisms of POT1 variants, in the Discussion.
The difference in telomere lengths for POT1 missense variant carriers when compared
to controls made us question whether there would be any effect in telomere length for
the splice variant carriers. Unfortunately, both the bioinformatic algorithm and the
PCR measurements are extremely sensitive to variations in DNA extraction methods,
sequencing methodology and the plate where the sample resides (see Subsection A.1.10).
These facts did not allow us to assess samples from the Australian cohort in this analysis.
However, the sample carrying the POT1 splice donor variant showed longer telomeres
when compared to samples from the Leeds case-control study when analysed by PCR,
suggesting that that this variant might have some effect on telomere regulation (Fig.
4.12).
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Figure 4.11: Linear model used to adjust PCR mean ΔCt values for age at
blood draw and sex. Residuals were used as the adjusted mean ΔCt values. Dark
circles represent male samples, and light circles represent females. The sex variable is
coded as 0=female, 1=male. Note that only two dimensions (mean ΔCt value and age)
are shown.
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4.2.2.2.5 Investigating the role of POT1 mutations in other cancers The
identification of POT1 mutations in CLL and the probable susceptibility of our POT1 -
mutated familial melanoma pedigrees to other tumour types (Fig. 3.2) suggest that
POT1 might have a more general role in tumourigenesis. To investigate this possibility,
we examined pan-cancer data from the COSMIC [438] and IntOGen [481] databases
(data from The Cancer Genome Atlas [TCGA] and the International Cancer Genome
Consortium [ICGC]).
To statistically assess the mutational patterns affecting POT1 in cancer, the COS-
MIC database, version 66, was mined for confirmed somatic mutations absent from
the 1000 Genomes Project affecting the ORF of POT1 across 14 cancer types (breast,
central nervous system, endometrium, hematopoietic and lymphoid tissue, kidney, large
intestine, liver, lung, ovary, parathyroid, prostate, skin, urinary tract and not specified).
This analysis yielded 35 somatic mutations, including 4 that were silent. The total
frequency of each reference/mutated base pair in the same COSMIC database was
compiled. Finally, a Monte Carlo simulation with 100,000 groups of 35 mutations at
random locations in the POT1 ORF was performed. The probability of a given mutation
from a reference base (e.g., A to G) was forced to equal the frequency for that pair in
the whole COSMIC database.
Of the 100,000 simulations performed with this method, only 2,971 contained 4 or
fewer silent mutations. Therefore, the COSMIC database contains fewer silent mutations
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affecting POT1 than expected by chance (P -value<0.03). To assess the clustering
of mutations at sites encoding DNA-interacting residues (Table 4.2), only missense
mutations were considered, as no selection would be expected for nonsense mutations.
In the COSMIC database, 27 POT1 missense mutations were found, 4 of which affected
telomere-binding residues. In the Monte Carlo experiment, 9,244 simulations had exactly
27 missense mutations. In only 176 of these simulations were 4 or more residues identified
that were classified as disrupting telomere binding. This result suggests that POT1
missense mutations affect DNA-binding residues at a higher than expected rate in the
COSMIC database (P -value<0.02). The Monte Carlo simulations were performed by
Víctor Quesada, at the University of Oviedo, Spain.
Finally, to assess the functional impact bias of somatic mutations in POT1, I also
considered all mutations in POT1 that are present in the IntOGen database [481]. We
chose this database because it integrates only samples that have been whole-exome
sequenced and thus can provide a valid, non-biased estimate of the functional impact of
mutations in POT1 when they are compared with mutations in the rest of the exome.
The frequency of POT1 mutations in this data set is ~0.01 across 9 cancer sites (all
of those available in the database, contained in the 14 sites listed above). P -values
for the three studies for which the gene passed set thresholds defined in the database
[481], calculated with Oncodrive-fm [482], were combined to yield a P -value of 0.021,
indicating that this gene is biased toward the accumulation of functional mutations.
Therefore, although mutations in POT1 have not been found at a high frequency
in the cancer studies deposited in COSMIC and IntOGen (which integrates only whole-
exome data from ICGC and TCGA as well as other studies), the mutations that have
been reported show a tendency to be missense (P -value<0.03), to alter residues in close
proximity to DNA (P -value<0.02), and to have a higher functional impact bias (P -
value<0.03) than expected by chance. These results suggest that, although rare, somatic
POT1 mutations may drive tumourigenesis across multiple histologies.
4.2.2.3 Conclusion
We identified five different variants in POT1 in melanoma pedigrees, three that alter
amino acid residues, one predicted to affect splicing and one of uncertain significance. In
this part of the study, we investigated the mechanisms by which POT1 variant carriers
might be predisposed to the development of melanoma, and possibly other cancers (Fig.
3.2).
The missense variants are found in highly evolutionarily conserved positions, in the
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OB folds of POT1 (Figs. 3.4 and 4.6). We show here that these not only abolish the
interaction of POT1 with telomeres in vitro (Fig. 4.7b) but also that variant carriers
have longer telomeres than melanoma cases without POT1 variants, and indeed that
members of their own families without POT1 variants (Fig. 4.10). These differences
persist when measurements are adjusted by age at blood draw and sex. Additionally,
POT1 variants falling in amino acids in close proximity to DNA seem to be extremely
rare, as only one variant allele was found when bases coding for these 24 amino acids
were examined in more than 6,500 control exomes. Accordingly, somatically acquired
variants in this gene in cancer databases show a tendency to be missense rather than
silent, to affect amino acids in close proximity to DNA, and to have a higher functional
impact bias than expected by chance.
We also show that one of the two splice variants affects POT1 mRNA splicing,
introducing a frameshift that leads to a premature stop codon (Fig. 4.5). Although we
could not show this effect for the other variant, some impact on telomere length was
suggested when we examined it by PCR (Fig. 4.12).
Given the essential role of POT1 in telomere protection and length regulation, the
effect that these variants have on carriers, and the dominant-negative effect that has
been described for similar mutations, it is not surprising that individuals with one non-
functional allele are predisposed to malignancy. I cover the biological mechanisms by
which this might happen in the Discussion.
4.2.3 The effect of ACD variants found in melanoma pedigrees
We identified two pedigrees with variants in ACD, one introducing a premature stop
codon and another affecting an amino acid in the POT1-binding domain (Fig. 3.4 and
Table 3.4). The QIMR Berghofer team led an investigation into the effect of these
variants in protein associations within the shelterin complex. Because ACD does not
bind DNA, an electrophoretic mobility shift assay could not be used. Therefore, in
order to analyse protein-protein interactions, our collaborators used Octet RED biolayer
interferometry technology, which is able to detect changes in biomolecular interactions
between an immobilised receptor attached to a biosensor surface and analytes in solution
[483]. Therefore, this method allows the comparison of binding wild-type and mutated
proteins to an immobilised binding partner.
Their preliminary data has shown that the ACD Q320X variant results in altered
binding to POT1, compared to ACD wild-type protein (Fig. 4.13). They are in the
process of generating the ACD N249S protein for testing in a similar manner. This
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work is on-going and the kinetics of the interactions, assessed by the same technology,
will be performed shortly. The protein-protein interaction assays were performed by Dr.
Antonia L. Pritchard, at QIMR Berghofer, whom I thank for supplying methods and
figure.
Figure 4.13: Biolayer interferometry investigation of wild-type and mutated
ACD interactions with POT1. The POT1-ACD binding curve for the ACD wild-
type protein is shown in red, whereas the one for the ACD Q320X protein is shown in
blue. A lower end point indicates a lower total association, a similar slope and end point
indicates a similar association between wild-type and mutated proteins, a higher end
point indicates a potentially higher degree of association, while a steeper slope indicates
a faster association rate. I thank Dr. Antonia L. Pritchard for this image.
Measurements for wild-type and mutant ACD when binding POT1, although they
vary, were not significantly different. Although a cumulative binding effect over a lifetime
cannot be discarded, we were unable to draw any conclusions from this experiment.
Telomere length measurements were also performed by PCR on the ACD variant carriers,
along with additional variants identified in other members in the shelterin complex (see
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Subsection 4.2.4), but telomere lengths were not found to differ significantly (data not
shown).
4.2.3.1 Conclusion
We identified two variants in ACD co-segregating with melanoma in two different ped-
igrees, one missense and another introducing a premature stop codon. The QIMR
Berghofer team performed protein binding assays and telomere length measurements,
but could not find any functional evidence for the mechanism by which these variants
might be predisposing to melanoma, if indeed they are. However, it is likely that the
stop codon is deleterious, as there are no stop codons found throughout the length of
the protein in dbSNP release 138 [381] or the 6,500 exomes released by NHLBI GO
ESP [17], but there are examples of somatically acquired stop codons in ACD in the
COSMIC database [438]. This observation evidences that these mutational events are
extremely rare in the germline, and, added to the perfect co-segregation with melanoma
found in pedigree AF19, might indicate that this variant plays a role in the melanoma
predisposition seen in this pedigree. However, more biological studies should be carried
out to address the mechanism definitively, and to determine whether these ACD variants
have any effect on telomere protection.
4.2.4 Other genes in the shelterin complex
Given their biological role in telomere length and protection, the rest of the members in
the shelterin complex represent attractive candidate genes in melanoma susceptibility.
The QIMR Berghofer team screened 601 individuals belonging to 510 families, from
Australia, UK, The Netherlands, Denmark and Sweden, for germline variants in any of
the members of the shelterin complex apart from POT1. The families tested did not
have variants in CDKN2A, BAP1, POT1, BRCA2, CDK4 and the promoter of TERT.
We found, in addition to the two variants in ACD described above, a nonsense variant in
TERF2IP co-segregating perfectly with melanoma in three members of pedigree UF3,
of which one member had been sequenced as part of the discovery phase (Fig. A.1.1 and
Table A.1.8).
Other variants they found co-segregating perfectly with melanoma in members of the
shelterin complex are a V272M substitution in ACD in two members of one pedigree, a
Q191R variant in TERF2IP in two members of another pedigree, and a M5I substitution
in the same gene in one evaluated member of a pedigree, all in Australian families.
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Also, they found other variants not co-segregating perfectly in these genes, as well as
other genes in the shelterin complex, but these were not convincingly associated with
melanoma.
4.3 Summary and conclusion
In this Chapter, I described the studies we performed to assess the biological function
by which the variants detected in prioritised genes might be predisposing carriers to
melanomagenesis. We were able to establish a role for variants in the shelterin complex
member POT1 in telomere length maintenance, with carriers of the variants having
longer telomeres than both other non-carrier members in their families and other melan-
oma patients without these variants. I discuss the mechanism by which longer, and
potentially unprotected, telomeres predispose to malignancy in the next Chapter.
We could not conclusively define the biological mechanism, if any, by which SMG1
and ACD variants might be contributing to tumourigenesis. In the case of SMG1,
difficulties such as cell culture contamination or assay irreproducibility prevented us
from drawing any conclusions from the experiments we performed. In the case of ACD,
although we could not pinpoint the function that might be altered in variant carriers,
its potential involvement in melanoma predisposition is supported by its biological role
and the absence of stop codon variants in common genomic variation datasets from
thousands of individuals. However, biological assays focusing in other aspects relevant to
melanoma, such as the efficiency of DNA repair upon UV damage, the rate of acquisition
of chromosomal aberrations, or cell replicative ability should be performed in order to
investigate the potential role of these variants.
In the next and final Chapter, I discuss the relevance of the findings presented in this
dissertation and I cover the biological mechanisms that might be behind the variants
identified in familial melanoma pedigrees.

Chapter 5
Discussion
5.1 Summary of the work described in this dissertation
In this dissertation, I have described the methodology we followed to search for genes that
predispose, with high penetrance, to the development of melanoma. This search started
with whole-exome sequencing from several individuals from families with a high clus-
tering of melanoma cases. We started an analysis of UK and Dutch families (European
phase), but during the course of that study, a large collection of Australian pedigrees
became available for analysis (integrative phase). For both phases, we implemented
different gene prioritisation strategies, and then attempted to experimentally validate
our findings.
The European phase was further divided into two parts, the discovery and replication
phases. The discovery phase involved sequencing 24 pedigrees from the UK and The
Netherlands and implementing a gene prioritisation strategy to define candidate melan-
oma susceptibility genes. This strategy took into account diverse criteria such as the
number, position and consequence of gene variants at the protein level, the probability
that these are shared among members of a given pedigree, their allelic frequency in
catalogues of common human genetic variation, the likelihood of finding variants in
these genes in a population matched by ancestry, and the biological function of the
gene. We reasoned that a high score in these attributes would increase the likelihood
that these are involved in melanoma predisposition.
Having a list of candidate melanoma susceptibility genes, we then sequenced these
in an additional 92 pedigrees (replication phase). We implemented a novel prioritisation
strategy taking into account results from both phases of the study, and validated by PCR
variants in the highest-ranked genes. From this part of the study, detailed in Chapter
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2, the highest-ranked candidate gene was SMG1.
For the integrative phase, we extended our dataset to include a large collection of
Australian melanoma pedigrees, bringing the total number of pedigrees that had been
whole exome- or genome-sequenced to 105. As this set included a large proportion of
families with multiple affected members sequenced, we performed a new prioritisation
strategy relying mainly on co-segregation of rare, potentially deleterious variants with
melanoma. From this strategy, we prioritised two genes that contribute to telomere
maintenance, POT1 and ACD. I cover the analyses we performed in this phase in
Chapter 3.
Although the experimental evidence we could gather for the involvement of SMG1
and ACD in melanoma predisposition was inconclusive, we were able to establish a
role for the variants within POT1 in the aetiology of this disease. We found that
POT1 variants in these families either interfered with mRNA splicing or rendered the
protein unable to bind to ssDNA, and therefore, affected its ability to mediate telomere
protection and regulate telomere length. Accordingly, carrier individuals had telomere
lengths that were significantly longer than POT1 wild-type melanoma cases and non-
carrier members of their own families. Variants affecting the ability of POT1 to bind
to telomeres seem to be extremely rare in the populations examined. I explain these
analyses and biological assays in Chapter 4.
In summary, this work describes the methodology we followed to identify candidate
melanoma susceptibility genes starting with exome sequencing data. It discusses the
difficulties that are faced by large-scale sequencing projects investigating genetic diseases,
namely, the diverse attributes that may or may not be indicative of the involvement of
a gene in disease risk, problems with sequencing errors, the need for availability of
control datasets and the suitability of biological assays to test genetic hypotheses. It
also touches on complications arising from the genetic heterogeneity of the disease and
the occurrence of phenocopies in familial studies. However, this dissertation also shows
a successful example of the use of exome sequencing to pinpoint causal variants in a
gene, and moreover, directly implicate a biological pathway in melanoma risk.
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5.2 The identification of telomere dysregulation as an
important contributor to familial melanoma
In this dissertation, I describe the identification of germline variants in POT1 in more
than 4% of familial melanoma pedigrees that do not carry variants in CDKN2A and
CDK4, and in 2 out of 34 pedigrees (almost 6%) with 5 or more cases, making POT1
the second most frequently mutated high-penetrance melanoma susceptibility gene re-
ported thus far. At the same time we reported our results, another group based
at the National Cancer Institute in the US independently reported French, US and
Italian melanoma-prone families with rare germline variants in POT1 [484]. They
found that in families from Romagna, Italy, the frequency of rare POT1 variants is
comparable to that of CDKN2A variants, and identified a founder mutation occurring in
five unrelated melanoma-prone families from this region. Carriers of this variant not only
had longer telomeres than controls, but also a significant increase in the number of fragile
telomeres, which indicates that these disruptive POT1 variants alter not only telomere
length maintenance but also telomere integrity. In accordance with these observations,
susceptibility to cutaneous malignant melanoma due to disruptive variants in POT1 has
recently been included in the Mendelian Inheritance in Man catalogue of human genetic
diseases (MIM #615848).
These results implicate telomere dysregulation as an important factor in the aetiology
of familial melanoma. It had been recognised by previous studies that both short and
long telomeres can be risk factors for cancer development. Some examples of telomere
shortening syndromes due to deleterious mutations in telomere-associated proteins are
dyskeratosis congenita, ataxia telangiectasia and the Bloom and Werner syndromes (re-
viewed in [200]). Individuals with these conditions have higher frequencies of cancer than
the general population [485–487], possibly due to chromosomal breakage and telomere
fusions.
Nonetheless, individuals with long telomeres are also cancer-prone. For example,
it has been observed that both breast cancer cases and women at high genetic risk
for developing the disease have longer telomeres than controls, with telomere length
displaying a positive correlation with risk [488, 489]. In fact, BRCA1 and BRCA2
mutation carriers have recently been found to have longer telomeres than controls [490],
and longer telomeres have also been associated with a worse prognosis in a subset of
breast cancer patients with advanced disease [489]. Other cancers in which longer
telomeres have been associated with increased risk are non-Hodgkin lymphoma [491],
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and lung cancer in both smokers [492] and non-smokers [493]. Interestingly, a higher
risk of developing melanoma, but not squamous or basal cell carcinomas, has also been
associated with longer telomeres [494]. This risk is not only seen in sporadic cases, but
in CDKN2A-negative familial cases as well [495], and in both studies, longer telomeres
were associated with a higher naevus count. In accordance with these results, shorter
telomeres have also been found to be associated with decreased melanoma risk [496].
The studies cited above report comparisons of telomere lengths, usually measured
in whole blood or leukocytes, between groups of cancer cases and controls. Here I
have described what is, to the best of our knowledge, the first hereditary mechanism
underlying telomere lengthening in humans. It is known that cancer cells activate te-
lomerase or the alternative lengthening of telomeres (ALT) pathway to bypass replicative
senescence (reviewed in [497]), and thus cells from individuals with inactivating POT1
variants might be behaving in a similar way: If POT1 cannot inhibit telomerase, then
cells might have a longer lifespan, allowing the accumulation of somatic mutations. A
non-functional POT1 might lead to progressive lengthening of telomeres, despite the
telomere erosion that ensues every cell division.
In accordance with this idea, previous experiments have shown that in POT1 -
deficient cells, telomeres get progressively longer with each cell division [460, 462].
In fact, although we have limited evidence, it is tempting to speculate that families
with POT1 variants in both our study and that one from the US might be showing
genetic anticipation, in the form of a higher number of primaries or an earlier age
of onset with each successive generation. It has long been known that families with
progressive telomere shortening show this effect due to shortening of telomeres in germ
cells (reviewed in [498]), and it might be the case that POT1 families display the same
effect. However, assessment of a higher number of families and molecular studies will be
necessary in order to address this question.
Moreover, telomere lengthening might not be the only mechanism by which POT1
loss-of-function variants might contribute to tumourigenesis, but telomere dysfunction is
likely to play an important role as well. As noted by previous publications [462, 484, 499],
cells with defects in POT1 display loss of telomeric overhangs, chromosomal fusions and
breaks, multitelomeric signals and fragile telomeres. Even so, this effect might not be
severe enough to arrest cell division or lead to cell death, thus rendering POT1 loss-
of-function variants compatible with life. In accordance with this hypothesis, it has
been shown that POT1 knockdown in primary fibroblasts reduced their proliferative
potential, but they nonetheless could continue dividing [459]. Interestingly, this effect
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could be rescued by the abrogation of the P53 or INK4A/RB1 pathways, which could
offer some clues as to the additional molecular events that are necessary for POT1 -
deficient cells to progress to malignancy. The effect of a POT1 knockdown is better
tolerated than that of TERF2 (which leads to severe telomere fusions [459]), which
might also explain why we did not find any deleterious variants in TERF1 and TERF2
when we examined 510 melanoma-prone families from around the world (discussed in
Chapter 4).
An interesting observation arises from the examination of pedigree UF23 (Fig. 3.2d).
Whereas the individual that was sequenced, III-3, is a carrier of the POT1 R273L
variant, her half sister (III-1), who also developed melanoma, is not. However, these two
individuals presented with very different clinical characteristics: The carrier of R273L
presented with three primaries, the first one at 45 years of age, whereas the non-carrier
presented with a single melanoma in situ at 62 years of age. Additionally, the POT1
R273L variant was found in one case part of the Leeds Melanoma Case-Control study,
who presented with MPM and an early age of onset, similar to the phenotype of the
familial cases. This fact could point to other cancer-predisposing genetic or non-genetic
aspects being shared by the two individuals of pedigree UF23, or just to the occurrence
of phenocopies within the same family. Notably, individual III-1 did not seem to have
longer telomeres when compared to POT1 wild-type melanoma cases (Fig. 4.10b),
further implicating the involvement of telomere dysregulation in the development of a
more severe phenotype.
It is still not completely clear whether the biological mechanism by which these POT1
variants predispose to familial melanoma is the same as that one by which mutations
in the promoter of TERT do so, but it is unlikely. Telomere length measurements for
germline TERT variant carriers have not been reported in the literature, but our own
bioinformatic measurements in the Leeds family that was found to harbour the TERT
promoter variant did not indicate that they had telomeres that differed significantly from
controls (data not shown). Although similar somatically-acquired variants in TERT do
lead to its increased expression [500], TERT has many other roles outside telomere
maintenance that could be contributing to the elevated cancer risk. For example, it
can act as a transcriptional modulator of the Wnt-β-catenin signalling pathway and
physically occupy Wnt-dependent promoters [501], and bind the RNA component of
mitochondrial RNA processing endoribonuclease (RMRP), [502] possibly to regulate
gene expression. In addition to this, individuals with activating variants in TERT
would not, in principle, show the fragile telomere syndrome displayed by POT1 -deficient
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cells. More experiments will be necessary to address how TERT over-expression affects
telomere maintenance, if indeed it does.
But why would variants in POT1 lead to the development of melanoma? What is
so special about the relationship between melanocytes and telomeres? This is indeed
something we do not know at the moment, not unlike the question of why germline
defects in the major tumour suppressor CDKN2A lead primarily to the development of
melanoma, with other cancers manifesting at lower frequencies in carriers. It may be the
case that defects in POT1 also predispose to other cancers, as we can see in the carrier
families (Fig. 3.2), and pedigrees with other cancers and germline variants in POT1
will be described in the future. However, as case-control studies analysing melanoma
risk factors have shown [494–496], longer telomere length seems to be associated with
melanoma, but not squamous or basal cell carcinomas. It can also be that longer telomere
length is indicative of a defect in the telomere maintenance machinery that also leads
to fragile telomeres and a higher tendency to suffer telomere breaks and fusions, just as
has been shown in POT1 variant carriers. This indeed points to the idea that there is
a special relationship between melanocytes and their telomeres.
Some clues as to the above question might come from experiments that have shown
that DNA-damaging agents, including UV irradiation, cause damage throughout the
genome but cause proportionately more damage in telomeric sequences [503]. Telomeres
have been shown to be hypersensitive to UV-induced DNA damage, and to be refractory
to DNA repair [504, 505]. Perhaps this effect could be exacerbated by the longer and
unprotected telomeres in POT1 variant carriers. This hypothesis would point to the
involvement of other genes that contribute to UV-induced melanomagenesis, such as
TERT and TP53, in melanoma tumours initiated by telomere dysfunction. However,
future experiments should be performed to address the biological pathway, or pathways,
by which these cells progress toward malignancy.
In conclusion, our study of the genomes of melanoma-prone pedigrees has led us to
describe what is, to the best of our knowledge, the first mechanism underlying hereditary
telomere lengthening in humans. This telomere lengthening is associated with high
melanoma risk, and possibly other cancers. Many questions are posed by this discovery,
for example, whether families with this defect display genetic anticipation, what other
genetic hits are necessary for melanoma progression, and whether there is a reason why
melanocytes would be more susceptible to telomere dysfunction or this is just an effect of
sample ascertainment bias. The investigation of these questions might have the potential
to facilitate better clinical management of families with POT1, and potentially variants
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of a similar consequence in other genes, in the future.
5.3 Future directions
As mentioned above, there are many questions that need to be addressed relating to
the manner by which individuals with germline variants leading to telomere dysfunction
develop cancer. Initially, to help translate this discovery to clinical practice, we need to
establish the true penetrance of the variants described in this study and the one from
the US. In the work presented here, we did not find any POT1 variant carrier that did
not develop melanoma, whereas the US group determined that the founder variant they
identified showed dominant inheritance with incomplete penetrance [484]. Whether this
effect is related to the positions of the variants themselves (i.e., the variants identified
in our study all affect DNA-binding residues whereas the founder mutation identified by
the US group does not) or whether we need a larger sample size to see the same effect
remains to be determined. We also need to determine the penetrance and biological
mode of action of the splice acceptor variant. Although we only have one family with
this type of variant (Fig. 3.2b), its affected members seem to have presented with
melanoma later in life than the missense carriers. This observation might arise from the
small sample size, but it can also mean that a variant affecting splicing does not generate
a protein able to compete with wild-type POT1 and perturb protein interactions at the
telomere [465]. This could imply that the mechanism by which this variant predisposes
to melanoma is not dominant-negative, but haploinsufficiency. We will be able to answer
these questions, hopefully, as we gather additional data from families with these types of
variants. We are in the process of doing so as part of the Melanoma Genetics Consortium
(GenoMEL, http://www.genomel.org/).
A mouse model might be useful in elucidating the additional somatic variants that
must occur in POT1 variant carriers to develop melanoma. Within our group, Chi Wong
has successfully created, via CRISPR/Cas9 technology [506], mice carrying variants or-
thologous to the human POT1 Y89C and Q94E variants. Analyses of their consequences
might be complicated by the fact that mice have much longer telomeres than humans
[507] and two POT1 orthologues, Pot1a and Pot1b [454]. Nonetheless, we hope to be
able to recapitulate the human cancer-prone phenotype, just as it was possible with
shortening telomere syndromes due to variants in TERC [508]. We can then seek to
answer questions such as whether telomeres get progressively longer throughout life, the
spectrum of cancer types that these mice are predisposed to and the contribution of UV
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irradiation toward melanoma development.
However, mouse studies should be compared to and supported by studies of human
tissue whenever possible, as it has been shown that mouse models not always recapitulate
human disease perfectly (reviewed in [509]). Undoubtedly, the study of tumours from
patients with POT1 variants will prove invaluable as we endeavour to establish the
genomic events leading to malignancy. We can then assess the contribution of UV-
induced damage in tumour DNA and find recurrently mutated oncogenes or tumour
suppressors, for example. As more patients with rare POT1 variants are being identified
by dermatologists part of GenoMEL, we hope to be able to obtain this important
biological material in the coming months.
Additionally, a more in-depth investigation into the biological consequences of rare
variants in ACD and TERF2IP should hopefully help us complete the picture of how
telomere dysfunction predisposes to the development of melanoma. Presumably, they
function as haploinsufficient alleles and lead to a malformed shelterin complex, as the
variants that segregate with melanoma in these pedigrees introduce premature termina-
tion codons into the affected proteins. We hope to be able to address these questions by
performing protein-protein interaction assays and introducing the detected variants into
cells in vitro, thus being able to assess their contribution to biological processes such as
cell cycle progression and telomere maintenance.
Finally, although we have identified a novel biological pathway relevant to melanoma
predisposition, we cannot disregard the bigger picture: We still have 100 families in the
Leeds and Leiden collections for which we have not identified any genetic predisposition
loci. It could be that some of these have high-penetrance variants in genes that we have
sequenced, such as SMG1, and we just need to identify a suitable biological assay to
test them. One of the genes prioritised in the integrative phase, NIMA-related kinase
10 (NEK10 ), which plays a role in G2/M cell cycle arrest upon UV irradiation [510], is
currently being investigated by our Dutch colleagues.
Variants in genes with roles in biological processes previously found to be important
in melanoma development could also represent interesting candidates. In this cat-
egory, we have variants segregating with melanoma within a single family in discs,
large homolog 1 (DLG1 ), proteasome 26S subunit, non-ATPase, 3 (PSMD3 ), PSMD12,
PSMD13, AKT1, minichromosome maintenance complex component 5 (MCM5 ) and
nuclear protein, ataxia-telangiectasia locus (NPAT ). All these genes encode proteins that
play a role in the G1/S checkpoint of the mitotic cell cycle, the same pathway in which
CDKN2A and CDK4 participate. Genes encoding proteins that participate in other cell
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cycle regulatory tasks or cell differentiation could represent interesting candidates, such
as centrosomal protein 250kDa (CEP250 ), CEP290, eukaryotic translation initiation
factor 4E binding protein 2 (EIF4EBP2 ) or SOX3. All these genes have variants
segregating with melanoma in the families we studied, and could represent plausible
melanoma susceptibility candidates.
Additionally, it could also be that these families have high-penetrance predisposition
variants in non-exonic regions, in which case we would not have the data as we did
not sequence the non-coding genome. A good example of this type of variant is the
activating mutations in the promoter of TERT [297, 298, 500], which have been found
subsequently in a large number of cancer types. In order to address this question, we
are in the process of whole genome-sequencing 29 familial melanoma pedigrees from
the Dutch cohort. Other possibilities that we need to consider relate to the occurrence
of several low-penetrance alleles within families or the contribution of non-genetic or
epigenetic effects.
In conclusion, there are many questions we are looking forward to answer relating
to the role of telomere dysregulation in melanoma susceptibility, and possibly other
cancers. We expect to be able to investigate these as we gather more families with
rare variants in POT1 and related genes, and with the generation of mouse models and
the study of human tumours from carriers. Additionally, we need to investigate the
involvement of other biological processes, and the contribution of non-genic effects, in
the remaining families for which have not been able to identify any predisposition loci
thus far. Hopefully, as we gather more data and exploit alternative technologies such as
whole-genome or bisulphite sequencing, we will be able to help complete the description
of the processes that influence genetic susceptibility to familial melanoma.
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Appendix A
Electronic files and supplementary
information
A.1 Description of electronic files
I have placed these files in the accompanying CD, as they are large files that I do not
think need to be printed. In this Appendix, I have written a short description detailing
each of these, as well as the file name with which they can be located.
A.1.1 Pedigree structures for 24 melanoma-prone families se-
quenced as part of the discovery phase
File name: Figure_A_1_1.pdf
This PDF file contains pedigree structures for the 24 pedigrees that were sequenced
as part of the discovery phase, one per page. Squares represent males, circles represent
females, diamonds represent individuals of undisclosed sex. Individuals that had their
whole exome sequenced are shown with a red outline. Types of cancer are indicated
in the legend. Note that pedigrees have been adjusted to protect the identity of the
families without loss of scientific integrity.
A.1.2 Detailed information about recurrently mutated genes
File name: Table_A_1_2.xlsx
This table contains the list of 344 genes that had mutations in two or more pedigrees.
The number of families with mutations, the number of members in each family and the
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coding length of the gene are indicated.
A.1.3 List of biological pathways ordered by P-value after hy-
pergeometric tests on list of recurrently mutated genes
File name: Table_A_1_3.xlsx
This table contains the results of the analysis to identify overrepresented biological
pathways in our set of 344 recurrently mutated genes. All pathways with a P -value<0.5
are in this table, pathways in green were the ones included in the list for targeted
sequencing. Note that the acute myocardial infarction pathway from Biocarta has an
adjusted P -value < 0.05 and was not included in the set for targeted sequencing; the
reason is that the original analysis was performed with the R package HTSanalyzeR
version 2.8.0, which had an error in the code for the hypergeometric function. This error
was corrected for the next version (2.8.3), which is the one I used to generate the table
presented here.
A.1.4 All genes included for capture in the replication phase
File name: Table_A_1_4.xlsx
All 701 genes in that were targeted for sequencing in an additional set of 94 melanoma
cases. The Ensembl identifier, along with the coding length and the reason for inclusion
are indicated. “Direct evidence” means the gene was mutated in two or more pedigrees,
“ABC transporter”, “Pantothenate and CoA biosynthesis pathway” and “Linkage to
MAPK signalling for integrins” indicate that the gene was included because it is part
of a pathway that was found to be overrepresented in the recurrently mutated genes.
“Disruptive consequence” means that the gene was included because it had a premature
stop codon, a frameshift variant or a splice acceptor or donor variant in any one of
the familial melanoma pedigrees. Genes marked as “previous evidence for involvement
in melanoma/cancer” were included because they have been found linked to processes
relevant to melanoma.
A.1.5 List of ranked genes after prioritisation stage
File name: Table_A_1_5.xlsx
This table includes the genes captured in both the discovery and replication phases,
with their respective values for the variables used in the prioritisation method. The
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genes highlighted in red are regarded as uninformative, as they have either a single
variant detected in the melanoma pedigrees and no variants in the control exomes, or
were found to have a coding length of 0.
A.1.6 List of variants in the analysis of founder mutations and
those in single pedigrees
File name: Table_A_1_6.xlsx
This table includes the list of variants predicted to affect protein function that were
present in more than one pedigree for which co-segregation information was available.
The position of the variants, the number of pedigrees with their respective number of
members and the consequences of the variants are indicated.
A.1.7 Genes found with only one variant in multi-case pedigrees
File name: Table_A_1_7.xlsx
List of the genes that were found with variants segregating with melanoma in only
one pedigree, and that were not present in the prioritisation stage.
A.1.8 Pedigrees sequenced as part of the integrative phase
File name: Table_A_1_8.xlsx
The number of cases in each pedigree is indicated, as well as the number of cases
sequenced (exomes or whole genomes). Whole genomes were only sequenced as part of
the QFMP cohort.
A.1.9 Genes with co-segregating variants from the 28 pedigrees
for which we had sequence data for 3 or more members
and their GO terms
File name: Table_A_1_9.xlsx
Genes that had variants co-segregating with melanoma from the 28 pedigrees for
which we had sequence data for 3 or more members and their GO terms.
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A.1.10 Wide variation in telomere measurements when samples
have not been processed in the same manner
File name: Figure_A_1_10.pdf
This graph shows the telomere measurements for the 41 samples that belong to
the discovery phase cohort and that were sequenced at the Sanger Institute alongside
telomere length estimates for samples part of the UK10K, sequenced at the same in-
stitute (all shown in a white background), and samples processed at QFMP (in a blue
background, sample origin is indicated at the bottom). Samples with POT1 variants are
indicated with red arrows, two whole genomes part of the QFMP cohort are indicated
with green arrows. Samples within the QFMP cohort showed much more variability
in telomere length measurement and thus could not be assessed with the bioinformatic
method.
A.2 Supplementary tables, figures and notes
A.2.1 Removal of genes likely to be false positives after filtering
I manually scanned the list of candidates after filtering and decided to remove four that
are likely to be false positives (titin [TTN ], obscurin [OBSCN ], dystrophin [DMD ] and
maestro heat-like repeat family member 2A [MROH2A]) due to their length and/or
their ubiquity in other cancer screens (based on analyses performed by Vertebrate
Resequencing Informatics at the Sanger). I also inspected the variants for their presence
in repeat regions, and a further five genes were excluded given that the mutations
we detected on these overlapped with the RepeatMasker track from the University of
California, Santa Cruz (UCSC) Genome Browser [511]: (lysine-specific demethylase 6B
[KDM6B ], WD repeat domain 87 [WDR87 ], Zinc finger protein 589 [ZNF589 ], choline
kinase alpha [CHKA] and abnormal spindle homolog, microcephaly associated [ASPM ]).
This left 344 genes for further consideration.
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Table A.1: Tools and parameters used for read alignment and variant calling in the
discovery and replication phases
Step Reference
dataset
Tool Version Parameters
Discovery phase
Read alignment
to reference
genome
GRCh37 BWA [377] 0.5.8c,
0.5.9
-q 15 -t 6
Alignment improvement
Duplicate
marking
- Picard MarkDuplicates
[378]
1.47 -
Indel realignment dbSNP
129
GATK IndelRealigner
[379]
1.1-5 -LOD 0.4
-model
KNOWNS_ONLY
–entropy 0.15
Quality score
recalibration
GATK
TableRecalibration [379]
1.1-5 -
Variant calling - SAMtools mpileup [380] 0.1.17 -DRS -d 10000
-C50 -m2
-F0.0005 -aug
-P ILLUMINA
Replication phase
Read alignment
to reference
genome
GRCh37d5 BWA [377] 0.5.9 -q 15 -t 6
Alignment improvement
Duplicate
marking
- Picard MarkDuplicates
[378]
1.5-9 -
Indel realignment 1000
Genomes
Phase 2
Indels [15]
GATK IndelRealigner
GATK CountCovariates
[379]
1.5-9 -LOD 0.4
-model
KNOWNS_ONLY
Quality score
recalibration
- GATK
TableRecalibration [379]
1.5-9 -
Variant calling - SAMtools mpileup /
Bcftools [380]
SAMTools:
0.1.18
Bcftools:
0.1.17-dev
SAMtools: -EDS
-d 10000 -C50
-m2 -F0.0005
Bcftools: view
-p 0.99 -vcgN

Appendix B
Articles published during my PhD
During the course of my PhD, I was part of several publications, that were either directly
associated with the work described in this dissertation or represented other work I carried
out. In this Appendix, I list these publications and provide a short explanation of their
main findings and my contribution to each of them. The physical articles can be found at
the end of the dissertation. An asterisk denotes that those authors contributed equally.
B.1 Articles directly associated with this dissertation
• Robles-Espinoza CD*, Harland M*, Ramsay AJ*, Aoude LG*, Quesada V, Ding
Z, Pooley KA, Pritchard AL, Tiffen JC, Petljak M, Palmer JM, Symmons J,
Johansson P, Stark MS, Gartside MG, Snowden H, Montgomery GW, Martin NG,
Liu JZ, Choi J, Makowski M, Brown KM, Dunning AM, Keane TM, López-Otín
C, Gruis NA, Hayward NK, Bishop DT, Newton-Bishop JA and Adams DJ (2014).
POT1 loss-of-function variants predispose to familial melanoma. Nature Genetics
45(5): 478-81. doi: 10.1038/ng.2947.
This is the main publication explaining the results from my dissertation. This letter
explains the finding of familial melanoma pedigrees with rare variants in POT1 and their
consequences in carriers. I performed most of the bioinformatic analyses, including data
processing and filtering, analysis and comparison with control exomes, computational
assessment of variant conservation and pathogenicity, and analysis of telomere length
data.
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• Aoude LG*, Pritchard AL*, Robles-Espinoza CD*, Wadt K*, Harland M*, Choi
J, Gartside M, Quesada V, Johansson P, Palmer JM, Ramsay AJ, Zhang X, Jones
K, Symmons J, Holland EA, Schmid H, Bonazzi V, Woods S, Dutton-Regester K,
Stark MS, Snowden H, van Doorn R, Montgomery GW, Martin NG, Keane TM,
López-Otín C, Gerdes AM, Olsson H, Ingvar C, Borg A, Gruis NA, Trent JM,
Jonsson G, Bishop DT, Mann GJ, Newton-Bishop JA, Brown KM, Adams DJ and
Hayward NK (2014). Nonsense mutations in the shelterin complex genes ACD
and TERF2IP in familial melanoma. Journal of the National Cancer Institute
(Accepted for publication).
This publication explains an extended search for variants in members of the shelterin
complex in 510 melanoma-prone pedigrees from Australia, UK, The Netherlands, Den-
mark and Sweden. We found additional nonsense variants that co-segregate with the
disease in ACD and TERF2IP, providing further support for telomere dysregulation as
an important contributor to this phenotype. I did the data analysis for samples from
the UK and The Netherlands, as well as comparisons with control exomes.
• Robles-Espinoza CD, del Castillo Velasco-Herrera M, Hayward NK and Adams
DJ (2014). Telomere-regulating genes and the telomere interactome in familial
cancers. Molecular Cancer Research (Accepted for publication).
This review explores the role that telomere-regulating proteins, including members of
the shelterin complex, have in cancer predisposition. The structures and functions of
telomerase, shelterin and the telomere interactome are discussed. I wrote most of this
review.
• Rashid M, Robles-Espinoza CD, Rust AG and Adams DJ (2013). Cake: A
bioinformatics pipeline for the integrated analysis of somatic variants in cancer
genomes. Bioinformatics 29(17): 2208-10. doi: 10.1093/bioinformatics/btt371.
This application note provides a tool for somatic variant discovery from NGS data in
cancer genomes. It combines other software tools previously developed and provides
a strategy to optimise the sensitivity and accuracy of candidate variant calls when
compared to any of these tools alone. I wrote some of the functions in this piece of
software, which were adapted mainly from the analyses I did during the discovery phase
of this study.
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B.2 Other articles
• Robles-Espinoza CD and Adams DJ (2013). Cross-species analysis of mouse and
human cancer genomes. Cold Spring Harbor Protocols 2014(4).
doi: 10.1101/pdb.top078824
• van der Weyden L, Rust AG, McIntyre RE, Robles-Espinoza CD, del Castillo
Velasco-Herrera M, Strogantsev R, Ferguson-Smith AC, McCarthy S, Keane TM,
Arends MJ and Adams DJ (2013). Jdp2 downregulates Trp53 transcription to
promote leukaemogenesis in the context of Trp53 heterozygosity. Oncogene 32(3):
397-402. doi: 10.1038/onc.2012.56
